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Abstract 
Blood samples from over 1600 schoolchildren revealed a prevalence 
of both trait and HbE trait, averaging 2.3% and 0.8% 
respectively. With the present popUlation estimate at 18.6 million, it is 
predicted that approximately 2650 patients with l3-thalassaemia major and 
956 with HbE/I3-thalassaemia should consume >5% of the current health 
budget for treatment of these patients. Patients with the phenotype of 
severe thalassaemia, from seven centres, were analysed to understand the 
molecular basis of the disease. 
Twenty-four l3-globin gene mutations were identified with three 
mutations accounting for 84.4% ofthe 1234 alleles: IVSI-5 (G--7C) 56.1 %; 
IVSI-l (G--7A) 15.2% and HbE 13.1 %. Sixteen mutations have previously 
been described on the Indian subcontinent and demonstrate close regional 
links between the popUlations, especially North East India, and were 
supported by haplotype association. The IVSI-l (G--7A) mutation occurs 
commonly in countries around the Mediterranean but very rarely on the 
Indian subcontinent. In Sri Lanka it is associated with a different 3' 
haplotype, suggesting a multicentric origin. Three new mutations were 
found; a frameshift codon 6-10 IVSI-129 (A--7C) in the consensus 
splice site and a second frame shift, CD55 (-A). 
Four a-gene arrangements were demonstrated. An allele frequency 
of the a+-thalassaemia gene deletions were 6.5% and 1.1% for the _a3.7 
deletion and the _a4.2 deletion, respectively. Cord blood analysis of Hb 
Bart's levels confirmed an estimated level of 7.1 % for a single a-gene non-
expression. Extra a-genes are common and the first instance of 
homozygosity for the aaaa arrangement was observed. No aO-
thalassaemia was revealed and only a single polymorphism was associated 
with a possible extremely mild a-thalassaemia allele. 
The phenotype associated with the various l3-globin genotypes was 
found to be extremely variable. Within the many factors that modify this 
phenotype the Xmn-I polymorphism was significantly associated with the 
level of haemoglobin expressed. A +1+ genotype appeared to be a good 
indicator of a milder outcome. The incidence of a-gene deletions was low 
in patients with HhElI3-thalassaemia and thus proposed this as a strong 
modifier for a mild phenotype. Other factors were associated with specific 
complications. 
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Chapter 1 Introduction 
In Sri Lanka, many patients present with a clinical diagnosis of 
thalassaemia. Generally, this group of patients have been neglected and have 
been considered a burden on society. Any biochemical knowledge of this 
disease on the island is anecdotal from protein studies on a handful of 
patients. The molecular basis for the thalassaemia syndromes in Sri Lanka is 
unknown. The population of Sri Lanka is thought to have derived from the 
subcontinent of India and hence the pattern of haemoglobinopathies would be 
predicted to be similar. 
An understanding of the nature and incidence of the thalassaemia 
syndromes in Sri Lanka will enable its Department of Health to develop a 
health plan to treat this disease and also to establish a system of education 
to improve the awareness within the population. Many factors modify the 
disease, some favourably and some to the patient's detriment. A close 
examination of this syndrome may help correlate phenotype with genotype. 
As each factor is identified further genetic and phenotypic variation can be 
scrutinised and may give a greater comprehension of the pathophysiology 
of the disease and subsequently modify the treatment of each patient. The 
spectrum and frequency of mutations will allow a better understanding of 
the evolutionary pressures and ties with other populations. 
1.1 Sri Lanka 
1.1.1 Sri Lanka: interaction with other countries 
Sri Lanka is a geological extension of the South Indian peninsular 
and is separated by a narrow strip of water called the Palk Straits, 25 miles 
wide. This separation is thought to have occurred on a number of occasions 
as determined by the fluctuations in the global climate, and last occurred 
about 7,000 years ago in the Miocene epoch of the tertiary period. The 
climate is tropical and warm all year, except for the centre of the island that 
is mountainous and cool (Encyclopaedia Britannica). 
The connection between South India and Sri Lanka was strengthened 
by archaeological findings. Similar artefacts were found in both regions 
dating from the Palaeolithic, or Old Stone Age (-1,750,000 years ago) and 
also from the Mesolithic period. The frrst settlers on the island were 
probably tribes of the proto-Australoid ethnic group akin to the pre-
Dravidian hill tribes of South India. They would have been a nomadic 
people, isolated from other populations. The population density for 'hunter 
gatherers' is estimated to be about 0.5 person/km2, giving an island 
population between 30-35 thousand. In fact, the land could have supported 
in good times up to 55,000 people. The current day Veddah population may 
have a direct genetic continuum from these people (Encyclopaedia 
Britannica). 
At the commencement of the 1 st Millennium Be there are indications of a 
rapid transition from Mesolithic culture to the Early Iron Age. The 
transfonnation from 'hunter gatherers' to farmers would have been 
responsible for this increase in the population size. Still, it was necessary 
for medium and long distance trade to increase the wealth and act as the 
catalyst for the increase in the density of settlements. Evidence of this 
population expansion can be seen at Anuradhapura with a large settlement 
dating back to 1,200 Be. The settlement exceeds 10 hectares and by the 3rd 
century BC it was estimated to be the 10th largest city on the Indian 
subcontinent (de Silva, 1997). 
The frrst implications of migrations to Sri Lanka from India are 
recorded in an early Indian legend, 'The Ramayana', that was written about 
500 Be. The epic of 'The Ramayana' tells of the conquest of Lanka in 
3,000 BC by Lord Rama to save his abducted wife Sita from Ravanna the 
demon god of Lanka and his hordes. 
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During the era of the Classical Age (c500 BC to 500 AD) a small 
number of records were passed on in written form. The most important 
early chronicle relating to the contemporary history and to the Buddhist 
faith on the island was 'The Mahavamsa' which literally means 'The Great 
Chronicle'. Its continuation was called 'The Culavamsa', meaning 'The 
Little Chronicle'. These accounts are credited to the Buddhist monk, 
Mahanama, in the fifth and sixth century AD and Dhammakitti in the 13th 
century AD. 
According to 'The Mahavamsa' a band of 700 Indian colonists 
headed by Prince Vijaya landed on the West Coast of Sri Lanka near 
PuttaIam in the 5th century BC. The precise origin of this legendary figure 
is obscure but he probably hailed from the North East of India. His father 
may have established himself in Gujarat from where the adventurers were 
put out to sea. This band of warriors defeated the local inhabitants, the 
yaks as (demons) whom they chased into the island interior. The prince 
married a yaksa princess and had two children. Later he drove her and the 
children away and their children are considered the ancestors of the present 
day Veddahs by folklore. Vijaya then sent to the Madurai court (Pandyan 
Kingdom) in South India for a princess for himself and for wives for his 
700 followers. As he had no heir he sent back a message to his brother so 
that he could accede to the throne. However, his younger brother had 
already ceded to the throne in North India after the death of their father. 
Instead his brother sent his son, Panuvasudeva, in a small entourage of 32. 
They landed at Trincomalee on the East Coast of Sri Lanka after travelling 
across the Bay of Bengal. He was enthroned and continued the Vijaya 
dynasty that lasted up until AD 65 but is considered to be the possible 
origins of the Sinhalese (de Silva, 1997; Encyclopaedia Britannica). 
Linguistic affinities between the Sinhalese speaking popUlation of 
Sri Lanka and the Prakit-speaking people of Eastern India strengthen the 
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hypothesis of a migration from this area. However, at this time North India 
was unsettled. The great Persian leader, Emperor Dareios (521-485 BC) 
conquered large parts of North India via the Indus valley and along the 
reaches of the Ganga. The far south remained isolated separated by 
mountain, river and a vast tract of barren inhospitable land. The great 
struggle for control of North India raged and may have ensued for many 
generations, creating a catalyst for the migration of a group to move south. 
Later, traders from the Roman and Persian Empires established outposts in 
South India and probably acquired goods from Sri Lanka. 
The precise date of the conversion of the people of Sri Lanka to 
Buddhism was thought to be during the reign of King Devanampiyatissa 
(250-210 BC). The founder of Buddhism, Gautama Buddha, was born in 
modern day Nepal. He died in 483 BC after teaching in Bihari and Eastern 
Uttar Pradhesh in India (at the same time as the arrival of Prince Vijaya in 
Sri Lanka). Buddha is thought to have made three trips to the island that 
may have implied a strong trading route. The Buddhist religion may have 
been carried along with this movement (Encyclopaedia Britannica). 
Dominion, by peoples of North Indian origin, was followed by the 
Lambakanna dynasty that ruled for about four centuries. The origin of this 
group of people is obscure. During this period a major irrigation system 
was constructed. This would probably have resulted in a population boom. 
A Pandyan invasion (a Tamil empire from the tip of south India) ended the 
dynasty in AD 432. However, Sinhalese rule was soon restored in AD 459 
with a line of Moriya kings. The capital was moved away from 
Anuradhapura for only a short time. 
Arab traders were active from around the time of 'Christ'. With the 
decline of the Roman Empire Roman trading waned and the Arabs and 
Persians filled up the vacuum. The Arabs formed settlements and land was 
set-aside for them around Anuradhapura. By the 8th century AD the Arabs 
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had fOImed colonies at important ports around India and Sri Lanka. The 
Moors of Sri Lanka have no direct connection with the people of North 
Africa. They were called Moors because the Portuguese gave this name to 
all Islamic communities they encountered in the Far East. The Moors of Sri 
Lanka are probably descendants of Arab, Persian and Indian settlers who 
intermarried with the local people but have retained their Muslim identity. 
In the middle Ages, especially from the 7th century there was an 
increase in the involvement of South Indian powers in the island's politics. 
With Indian backing Manvamma founded the second Lambakanna dynasty 
that reigned in Anuradhapura for about 400 years. Sinhalese kings were 
drawn into the dynastic battles between the three empires of South India; 
the Pandyas, the Pallavas and the Colas. The Pallavas had an empire near 
modem day Chennai, the Pandyas were furthest south and the Colas had an 
empire between the others. Invasions from South India and retaliatory raids 
were recurrent phenomena. In 993 the Colas occupied the kingdom and 
annexed Rajarata (part of Sri Lanka) as a province of the Cola Empire. The 
conquest was complete in 1017, when the Colas seized the southern 
province of Ruhuna. 
The Colas occupied Sri Lanka until 1070, whereupon Vjayabahu 
liberated the island and re-established Sinhalese power. During this period 
the kingdom enjoyed its greatest prosperity. The most colourful king, 
Parakrambahu, followed a strong foreign policy and sent a punitive naval 
expedition to Burma and an army to invade the Panyan kingdom but 
achieved no permanent success. After Parakrambahu the throne passed to 
the Kalinga dynasty and the influence of South India increased. The last 
Polonnaruwa king was Magha (1215-1236), an adventurer from South 
India who ruled as a dictator. 
Vijayabuhu was a feudal chief who, after many years of successful 
campaigning, made himself overlord of Mayarata and the western seaboard 
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of Rohana. By 1232, he assumed royal status and was succeeded by his son 
Parakramabahu II in 1236 who became the main ruler of the country until 
his death in 1270. In 1247 the Malay king, Chandra Bhanu, invaded Sri 
Lanka to possess the relics of Buddha. He ruled Northern Sri Lanka for 50 
years and can be remembered by place names like J affna. During the 13th 
and the first half of the 14th century control of the island switched between 
parts of South India (de Silva, 1997). 
In 1406 the Chinese attempted to take over the island and managed 
to capture the chief minister. They took him to China and then returned 
with a new fleet to gain power. However, although present for 8 years the 
Chinese never gained a real power base. In the interim Parakramabahu VI 
had already pre-empted them and continued his reign from 1411 to 1465 in 
peace and tranqUillity. The succession of his grandson lasted for only two 
years before the dominion of the whole country came under dispute. This 
changed hands between different groups over the next 50 to 60 years (de 
Silva, 1997). 
In 1506, the Portuguese discovered the island and were desperate to 
set up a trading post. As the fIrst western power to gain dominion over the 
island they would have access to the island's riches. In time the demands of 
the Portuguese became greater and they converted many to Catholicism. By 
1551, the island was split into three power bases; the Indian controlled 
Sitavaka in the north, the Portuguese around the Kotte and the indigenous 
forces of Kandy. The more powerful forces of the North tried to gain 
control but were rebuffed by an alliance between the other two powers. A 
new king in Kandy seized power and returned the populous to the Buddhist 
faith and expelled the Portuguese. The Portuguese turned their attention to 
the North and were soon in control of the Kingdom of Jaffna. By forming 
alliances with the people of the north, and with naval support, the 
Portuguese retained control of J affna. The Portuguese were keen to gain 
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complete dominion over the island. By 1620 only Kandy remained out of 
their control. Numerous attempts to gain control of Kandy were 
unsuccessful. 
The Portuguese control of Sri Lanka rested on their command of the 
sea by their superior military technology. This pattern was changed upon 
the arrival of the Dutch. In 1636, the Kandyan leader Rajasinha II, appealed 
to the Dutch to help vanquish the Portuguese. Incensed, the Portuguese 
invaded Kandy but were annihilated by a decisive battle. In 1638 the Dutch 
seized control from the Portuguese and finally ousted them completely 
from Colombo in 1658. Pockets of people, Burghers, speaking a 
Portuguese Creole survive to the present day that also includes descendants 
of other groups like the Dutch (de Silva, 1997). 
The first Dutch ships anchored off the port of Batticaloa in 1602. 
After the exit of the Portuguese, Rajasinha II requested control of all 
formerly Portuguese held land. The Dutch gave back some land but 
retained possession of the ports and some coastal areas and demanded 
unrealistic tribute for their assistance. The Dutch began to take control over 
the import and export of all goods. Malay immigrants were brought across 
to help work on the plantations. The Kandyan people began to become 
impoverished. In the 1670's the ruler, Rajasinha II, organised attacks on the 
Dutch-held territories. Although they could not retain control of these areas 
they changed the Dutch policy in Sri Lanka from one of aggression to one 
of peace. Hence, the Dutch did not attempt to control these areas but tried 
to gain sovereignty instead and act as agents of the king of Kandy. Mutual 
restraint upon each other existed up until the 1750s. The Dutch attempted 
to promote mixed marriages but the policy was a clear failure. 
In 1762 the king of Kandy, Kirti Sri Rajasinha, entered into 
negotiations with the English. This stimulated a great reaction by the 
Dutch. In 1764 they devastated Kandy and in 1766 the Dutch were granted 
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sovereignty over the 'maritime regions' that included all coastal areas up to 
four miles inland. The landlocked Kandyans were humiliated and resentful 
of the treaty. Control over the island remained in tense state for another 30 
years. In 1782 the English, who were at war with the Dutch in the War of 
American Independence, extended this globally (de Silva, 1997). 
In 1796 the English conquered the 'maritime provinces' of the 
island. The replacement by the British occurred without any territorial or 
commercial benefit to the Kandyan Kingdom. By a process of divide and 
conquer the British were ceded power by 1815. They did not respect 
treaties to allow unreserved acceptance of Buddhism. This resulted in early 
attempts at rebellion that were overwhelmed by superior military 'fire 
power'. 
By the beginning of the 19th century the mainstay of the Sri Lankan 
economy was subsistence agriculture. Even though major cities had road 
connections by 1830, most people lived in village communities whose 
communication was along jungle paths. The development of a network of 
modem roads and railways led to a much greater economic integration. 
Between 1840 and 1870 a coffee boom led the development of a great 
number of plantations on the island but came to a premature halt with the 
advent of the leaf fungus. The coffee picking season coincided with the 
slack season in the paddy fields of South India. Thousands of Indian 
workers began to make a seasonal journey even though the death rate was 
high whilst travelling across the malarial regions of the dry zone. From 
about 1860 there was a conversion to the production of tea in the highlands 
and rubber at lower elevations. The tendency was now for Indian labourers 
to settle down in the estates as a permanently resident labour force. From 
1891 to 1911 the population of Sri Lanka increased by 517,000 due to the 
migration of Indian Tamils that settled mainly in the central highlands. 
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A system of government was slowly evolving that included an input 
from the people of Sri Lanka (de Silva, 1997). Only with the advent of two 
world wars and the decline in power of the British Empire was 
independence granted to Sri Lanka in 1948. Since independence, transitory 
conflicts between linguistic and religious groups have occurred. The 
exception is the rift between the Sinhalese and the Tamils. 
India exerted a great influence as a powerful neighbouring force in 
favour of the Tamils. In 1964, an agreement between the two powers was 
reached. 525,000 persons were to be repatriated over a period of 15 years 
into India as long as 300,000 were accepted as citizens of Sri Lanka. In 
1974, the equal sharing of a further 150,000 was agreed. In 1986, Sri Lanka 
accepted 96,000 from what was originally the Indian share. Finally, by the 
early 1990s the Indian Tamils (Tamils that had emigrated within the 
previous hundred years) who still remained in Sri Lanka were granted 
citizenship. 
Sinhalese-Tamil violence began between 1972 and 1976 with Tamil 
youth in Iaffna and gained support to become the Liberation Tigers of 
Tamil Ee1am. This erupted into widespread riots in 1977. These troubles 
were to flare up onto a larger scale on a number of occasions. In 1983 the 
riots became so bad that 30,000 people crossed over to South India. Tamil 
refugees have been accepted in many parts of the world (- 100,000 in India 
225,000 in Europe and North America). This ongoing social unrest in Sri 
Lanka has made parts of the island hazardous. 
1.1.2 Population dynamics 
The greatest check on population size was food limitation. Even though 
great areas of the earth became populated the size of the human population 
remained relatively small. As man learnt to farm and increase the supply of 
food a subsequent rise in the population number ensued. The life span of 
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these early humanoids was short and susceptible to disease. Irrigation 
allowed crop size to flourish but these conditions were also ideal for 
expansion of disease. An increase in the population size also increased the 
number of hosts to infect. Small populations were prone to devastation by 
disease and only when a population size reached a critical level, over half a 
million, would populations have a greater chance of surviving the infection. 
Re-population would need to occur either by greater reproductive capacity 
or by migration from surrounding areas. In early times epidemiological 
barriers were present due to the isolation of different evolving centres. 
However, large groups of people in quest of trade or emigration could carry 
infectious agents with them and increase the chances of spreading disease. 
Areas closer to the equator represent areas with a greater number of 
more aggressive infectious diseases. Hence, north to south migrations or 
invasions would also have to contend not only with unfriendly endogenous 
populations but also with hostile new environmental dangers. The host 
popUlation on the other hand had to adapt to survive and may have 
developed innate defence mechanisms against disease. Short periods 
between episodes of the same infestation could result in increased survival 
rates of those who originally survived that would be passed on to their 
children. Fitness to exist against disease was probably achieved very early 
in history 
Historical records of human disease are poor but are present in some of 
the fIrst writings of humans. Around 2,000-3,000 BC 'The Epic of 
Gilgamesh' from Babylon describes pestilence. In chronicles from China 
around 1,300 Be there are also reports of pestilence. The Old Testament of 
the Bible records many plagues resulting in the death of large numbers of 
people. The exact nature of these diseases remains unknown but appears to 
occur in cyclical waves. Early diseases observed are thought to include 
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malaria, dengue fever, yellow fever, schistosomiasis, mumps, diptheria, 
tuberculosis and influenza (M'Neil, 1976). 
Growth 
The world population from the year 10,000 BC has been estimated, 
allowing for all known census documentation and the 'best guess' for 
sustainable population sizes (http://www.census.gov/ipc/www/worldhis.html). The 
world population size has only rapidly increased in the last 500 years. A 
census of the population of Sri Lanka has been conducted since 1871 
(http:www.statistics.gov.ll) and has shown an increase in size over that time 
period by almost 8 fold up to 18.6 million (Table 1.1). 
Table 1.1 Census figures for tbe population of Sri Lanka from 1871 to 1997 
Year Population (millions) 
1871 2.4 
1881 2.8 
1891 3.0 
1901 3.6 
1911 4.1 
1921 4.5 
1931 5.3 
1946 6.7 
1953 8.1 
1963 10.6 
1971 12.7 
1981 14.8 
1997 18.6 
Using these data and the estimate for world population size an 
estimate of the population of Sri Lanka can be extrapolated. The data are 
summarised as a population time line (Figure 1.1) highlighting some of the 
important migrations, mainly onto the island. 
From 10,000BC to 1,500AD the population size remained relatively 
small and the influence from external genetic input may have been large. If 
one generation is considered to cycle in 20 years 575 generations would 
have occurred to make that group relatively homogenous. In the last 500 
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years (25 generations) the population admixture would have been relatively 
small but a dramatic increase in the population size, over 20 fold in this 
same time period, may have skewed the relative importance of any group 
within the popUlation greatly, either up or down. 
Figure 1.1 Time chart to show the rise in the popUlation size in 
conjunction with migrations onto and from the island 
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The genetic variation observed demonstrates the extended influence 
from the Indian subcontinent. The purity of the migrants entering Sri Lanka 
needs to be considered and the resulting ethnic groupings should not be 
considered to be distinct. The number in each different ethnic group was 
estimated as part of the government ' s annual census (Table 1.2) 
(http :www.statistics.gov. ll) . 
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Table 1.2 
Mortality 
The 1981 census; highlighting the prevalence of the ethnic groups in 
the population 
Ethnic Group Prevalence (%) 
Sinhalese 74 
Tamil 18.2 
Moor 7.1 
BurgherslEurasian 0.3 
Malay 0.3 
Veddah 0.01 
Others 0.09 
In 1993, a world-wide survey into causes of death was conducted by 
the WHO (WHO, 1995). The death toll was about 51 million people and 
the biggest killers were infectious and parasitic diseases that accounted for 
nearly one third. Diseases of the circulatory system accounted for nearly 
one fifth. Causes of death differ dramatically between the developed and 
the developing countries. In the developed countries chronic diseases have 
become the major causes of death. Diseases of the circulatory system 
(primary heart disease and cerebrovascular disease, e.g. stroke) and cancer 
accounted for over 40% and infectious diseases accounting for less than 1 % 
of deaths. In the developing countries infectious disease accounted for 
41.5% of deaths as listed in Table 1.3. 
Sri Lanka has excellent health statistics (http:www.statistics.gov.I1) 
for a developing country. The present death rate is about 6.5 per 1000 and 
the infant mortality rate 16.5 per 1000 live births. Many of the disorders in 
Table 1.3, including all 5 of the most common causes of death, are still 
prevalent on the island. The island population would have been subjected 
to an array of these diseases for thousands of years. These disorders have 
contributed towards the selection of the genetic makeup of different people. 
As the quality of life increases the number of deaths due to infectious 
disease decreases resulting in a rise in the population. The nature of the 
cause of death changes and a switch to chronic disorders in more elderly 
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patients occurs. All age groups benefit from these decreases in mortality 
but the most sensitive group to poor health conditions are the under 5 years 
of age group and these are used as an indicator of a population's health. 
Table 1.3 Deaths due to infectious disease globally in decreasing order of 
prevalence 
Number Disease/Condi tion 
of deaths 
1-5X106 
Acute lower respiratory infections (<5 old) 
Diarrhoea including dysentery_ «5 -'years old) 
Tuberculosis 
Malaria 
Measles 
B 
105_106 AIDS 
Whooping cough 
Bacterial meningitis 
Schistosomiasis 
Leishmariasis 
syphilis 
Tetanus 
Hookwonn disease 
104_105 Amoebiasis 
Ascariasis (roundwonn) 
African trypanosomiasis (sleeping sickness) 
American trypanosomiasis (Chagas' disease) 
Onchocerciasis (river blindness) 
Meningitis 
Rabies 
Yellow fever 
Den.Eue haemorrhagic fever 
J encephali tis 
Foodborne trematodes 
Cholera 
<104 Poliomyelitis 
D!£htheria 
PI'!gue 
(Adapted from Table 5 of WHO, 1995) 
Since 1955, the fall in the mortality rate of children, under 5 years of 
age, in Sri Lanka has dropped by a factor of five. From 1995 to 1999 the 
death rate in this group was about 25 per 1000 live births and only Europe 
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had lower rates (Ahmad et ai., 2000). Individuals survIvmg include a 
greater number of those with debilitating disorders that may survive on into 
child bearing age to pass on their condition to another generation. It 
therefore follows that the total number of people with rare conditions is on 
the increase. This concurrent increase in chronic disease needs to be 
considered in all health care plans. The spectrum of genetic disorders seen 
is dependent on the range of selective forces, including infectious agents 
(Table 1.3), imposed on a population. 
The significance of these types of changes was illustrated in Cyprus 
shortly after the Second World War. Thalassaemia had not previously been 
described in Cyprus. However, after a major programme to eradicate 
malaria and an improvement in public health measures, a common form of 
anaemia not due to infection was observed in the children of the island. 
Later studies demonstrated a very high incidence of thalassaemia on that 
island (reviewed in Weatherall & Clegg, 2001). A similar pattern of events 
was noticed in Sri Lanka and suggests a similar situation. 
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1.2 The thalassaemia syndromes 
Haemoglobin is found in a wide variety of organisms in a broad 
diversity of forms. They are all considered to originate from a single 
ancestral gene and to have arisen by duplication followed by selection 
of adaptive sequence changes in a period of over 500 million years. The 
development of organisms from simple single cell to specialised 
multicellular forms could not have occurred without these molecules 
and their complex expression patterns have been investigated for over a 
hundred years. 
Although the cessation of expression of haemoglobin is not 
compatible with life, intensive study has shown that this gene has 
undergone many alterations and has been subjected to extreme selection 
pressure. Genetic disorders of haemoglobin are the most common 
monogenic disorder in the world with over 250 million carriers for a 
haemoglobinopathy. 
1.2.1 Normal structure and function of Haemoglobin 
The haemoglobins 
In 1863, Hoppe-Seyler coined the term "haemoglobin" to describe 
the oxygen-carrying pigment of blood. All human haemoglobins are 
tetramers with a molecular weight of 64,500 daltons. They consist of two 
a-like and two non a-like globin polypeptide chains, each of which has a 
single covalently bound heme group made up of an iron atom bound 
within a protoporphyrin IX ring. In humans, the six known different 
globin polypeptide chains are designated a, 13, y, 8, E, and Each chain 
consists of a specific sequence of amino acids. The primary structure was 
established for the a chain, containing 141 amino acids, and also for the 
cS and E-chain, that contained 146 residues (reviewed in Weatherall & 
Clegg, 2001). 
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The haemoglobins vary in structure during different stages of 
development, designed to meet different oxygen-transport requirements. 
During development two major 'switches' occur in the type of 
haemoglobins manufactured (Figure 1.2). Hb's Gower I Gower II 
(a2C2) and Portland are embryonic haemoglobins found in foetuses 
before 7 to 10 weeks of gestation (reviewed in Weatherall & Clegg, 
2001). From 5 to 10 weeks of gestation, the first switch involves the 
simultaneous decrease in and E-chain production and an increase in a-
and y-chain production (HbF;a2Y2)' The second switch occurs around the 
time of birth substituting 13- and 0- for y-chain production (HbA;a2J32 and 
HbA2;(202). 
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At birth, the normal foetal haemoglobin (HbF) levels are 64.8 ± 
1.2 % and for 15 days remain at the same level. A rapid drop occurs over 
the next 15 weeks down to 10.2 ± 1.2% after which the rate of decrease 
slows dramatically and adult levels of less than 1 % are reached by 3 to 4 
years of age (Colombo et al., 1976; Cheron et al., 1989). Normal adults 
have 97% HbA and 2-3% HbF with a minor trace of HbA2 (reviewed in 
Weatherall & Clegg, 2001). Other minor haemoglobin components are 
the result of post translational modification. 
In the neonatal period during switching from foetal to adult 
haemoglobin both y- and compete for a-chains. As a-chains 
bind to l3-chains in preference to y-chains a small amount of Hb Bart's 
(Y4) results. Hb Bart's was first described in patients with clinical 
features of thalassaemia. During normal development Hb Bart's 
disappears over the frrst six months of life and is not replaced by HbH 
(134) (reviewed in Weatherall & Clegg, 2001). This is partly due to the 
chemical properties of these monomers as Hb Bart's is a stable protein 
compared to its adult counterpart HbH. 
Functional Properties 
The affinity of haemoglobin for oxygen is essential for it to fulfil 
its physiological role. Haemoglobin has a sigmoid-shaped oxygen 
dissociation curve that allows large changes in oxygen binding with slight 
changes in the partial pressure of oxygen. Binding of oxygen to one haem 
molecule facilitates binding to the other three. The quaternary structure of 
haemoglobin was shown to exist in two states; oxy- or 'relaxed' (R) and 
deoxy- or 'tense' (T) without any stable intermediates (reviewed in 
Weatherall & Clegg, 2001). The number and nature of contact points 
between the a,- and chains changes between these two 
states. The al3 contact points are highly conserved and any mutations at 
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these sites can change the quaternary structure and possibly the affinity of 
haemoglobin for oxygen. Oxygen affinity is also affected by a number of 
small molecules and environmental factors including organic phosphate, 
peo2, temperature and pH. Haemoglobin is very sensitive to small 
changes in pH. In the body tissues the production of CO2 results in the 
formation of HC03- and W. Protons can combine with deoxy 
haemoglobin and stabilise this state. The lower oxygen affmity of 
haemoglobin facilitates oxygen unloading in the tissues (reviewed by 
Perutz, 1978). Excess oxygen in the lungs enhances the opposite changes 
in pH and pC02. 
Red cells have unusually high concentrations of 
2,3-diphosphoglycerate (2,3-DPG). One molecule of 2,3-DPG sits in a 
pocket in deoxyhaemoglobin bound to specific f3-chain residues (1, 2, 82, 
and 143 of both f3 chains). The importance of the binding is that 2,3-DPG 
stabilises the deoxy fonn of haemoglobin in preference to the oxy- form, 
thereby lowering the oxygen affinity of the molecule. The y chain of Hb F 
lacks the [3143 histidine residue, and the resultant decrease in binding of 
2,3-DPG to Hb F accounts for the increased oxygen affinity of foetal red 
cells compared to that of adult red cells (reviewed in Weatherall & 
Clegg, 2001). This has a great significance in disorders that elevate levels 
ofHbF. 
1.2.2 Abnormal structure and function of haemoglobin 
Background 
The first clear clinical description of a patient with the condition later 
to be termed thalassaemia, as opposed to other childhood forms of 
anaemia, was made in the fIrst part of the 20th century by Cooley and Lee, 
1925 (reviewed in Weatherall & Clegg, 2001). The name "Cooley's 
anaemia" is still used to describe transfusion-dependent 
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major. In Italy, at the same time, a similar though milder condition was 
described in adult patients, by Rietti (reviewed in Weatherall & Clegg, 
2001). By 1960, it became clear that thalassaemia was not just one 
disease but a set of syndromes and that the incidence was extremely 
widespread and not localised to the Mediterranean (reviewed in 
Weatherall & Clegg, 2001). 
Over the same time period different types of haemoglobin were 
observed that included HbA, HbF, HbS and HbC. These molecules 
were not just involved in development but also linked as the underlying 
molecular defect. By the 1950s, it was suggested that haemoglobin was 
controlled by a pair of genes, at loci that were not linked (reviewed by 
Weatherall & Clegg, 2001). This was consistent with the observation 
that the chemical structure of haemoglobin consisted of two identical 
half molecules by Ingram in 1956 and Perutz and others in 1960 
(reviewed in Weatherall & Clegg, 2001). 
In the same period, the molecular basis of thalassaemia was 
suggested to be a defect, not only in the structure, but also in the rate of 
production of globin (reviewed by Weatherall & Clegg, 2001). The 
sequence of these constitutive polypeptide chains was determined and 
Ingram demonstrated that HbS differs from HbA by a single amino acid 
substitution in the f3-chain (reviewed by Weatherall & Clegg, 2001). By 
1981, the globin genes had been sequenced (Baralle et ai., 1980; Lauer et 
ai., 1980; Lawn et ai., 1980; Slightom et aI., 1980; Spritz et ai., 1980) and 
paved the way so that molecular diagnosis for thalassaemia could be 
undertaken. Many studies have since been made to define the molecular 
lesions underlying the thalassaemia's and their global distribution 
(reviewed by Weatherall & Clegg, 2001). 
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Classification 
Genetic disorders of haemoglobin can be broadly placed into three 
groups. The first is that of the structural haemoglobin variants involving 
a change in the primary structure of one of the globin chains. The 
second are the thalassaemias that involve a reduction in the rate of 
production of globin(s) and the third group embodies a diverse set of 
conditions that result in the persistence of foetal haemoglobin. 
1.2.2.1 Structural variants 
Structural haemoglobin variants are common in many populations. 
These proteins have a substitution of one or more amino acids in at least 
one of the polypeptide chains. Many simple and rapid methods have 
been developed to characterise proteins by their chemical composition. 
These have been applied to whole red cell lysates rich in the protein 
haemoglobin. Identification of these haemoglobins was first reliant on 
protein analysis but has now switched to DNA analysis. The result has 
been the characterisation of over 800 haemoglobin variants 
(http://globin.cse.psu.edul). Haemoglobin variants can directly or in 
conjunction with a thalassaemia be associated with a serious health 
problem. The common variants (HbS, Hbe and HbE) are associated 
with disease but many of the rare variants are 'silent' and behave in an 
innocuous fashion. 
Structural variants can be classified into five groups depending 
upon their physiological effects; 
(i) Haemolytic anaemia that cause an increase in the destruction of 
red cells. These include unstable haemoglobins and those that 
cause red cell 'sickling'. 
(ii) Hereditary polycythaemia due to haemoglobins that have a high 
oxygen affinity. 
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(iii) Hereditary cyanosis due to those haemoglobins that have a low 
oxygen affinity. 
(iv) Thalassaemia phenotype type due to those haemoglobins that 
result in a reduced output of globin. These include highly unstable, 
chain termination mutants and chain fusion haemoglobins. Some 
haemoglobins behave differently in conjunction with either a 
normal or thalassaemic counterpart. 
(v) Innocuous haemoglobins that still function like HbA. 
These classifications are simplistic and overlap greatly and their 
importance depends upon the prevalence of these variants. HbS and 
HbC both cause haemolytic anaemia and reach polymorphic levels in 
parts of Africa. HbE is found at high frequencies in Asian populations 
that also express high levels of {3-thalassaemia (reviewed in Weatherall 
& Clegg, 2001). 
1.2.2.2 The thalassaemias 
Thalassaemia syndromes are genetic disorders characterised by 
absent (globin 0) or deficient (globin +) synthesis of one or more of the 
normal globin chains. A reduction in the production of any globin chain 
defines that type of thalassaemia. 
a-globin gene locus 
The human a-globin gene cluster is localised to the distal segment of 
the short arm of chromosome 16p13.3 approximately 130kb from the 
sub-telomeric region (Flint et at., 1997). The entire telomeric region is 
G-C rich (54%) with a modal variation with peaks 80-90kb apart 
(troughs 46% and peaks 63%). Fourteen sharp peaks of high G-C 
content were observed that corresponded greatly with the CpG islands. 
The region is rich in repeat elements including CpA, short tandem 
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repeats and Alu repeats. The repetitive DNA has similarities to 
sequences at the ends of other human chromosomes that could allow the 
genetic exchange between non-homologous subtelomeric regions (Flint 
et al., 1997). 
The a-cluster is comprised of three expressed genes (S, az and 
al), one non-expressed gene (8) and three pseudogenes (CPS, cpaz and 
CPal). Each a-gene is divided into coding regions (exons) separated by 
intervening sequences (introns). The exon and intron-l of the two a-
genes have identical sequences. Intron-2 shows some sequence 
divergence but most differences are seen in the 3' untranslated region. 
There are also extremely important regulatory sequences, which lie 
outside the gene itself, that are essential for the expression of this gene. 
Three highly conserved promoter elements 5' of the gene (ATA box, 
CCAAT box and CACCC sequence) and the polyadenylation signal 3' 
of the gene (AATAAA) are involved in the initiation of transcription 
and subsequent cleavage of the RNA transcript. Regulation of the a-
cluster is controlled by a locus control region (HS-40) positioned closest 
to the telomere (Flint et a!., 1997). The HS-40 is a DNase I 
hypersensitivity site that is thought to be the major regulatory element 
whose removal results in the inactivation of expression of a-globin 
(Higgs et al., 1990). 
Regulation of the a-globin locus 
The control of a-globin expression is similar to any gene expression. 
DNA is 'made available' so that DNA sequence elements, gene 
transcription and translation can take place in a highly controlled 
fashion. Anything that upsets this balance can result in a reduced or 
altered expression of the a-chains (Table 1.4). If there is a deficiency of 
a-chains then the level of Hb Bart's, in the neonate, is increased which 
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may be the most sensitive indicator for a-thalassaemia (Weatherall, 
1963). Elevated levels of this haemoglobin have been used as a crude 
indicator of the level of a-thalassaemia within many different 
popUlations (reviewed in Weatherall & Clegg, 2001). 
Table 1.4 Main a-cluster gene re-arrangements 
Condition/Genotype Phenotype Number of 
mutations identified 
Duplicated ?Normal 3+ 
Dllplicated a-gene aaa+ Normal 5 
Single a-gene deletion -a or a- a+ 7 
a- aO 1 
Double a-gene deletion (small) -- aO 20 
Double a-gene deletion (large) -- aO 8 
Upstream deletions aa aO 12 
ATR-16 -- aO 17 
Non-deletion change of either a-gene aTaor aaT a+ 42 
ATR-X aa a+ 33 
a-gene insertions 
The a-globin gene is thought to be the ancestral gene of all the 
other globin genes that resulted by gene duplication and subsequent 
alteration and thus is part of an ongoing evolutionary process. 
rearrangement has been reported (Weatherall & Clegg, 2001) but its 
clinical significance is uncertain. Any effect would only be observed 
early in embryogenesis as the genes are normally switched off early in 
pregnancy. The clinical significance of extra a-genes becomes apparent 
when found in combination with (Trent et ai., 1981; 
Kanavakis et ai., 1983; Kulozik et ai., 1987; Garewal et ai., 1994; Oron-
Karni et al., 1994; Ho et ai., 1998a; Beris et ai., 1999). The 
imbalance exaggerates and a greater degree of erythropoiesis results in 
intermedia. 
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a-gene deletions 
The primary cause of reduced a-chain expreSSlOn is due to 
deletions that remove one or both of the a-genes (reviewed III 
Weatherall & Clegg, 2001). The a globin genes are embedded within 
two highly homologous, 4kb duplication units. It is thought that the 
homologous regions have resulted from gene duplication and that the 
non-homologous segments may have arisen subsequently by insertion 
of DNA. Three homologous subsections (X, Y and Z) are divided by 
non-homologous elements (I, II and III). The most common deletions or 
insertions occur due to misalignment of the chromosomes during 
recombination. Reciprocal recombination, between Z segments (3.7 kb 
apart) produce, chromosomes with only one a gene (_a3.7) that cause a-
thalassaemia or chromosomes with three a genes (aaaanti3.7). 
Recombination between homologous X segments (4.2kb apart) also 
produce chromosomes with one a gene (_a4.2) that cause a-thalassaemia 
or with three a-genes (aaaanti4.2). Further recombination events 
between the resulting chromosomes (a, aa, and aaa) can occur and 
may even result in a patient with even more a-genes (aaaa) on one 
chromosome. Single a-gene deletions result in a+ -thalassaemia and are 
usually clinically and haematologically 'silent'. A different single gene 
deletion associated with aO -thalassaemia may involve antisense RNA 
transcribed from the complementary strand (Tufarelli personnel 
communication). 
Mutations that remove both a-globin genes are much less 
common but can result in no a-gene expressed from that chromosome 
(ao-thalassaemia). Heterozygotes have a similar phenotype as 
homozygous a+ -thalassaemia patients. Upstream deletions that remove 
a segment of DNA associated with an erythroid-specific DNase 1-
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hypersensitve site (HS-40) can ablate downstream globin expression 
(Hatton et al., 1990; Higgs et al., 1990). 
Another fonn of aO-thalassaemia is that of ATR-16 that is linked 
to mental retardation. Only a small number of patients with this disorder 
have been studied but the patients fail to inherit the entire a-cluster 
region on one chromosome and in some cases have other chromosomal 
abnormalities (reviewed in Weatherall & Clegg, 2001). 
Non-deletion changes of the a-gene 
Mutations that do not delete the genes include small changes in 
and around either a-gene, the non-deletion a-thalassaemias. These 
changes down-regulate the expression of a-chains by a number of 
different mechanisms. The change may result in a truncated, elongated 
or nonsense protein that may interfere with the normal globin chain 
subunits. This may have a direct effect on haemoglobin function or 
result in a protein that is unstable either as an mRNA or as a protein. 
The change in the sequence may involve motifs in the DNA that 
regulate enhancers, promoters, splicing or termination. Some 
mechanisms have still not been unravelled. 
Another fonn of non-deletion a-thalassaemia is linked with 
mental retardation. No structural abnormalities of the a-cluster or of 
16p have been found. All patients are male with mild a-thalassaemia 
and have a severe mental retardation with a remarkably similar facial 
appearance. This unusual syndrome results from an X-linked 
abnormality. The ATR-X protein is a novel member of the SNF2 
subgroup of a superfamily of proteins with ATPase and helicase motifs. 
This group of proteins is involved in a wide variety of cellular functions 
including the regulation of transcription. 
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a-thalassaemia phenotypes 
There are four clinical states depending upon the number of cx-
genes affected. The most severe form is Hb Bart's hydrops that have no 
functional a-genes. This condition is found in infants who are 
spontaneously aborted or die of severe hydrops shortly after birth (Lie-
Injo & Jo, 1960). In these usual cases, over 80% of the haemoglobin is Hb 
Bart's (Y4), which has a very high oxygen affinity, causing severe tissue 
hypoxia; the remainder is Hb Portland and Hb H (B4). A handful of 
these cases have survived (some with the help of intra-uterine 
transfusions) and are treated in a similar fashion to B-thalassaemia major 
patients (reviewed by Chui & Waye, 1998). 
An intermediate form is Hb H disease that has a single functional cx-
gene with anaemia, hepatosplenomegaly and jaundice. The red cells are 
microcytic and their haemoglobin content is decreased. On the peripheral 
smear, poikilocytosis (abnormally shaped), polychromasia (variation in 
haemoglobin content), and target cells are seen. Hb H inclusions are 
easily seen following incubation with 1 % brilliant cresyl blue. Studies of 
globin chain synthesis suggest a alB ratio of 0.3 to 0.4, rather than 1. This 
imbalance causes 20% or higher levels of Hb Bart's at birth and Hb H 
levels of 4% to 30% after the switch from y- to B-chain synthesis is 
complete. Deficiency of a-chain synthesis causes a concomitant drop in 
HbA2 (a20z) levels to 1-1.5% (reviewed in Weatherall & Clegg, 2001). 
Heterozygous a,0 -thalassaemia and homozygous a+ -thalassaemia 
individuals are relatively asymptomatic, but have a mild microcytic 
anaemia (10-12 g of haemoglobin per 100 ml of blood) and mild 
poikilocytosis and anisocytosis (excessive variation in size). At birth, Hb 
Bart's may reach 5% in cord blood and HbH can sometimes be observed 
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at very low levels. The synthesis ratio is 0.6 to 0.75 (reviewed in 
Weatherall & Clegg, 2001). 
Silent carriers, with the deletion of a single a gene (-a/aa), present 
with a slightly reduced or nonna! set of red cell indices. The reduction of 
a mRNA is insufficient to produce significant globin chain imbalance 
(a/f3 = 0.8 to 0.9) (reviewed in Weatherall & Clegg, 2001). 
Non-deletion forms of a-thalassaemia that alter either the al or az 
gene can also cause a loss of a-gene expression (aT for -) and were first 
described in 1977 (Kan et ai., 1977). At present there are over 40 types 
that appear to have a more severe effect on a-globin gene expression 
compared with simple deletions that remove one or other of the a-genes. 
In the heterozygous condition they tend to be associated with normal or 
mildly reduced red cell indices but in the homozygous, hemizygous or 
compound heterozygous condition are associated with HbH disease. This 
may be due to the bias in which patients with a more severe condition 
have been studied. However, there does not appear to be a compensatory 
increase in the expression of the remaining functional a-globin gene. 
fJ-globin gene locus 
The human gene cluster is localised on the short arm of 
chromosome 11 embedded in an array of olfactory genes (Bulger et ai., 
1999). The entire region has a balanced pyrimidine:purine content but 
has both Alu and Ll families of repeats. 
The is comprised of five expressed genes (E, Gy, cS 
and one pseudogene The is split into coding regions 
separated by intervening sequences (introns). All the globin genes show 
a high degree of sequence homology. A similar set of promoter 
elements and a transcription cleavage signals exist around the 
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gene as described in the a-globin gene. The are controlled by a 
locus control region (LCR) positioned upstream of the £-gene. These 
are a group of DNase I hypersensitivity sites akin to the HS-40 in the cx-
cluster. 
Regulation of the fJ-globin locus 
The control of expression is similar to a-globin expression. 
However, along with all the control elements and protein structures that 
accompany transcription and translation, switching and coexpression 
between different forms of the can occur. Anything that upsets 
the normal chain balance can result in a reduced or altered expression of 
the globins. The multitude of different mutations results in a 
diverse set of clinical conditions (Table 1.5). 
Table 1.5 Main tJ-c1uster gene arrangements 
Condition! Genotype Phenotype Number of mutations identified 
Insert tJ +6-7kb (3+ 1 
J1:Kene m Normal 3+ 
Fusion Qli Jr+iHbF 3 
A.y(3 Normal 1 
Deletion /3+ or 13° 14 
+iHbF 
HPFH 6 
10/ (3+ 1 
(oj3)u j3++iHbF 8 
J:Jl0 y+ or yO 1 
(A.yoj3)o Normal 10 
(e<yyoj3)o j3u 6 
Non-deletion j3T (3+ or /30 167 
Dominant 31 
ST 0+ or SO 18 
Y HPFH 13 
Unlinked Normal 13- iHbP 2 
cluster 
Trichothiodystrophy Nonnal 13- W 1 
cluster 
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/3-gene insertions 
Gene insertion within the f3-gene is extremely rare in and has only 
been found in an isolated case. 6-7kb of sequence was inserted into the 
second intron and resulted in the reduction of nonna! expression from that 
allele down to about 15% (Divoky et al., 1996). Gamma gene 
rearrangements, including extra gamma genes, have been observed in 
some populations especially in the Pacific Islands (Phillippon et al., 1995). 
p.gene deletions 
Many different f3-c1uster mutations have been described mostly in 
isolated families. They are classified in accordance with the genes that 
have been deleted. Mutations that affect the f3-gene or f3- and 8-genes 
have been found in nearly all popUlations. These mutations have been 
found in individuals with reduced red cell indices. Heterozygous 
deletions that extend further 5' to the f3-gene to remove the 8- and 
genes, (Ay8f3)o thalassaemia, have microcytosis, hypochromia but no 
anaemia. Deletions that remove the f3-gene and extend 3' of the f3-gene 
form a set of conditions called hereditary persistence of foetal 
haemoglobin (HPFH). Patients with these mutations have nonna! red 
cell indices but elevated levels of HbF. Patients heterozygous for even 
larger deletions (cGyY8f3)o that remove nearly all the cluster are 
associated with the clinical phenotype of f3-thalassaemia trait. 
Homozygosity for this condition would be incompatible with life. 
Upstream deletions led to the discovery of the importance of the LCR 
(reviewed in Weatherall & Clegg, 2001). 
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Non-deletion changes in the p.gene 
Nearly 200 smaIl aberrations are found in or around the {3-gene. 
These changes down regulate the expression of {3-chains by a number of 
different mechanisms (reviewed in Weatherall & Clegg, 2001). 
Gene expression is a dynamic process that requires a balance 
between transcription, translation and degradation. The correct 
positioning of this transcription machinery is brought about by 
recognition of specific DNA sequences, before each gene, under the 
control of the LCR. The transcription complex is a multiprotein 
complex including RNA polymerase that transcribes DNA into mRNA. 
Many cofactors are required including basal transcription machinery as 
well as erythroid specific factors that include GATA-l, NF-E2, EKLF, 
FKLF and SSP. Pre-mRNA production requires the correct initiation, 
elongation and termination of the message. The pre-mRNA is then 
processed to splice out all introns and to have a cap and a 
polyadenylation signal. The resultant mRNA undergoes translation of 
the nucleotide sequence into a polypeptide. The polypeptide chains are 
then assembled and can be post-translationally modified into functional 
proteins. Unstable or damaged proteins are marked for degradation. A 
problem at any part of this complex process can result in the aberrant 
expression of any globin polypeptide. 
The most common errors occur in the primary structure in or 
around the gene and cause a reduced expression of that subunit. 
Mutations involving promoter or enhancer motifs down regulate 
expression. Changes within the exons or introns may result in a 
truncated, elongated or nonsense protein that may interfere with the 
normal globin chain subunits. This may have a direct effect on 
haemoglobin function or result in a protein that is unstable either as an 
mRNA or as a protein. Conversely dysfunctional haemoglobins can 
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interfere with the nonnal tetramer and result in a dominant fonn of 
thalassaemia. 
Several loci unlinked to the have been identified as 
associated with the expressed phenotype of this cluster. Specific 
markers on chromosome 6q were found to be associated with an 
elevated level of HbF in an Indian family (Craig et at., 1996) and cases 
of were found associated with mutations in the general 
transcription factor TFIIH in individuals with trichothiodystrophy 
(Viprakasit et al., 2001). 
p-thalassaemw phenotypes 
The can be classified into three levels of severity. 
The most serious fonn is major. At birth, affected infants 
are relatively normal because the change from y-chain synthesis to 
synthesis has not occurred. However, by 6 months of age the 
infant develops a severely microcytic anaemia with anisocytosis, 
poikilocytosis and polychromasia (reviewed in Weatherall & Clegg, 
2001). To maintain an adequate haemoglobin level, transfusions are 
usually required every 4 to 8 weeks. Affected children develop 
hepatosplenomegaly secondary to extramedullary hematopoiesis, and a 
characteristic facial appearance due to excessive intramedullary 
hematopoiesis. The bones have expanded marrow cavities resulting in 
pathologic fractures and a "hair-on-end" appearance on skull films. Other 
complications include cholelithiasis, susceptibility to infections, 
secondary hypersplenism, and delayed growth and maturation. Excess 
iron deposited in the heart, pancreas, liver, and other organs, damages 
tissue and leads to cardiac failure, arrhythmias, diabetes mellitus, and 
liver failure (reviewed in Weatherall & Clegg, 2001). 
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Individuals heterozygous for are usually 
asymptomatic. They have a mild anaemia with decreased MCV and MCH 
and a raised HbA2• Chain synthesis studies in most 
heterozygotes yield ratios of 1.5 to 2.5. Microcytosis, anisocytosis, 
poikilocytosis, and targeting and stippling of the red cells can be seen on 
the blood smear. 
intermedia is a condition between the major and 
minor syndromes showing a moderate anaemia with decreased MCV and 
MCH and a raised HbA2• Transfusions are only required on occasions in 
these patients. The condition may be due to the patient having only mild 
molecular lesions or severe molecular lesions in combination with a 
modifying factor (Ho et al., 1998b). 
Foetal haemoglobin may be increased in and 
hereditary persistence of foetal haemoglobin, Dl trisomy, some cases of 
thyrotoxicosis, megaloblastic and aplastic anaemia, leukaemia and 
various malignancies involving marrow, sickle-cell anaemia, and during 
pregnancy (reviewed by Cooper & Hoagland, 1972). 
Interaction o/thalassaemia with haemoglobin variants 
Thalassaemia and structural variant haemoglobin genes mayor may 
not interact. An interacting thalassaemia gene is one that causes an 
increased level of the variant haemoglobin chain in the individual 
heterozygous for the variant gene and a thalassaemia gene. When the 
presence of both the thalassaemia and variant genes do not increase the 
level of the haemoglobin variant, then the thalassaemia is non-interacting. 
a-thalassaemia and a-chain variants 
Patients with aO -thalassaemia and also Hb Q-Thailand have a 
clinical picture similar to that of Hb H disease (Lie-Injo et aI., 1979). 
33 
Patients with Hb G-Philadelphia are found with the amount of the variant 
observed in a tri-modal pattern (Baine et ai., 1976). Individuals with 22% 
Hb G-Philadelphia have three normal a genes in addition to a aG-Phil gene 
(aaJaG-Phila). Individuals with 30% Hb G-Philadelphia have a single a G-
Phil gene and two normal a genes (aaJaG-) and those with 41 % Hb 
G-Philadelphia have one chromosome containing a single cP gene and 
another with a single a gene (a-laG -) (Sancar et ai., 1980). 
fJ-thalassaemia and pvariants 
In Hb SIB-thalassaemia, the B-thalassaemia gene interacts with the 
W gene in the heterozygote to increase the level of Hb S near Hb SS 
levels. The Hb SIB-thalassaemia compound heterozygote has a milder 
clinical course than the Hb S homozygote, and splenomegaly is a 
common physical finding. Anaemia is present in Hb SIB-thalassaemia and 
is characterised by microcytic red and target cells with occasional sickled 
forms (Serjeant et ai., 1979). 
The first description of HbFlB-thalassaemia was made by Minnich 
and colleagues in 1954 (reviewed in Weatherall & Clegg, 2001). The 
base change at codon 26 leads to the partial activation of 
a cryptic splice site resulting in a proportion of abnormally spliced 
mRNA (Orkin et ai., 1982a) and less HbE mRNA. In addition HbE is 
thought to be mildly unstable and susceptible to oxidant damage. HbE 
heterozygotes have about 25-30% HbE and are clinically normal and 
homozygotes for this condition are mildy anaemic. In homzygotes for 
this haemoglobin variant a very mild anaemia can be observed with 
little or no HbF (reviewed in Weatherall & Clegg, 2001). HbE is most 
commonly found in combination with BO - or severe B+ -thalassaemia and 
presents in a wide spectrum of forms. Patients can be similar to the 
34 
severest forms of f3-thalassaemia or conversely remam as 'silent 
carriers'. The rationale for this diversity is still poorly understood but 
the level of HbF is high in the cases that present with a milder 
phenotype and lower in those with profound anaemia. 
DNA haplotype analysis to map globin genes and its regulators 
DNA sequence variation is abundant in wild populations. All new 
variations start as a mutation that alters the primary structure of DNA. 
These alterations may occur at any point and depending upon that 
location may change the function of a protein. Such mutations may 
confer selective advantage or disadvantage or may be neutral to the 
survival of the host. The more advantageous the ensuing phenotypes or 
the older the age of the mutation results in a higher prevalence of the 
mutation in a popUlation. Each mutation may be advantageous to 
different populations depending on the selective pressures that 
popUlation is subject to. Mutations can take on many forms but the most 
common types are point substitutions. These single nucleotide 
polymorphisms (SNPs) can help unravel the change in populations to 
determine if they have migrated or have arisen on more than one 
occasion. Such selection forces can also help understand the 
susceptibility to change that human DNA can undergo. 
The fIrst DNA polymorphism described in the f3-gene was Hpa-1. 
Its presence was linked to the normal expression of HbA and its absence 
linked to the expression of HbS (Kan and Dozy, 1978a). An intensive 
search was made for restriction endonuclease site polymorphisms along 
the f3-cluster and led to the recognition of 17 common polymorphisms. 
Of these, 14 were found in all racial groups and were termed 'public' as 
opposed to 'private'. Patterns of DNA polymorphisms along a 
chromosome are termed haplotype. Several of these polymorphisms are 
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linked to each other and some fOlTIl part of the framework of the 
Only seven of these sites are routinely used to characterise the 
and are arranged around a hot spot for recombination between the 0-
and (Figure 1.3). Hence, the cluster is described as having a 5' 
and a 3' haplotype arranged around this hotspot. 
Figure 1.3 Schematic of the a- and [3-gIohin gene clusters to show the 
arrangement of the genes and some polymorphisms 
(BS = DNase hypersensitivity sites; LCR = locus control region; 
URR = upstream regulatory region; HVR = hypervariable region; 
SIMIL = small! medium! large; PZlZ = pseudozetaJ zeta) 
(Restriction enzymes: Acc I; Ava II; Bam HI; Bgl II; Hind II; Hind III; Pst I; 
Rsa I; Sac I; Xba I and Xmn l). 
The scale on both clusters is lOkb between vertical bars. 
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Common sequence variation 111 the must be extremely 
tightly linked to any mutation that occurs in or around the gene and can 
be classified as part of that association or framework as reviewed in 
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3' 
3' 
Orkin and Kazazian (1984). Population based background haplotype 
have been determined (Flint et al., 1993) and the non-random 
association of these haplotypes with {3-thalassaemia mutations observed 
(Antonarakis et aZ., 1982). The assessment of the different biallelic 
markers were originally performed by Southern blot analysis but PCR-
RFLP has substantially improved the ability to genotype many 
individuals rapidly (reviewed in Old, 1996). 
In a similar fashion, the a-cluster has also been screened for 
restriction endonuclease site polymorphisms and multiallelic genetic 
markers (Higgs et aI., 1986). Nine of the most common polymorphisms 
have been used to obtain background baselines to observe the 
heterogeneity of different haplotypes associated with many populations 
(Figure 1.3) (Flint et at., 1993). Recently, these sites have been 
successfully genotyped by PCR or by PCR-RFLP to allow a rapid 
popUlation screen to be made (Miles et al., 2001). 
Pathophysiology 
The symptoms of thalassaemia are mainly caused by ineffective 
erythropoiesis. Red blood cell precursors are extensively destroyed in the 
bone marrow leading to ineffective red cell maturation. Peripheral red 
cells are prone to haemolysis and hence have a shortened 'lifespan'. 
Microcytic hypochromic anaemia results in a positive feedback regulation 
for erythropoiesis and a massive expansion of bone marrow and this 
further exacerbates the condition (reviewed in Weatherall & Clegg, 
2001). 
In the thalassaemia syndromes there is reduction or ablation of 
synthesis of the affected globin chain. The failure in {3-globin production 
leads to imbalance in Ct- and {3-globin synthesis (Weatherall et al., 1965; 
Weatherall & Clegg, 1969) as the unaffected chain continues to be 
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synthesised at relatively norrnallevels. The resultant imbalance causes 
aggregation and precipitation of excess unpaired a-chains. Excess a-
chains aggregate in nucleated erythroid precursors in the bone marrow 
causing dyserythropoiesis. Red cells that enter into circulation are clonal 
and tend to be enriched for those containing HbF. Cells with excess a-
chains become targeted for haemolysis and sequestration by the spleen. In 
contrast, in a-thalassaemia there is an excess ofY4 (Hb Bart's) or (34 (HbH) 
chains. These tetramers are more soluble and can be destroyed by 
proteolysis. Inclusion bodies can be seen in mature erythrocytes (a 
reflection of the magnitude of excess (3-chains) followed by haemolysis 
(Bank & O'Donnell, 1969). Indeed patients with both homozygous (3-
thalassaemia and a-thalassaemia have a more even chain balance, less 
globin precipitation and hence more effective erythropoiesis (Weatherall 
etat., 1981). 
Haemolysis is associated with progressive splenomegaly. If the 
spleen is removed, cell destruction continues at a decreased rate in the 
liver, and the number of red cell inclusions may increase greatly. The 
large number of erythroid precursors expands the marrow cavities, and 
bone deformities, thinning, and occasional pathologic fractures result 
(reviewed in Weatherall & Clegg, 2001). 
Iron overload is a major complication in thalassaemia. Iron 
accumulation results from increased gastrointestinal absorption stimulated 
by the anaemia, blood transfusions, and decreased utilisation for 
haemoglobin synthesis. Deposition of excess iron causes damage to the 
heart, pancreas, and other tissues. The major causes of mortality are due 
to excessive iron deposition as a result of blood transfusions and increased 
gastrointestinal absorption (Bannerman et at., 1964) and overwhelming 
infections following splenectomy. 
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Management and treatment of thalassaemia 
Pre-natal diagnosis (PND) and a programme of birth selection can 
prevent the birth of affected individuals. For maximum benefit of genetic 
counselling, heterozygotes should be identified before they bear affected 
children. In some communities this is an unacceptable practice 
contravening either moral or religious boundaries. However, the 
procedure has become widely used and in some communities couples are 
required to perfonn premarital blood tests to avoid the possibility of 
having an affected child. 
Blood transfusions immediately replace the lack of fully functional 
red blood cells to allow tissue oxygenation but unfortunately introduce 
extra iron into the body that leads to iron overload. Iron chelation therapy 
clearly reduces the incidence of iron-related organ damage and prolongs 
survival of patients with severe thalassaemia (Olivieri et al., 1994). 
However, side effects of transfusions include transmission of disease 
agents such as hepatitis and cytomegalovirus infections, isoimmunization 
to minor blood groups and sensitivity to plasma antigens (reviewed in 
Weatherall & Clegg, 2001). 
Splenectomy has an immediate effect by halting the removal of 
immature or defective red blood cells and prevents pooling in the spleen. 
The release of a mass of ineffective erythropoietic tissue can temporarily 
provide great benefits especially during periods of growth. However, if 
carried out early in life splenectomy can leave children more prone to 
serious infection (reviewed in Weatherall & Clegg, 2001). 
Allogeneic bone marrow transplantation using related donors has 
been used in a large number of patients, predominantly in Europe, with 
disease-free survivals in the range of 80 to 95% (Lucarelli et al., 1990). 
HLA matching of donor and recipient must be near identical for a 
successful graft. Better outcomes are associated with adequate iron 
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chelation and the absence of significant hepatic disease. Nowadays, cord 
blood is seen as a rich source of stem cells, pluripotent precursors of 
different blood lineage and can be used in both homologous and 
heterologous transplants. 
Patients with unusually high levels of HbF tend to have a milder 
disease and any augmentation in the level of HbF should diminish the 
severity of the· disease. In preliminary studies, hydroxyurea and butyrate 
derivatives have shown promise in ameliorating anaemia (Jane & 
Cunningham, 1998; Olivieri & Weatherall, 1998). Pharmaceutical 
companies continue the search for effective pharmacological agents. 
Gene therapy has been proposed as a preferred method so that the 
body can regulate the nonna! globins. Methods for insertion of DNA into 
eukaryotic cells include the use of viral or retroviral transfer, liposome 
mediated transfer, targeted gene transfer, artificial chromosomes and 
antisense oligonucleotides. Technical as well as ethical problems remain 
and these therapies remain to be resolved in the future (reviewed in 
Weatherall & Clegg, 2001). 
Distribution of haemoglobinopathies 
Thalassaemia has a high incidence in a broad region extending 
from the Mediterranean basin and parts of Africa, through the Middle 
East, the Indian Sub-continent, Southeast Asia and Melanesia and out into 
the Pacific. Elsewhere, thalassaemia occurs at very low frequencies. 
Countries in Central and South America have individuals with 
haemoglobinopathies due to migration from Europe. The mutation rate 
for 'thalassaemia' appears quite high and when coupled with the 
movement of populations result in the sporadic occurrence of 
thalassaernia in most populations. The prevalence of 
haemoglobinopathies in any region is taken as the sum estimate of all 
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the populations within that region. Vast differences occur between 
closely located populations so that micromapping of each area needs to 
be assessed. 
aO -thalassaemia is generally not found except in isolated families 
in most parts of the world. The exceptions are that of the Mediterranean 
basin where the __ MED and _(a)20.5 gene deletions occur and the Far East 
that has a relatively high frequency for the __ SEA deletion. In contrast, the 
a+-thalassaemia has been reported at polymorphic frequencies in parts 
of Africa, Europe, the Middle East and Asia (reviewed in Weatherall & 
Clegg, 2001). 
and some clinically important variants 
(HbC, HbD, HbE and HbS) reach very high frequencies in many sub-
tropical and tropical countries. trait is generally found at 
frequencies below 10% but these variants may constitute up to 50% of 
some regional groups. A wider variety of molecular lesions cause 
thalassaemia with 21 different mutations accounting for over 80% of the 
global incidence of Each country appears to have its own 
particular spectrum of about 15-25 mutations with 2 or 3 of these 
mutations predominating (reviewed in Weatherall & Clegg, 2001). 
The high prevalence of haernoglobinopathies in sub-tropical 
climates is not just a random phenomenon. It was suggested that 
patients with heterozygous {3-thalassaernia have some form of selective 
advantage described by Silvestroni & Bianco in 1948 (reviewed in 
Weatherall & Clegg, 2001). This advantage was proposed as a greater 
resistance of red blood cells to invasion by merozoites that cause 
malaria (reviewed in Weatherall & Clegg, 2001). This associated 
protection was extended to the structural variant HbS and more recently 
that HbC may confer an even greater protection against Plasmodium 
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Jalciparum (Modiano et ai., 2001». This theory has widened to include 
a+-thalassaemia protection against severe childhood disease (Allen et 
ai., 1997). Hence, different forms of thalassaemia are prevalent in some 
regions and not others due to a primary event that allowed selective 
advantage. This enabled pockets of individuals with particular 
genotypes to flourish. The presence of one type of haemoglobinopathy 
negates the necessity for another and so the regional incidence appears 
non-uniform. 
1.3 Haemoglohinopathies in Sri Lanka 
Very little is known about the occurrence and the molecular basis 
of u- and {3-thalassaemia in Sri Lanka. Structural variants have been 
described by a number of different studies but the true incidence on the 
island remains unknown. 
a-thalassaemia 
Two case reports have been published. The first was of a child of 
5 months of age who presented at hospital with fever, pallor and icterus. 
She already had a history of breathlessness, listlessness and fever. Upon 
investigation she was found to have a severe anaemia and the erythrocytes 
had inclusion bodies. The haematology of both parents appeared normal 
(Nagaratnam & Sukuram, 1967). The second case was a Muslim boy, 25 
years old, from Matale who presented at hospital with a haemolytic 
anaemia, pallor, mild icterus and hepatosplenomegaly. Upon investigation 
by electrophoresis he was found to have a fast running haemoglobin 
consistent with HbH (de Tissera et ai., 1988). The molecular lesion 
underlying either of these cases remains obscure. 
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(3-Thalassaemia and structural variants 
Typical cases with Cooley's anaemia were fIrst described in three 
different families (de Silva & Weeratunge, 1951) and also in a few more 
families later in the 1960s (Nagaratnam & Sukumaran, 1967; 
Parameshwaran, 1967). A slow running variant was described in 2/9 
Veddahs (Graff et al., 1954). HbE was formally confirmed in this 
population and a carrier frequency of 4% estimated (Lehman, 1956). 
Four Veddah villages were studied and showed an extremely varied 
incidence ranging between 0% to over 40% (Wickramasinghe et al., 
1963). Patients with were described whose clinical 
manifestation varied greatly (Nagaratnam et ai., 1958). Three cases of 
HbSlf3-thalassaemia presented at hospital in Colombo and were 
described as having a severe anaemia and hepato-I cardio-I 
splenomagaly (de Silva et al., 1962). The variant HbD was also found in 
a few families (Nagaratnam, 1989). 
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Chapter 2 Materials and Methods 
2.1 Ethical permission 
Approval for the study of patients from Sri Lanka was obtained from 
the Oxford Research Ethics Committee, the Oxford Tropical Research 
Ethics Committee, the Ethics Committee of the Faculty of Medicine at the 
University of Colombo and by the Ministry of Health Sri Lanka. 
Permission to investigate patients referred to the National 
Haemoglobinopathy Reference Laboratory was obtained by the referring 
physicians. Consent to conduct the Homerton Hospital cord blood study 
was organized by Dr A. Stephens. 
2.2 Patients 
Sri Lanka: School children survey 
Capillary blood samples were collected by Dr S. de Silva, from over 
1600 children and some of their teachers attending 15 different schools 
around the island (Figure 2.1). The schools were widely selected and 
included a Hindu Teaching college. The degree to which these samples 
represented the general population was not assessed as they were collected 
anonymously without a questionnaire. Specimens were successfully 
collected from eight provinces (Central, Eastern, North Central, North 
Western, Sabaragamuwa, Southern, UV A and Western) but the ninth 
province (Northern) was deemed too dangerous because of the ongoing war 
between the Government troops and the Tamil Tigers. Blood samples were 
taken into micro-haematocrit tubes, sealed at each end, and maintained at 
4°C until they were transported to Oxford frozen on dry ice. 
Sri Lanka: Hospital based patients 
Patients with a clinical diagnosis of thalassaemia attending clinics as 
outlined in Figure 2.1 were included in the study. Prior to blood 
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transfusion, 2-5ml 'whole blood' was collected into EDTA. The plasma 
was removed and the cells stored at -20°C before shipment to Oxford on 
dry ice. Blood samples from siblings of major patients 
attending the teaching hospital in Kurunegala were treated in the same 
fashion as those in the school children survey. 
4S 
Sri Lanka: Family studies 
Family studies were initiated on cases presenting with more unusual 
or novel mutations. These were collected in the same manner as the 
Hospital based patients. 
Sri Lanka: Cord blood study 
The cord blood study was planned so that a medical student, S. 
Rajapaksha, could visit Sri Lanka to help co-ordinate the collection of 
specimens. Shortly after delivery cord blood was collected by midwives, 
and the blood stored at 4°e. Technicians then transferred the blood to a 
-20°C freezer prior to shipment to Oxford on dry ice. 
United Kingdom: d-thalassaemia 
The National Haemoglobinopathy Reference Laboratory (NHRL) is 
a tertiary referral centre. Blood from patients is routinely studied for a,-
thalassaemia, {3-thalassaemia and identification of structural variants by 
DNA analysis. Whole blood was collected into tubes containing EDT A and 
sent by first class post from the referral centre to the laboratory in Oxford. 
United Kingdom: Cord blood study 
The district Haemoglobinopathy Unit at St. Bartholomew's hospital 
undertakes screening for thalassaemia and abnormal haemoglobins for the 
City and Hackney health district. Cord bloods of all newborns are routinely 
screened using a Biorad sickle cell thalassaemia column on the Biorad 
Variant Analyser. The remainder of the study cord blood, 2-3m1s, was 
transported by first class post to Oxford in smaIl batches. 
2.3 Haematology and biochemical analysis 
Full blood count 
In Sri Lanka a full blood count was measured on whole blood using a 
Coulter counter microdiff 8. This was performed as per manufacturer's 
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instructions by a trained technician. Specimens referred to the NHRL were 
analysed on a Coulter counter (MD8 Model, Beckman Coulter Electronics) 
as per manufacturer's instructions. 
Cation Exchange-High Performance Liquid Chromatography (CE-
HPLC) 
Fresh or frozen blood was analysed as per the manufacturer's 
instructions. 5J.11 whole blood was lysed in Iml haemolysis reagent and 
maintained at 12°C until analysed. Specimens were allowed to bind to the 
positively charged resin. An increasing ionic strength elution buffer was 
then passed across the resin. Haemoglobin elution was detected at 415nm 
and the baseline was corrected for the effects of different ionic strength 
buffers by monitoring the eluate at 690nm. An absorbance chromatogram 
versus time was generated and the relative proportion of each haemoglobin 
estimated by calculation of the area under each peale Every run was pre-
calibrated with standards provided. All haemoglobins have a characteristic 
retention time but may share this elution profile with other variant 
haemoglobins. The short program was optimised for the 
evaluation of HbF and HbA2; it also identified HbA and also proposes 
candidates for other haemoglobin variants. The sickle cell short program is 
a shortened version of the t3-thalassaemia short program lasting 3 minutes 
rather than 6 minutes that was developed for high throughput of samples. 
The a-thalassaemia short program was optimised for the evaluation of Hb 
Bart's. It required a pre-heating coil to prevent sample-run variation and a 
different column to study the fast eluting proteins. 
Iso electric focusing (IEF) 
IEF separation of haemogiobins was performed using the 'Isolab 
system' as per the manufacturer's instructions (Isolab Inc. Akram, USA). 
Packed red cells were prepared by mixing with 10 volumes of 'lysis' buffer 
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that containing a small amount of potassium cyanide. 10).11 was loaded onto 
pre-cast gels and focused by applying 300v at 15°C for 45 minutes. The gel 
with separated proteins was then fixed by immersion in 10% trichloroacetic 
acid for 20-30 minutes, washed in water for an equal length of time and 
then allowed to air-dry overnight. Haemoglobin focuses within an electric 
field according to the isoelectric point of the individual protein. The 
relative positions of any observed haemoglobins can then be related to 
standard haemoglobins focused at the same time (HbA, HbF, HbS and 
HbC). 
Cellulose acetate electrophoresis (CAE) 
CAE is a rapid and simple method to separate proteins according to 
net charge and size. CAE was performed using a Shandon system (Shandon 
Model U77 Electrophoresis tanks). Red cell lysates were prepared by 
washing in 0.9% saline. An equal volume of distilled water and 0.4 
volumes of carbon tetrachloride were added and vortexed for 30 seconds. 
The mixture was then centrifuged at 3000g for 20 minutes. The clear 
supernatant contained the haemoglobins and was stable at -70°C. For 
frozen blood 1 or 2 drops of 1 % potassium cyanide was added to 1-2m1 of 
red cell lysate. Cellulose acetate strips (25mm x 120mm; Shandon, 
Celogram) were used with a phosphate buffer system at pH 6.5. 
Electrophoresis was completed in 1-2 hours using a constant current of 
5mA. Hb Bart's was observed as a fuzzy band distinct from all other 
haemoglobins. 
Glucose-6-phosphate dehydrogenase (G-6-PDH) deficiency 
G-6-PDH deficiency was determined using a simple colorimetric test 
from Sigma Chemical Co. (Cat No. 400-K25) as per manufacturer's 
instructions. G-6-PDH released from lysed erythrocytes catalyses the 
conversion of glucose-6-phosphate to 6-phosphogluconate with reduction 
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of nicotinamide adenine dinucleotide phosphate (NADP) to NADPH. In the 
presence of phenazine methosulphate (PMS), NADPH reduces the blue 
dye, dichlorophenol indophenol, to the colourless form. The rate at which 
colour disappears in the reaction mixture is proportional to the G-6-PDH 
content of red cells. 
Red cell haemolysates were prepared by pipetting SOIlI whole blood 
into 2.Srnl water and allowed to stand at room temperature for S minutes 
after gentle agitation. 1.0rnl haemolysate was added to O.Sml substrate 
solution containing glucose-6-phosphate and NADP in a tris buffer, mixed 
gently and then overlayed with 2.0ml mineral oil. The vial was then placed 
at 37°C in subdued light. The mixture immediately turns maroonishlblue 
that will clear over a 20-60 minute period. Any failure to convert the dye 
from its 'blue' colour was interpreted as a G-6-PDH deficiency. This 
reaction was compared visually against reference samples (nonna!, 
intermediate and deficient controls). 
2.4 DNA analysis 
a-gene analysis: Southern blot 
Genomic DNA was digested overnight at 37°C with either restriction 
enzyme, Bam HI or Bgill. The fragmented DNA was electrophoresed on 
0.8% agarose and then capillary blotted (Sambrook et ai., 1989) onto 
nitrocellulose membrane (Zeta probe, Biorad). Southern blot hybridization 
was performed, at 6SoC, using a Church & Gilbert based buffer (7.S% 
dextran sulphate, l.SX SSPE, 1.0%SDS, SX Denhardt's solution, IOOllg/rnl 
denatured and sonicated salmon sperm DNA). Previously described probes; 
(a) a l.Skb Pst I fragment and a 1.8kb Sac II fragment (Lauer et al., 
1980; Proudfoot et ai., 1982) were radio-labelled with 32p_dCTP using a 
Megaprime DNA labelling system (Amersham Pharmacia). These 
conditions allow the detection of common forms of a-gene rearrangement; 
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rv3.7 4.2 ( 205 Med SEA SA 
-u. ,-a ,aaa, aaaa, - a) " -- ,-- ,-- (Table 2.1) and some 
extremely rare deletions. 
Table 2.1 Fragment sizes observed by Southern blot analysis for different a-
gene arrangements 
a Allele Restriction digest and hybridisation probe 
BamH 1- a BglII - a BamH 1-1; BglII -1; 
aa 14 12.617.6 10 -11.3/5.9 12.6 or 5.2110 -11.3 
aaailUU.:J. 17.7 12.617.6/3.7 10 -11.3/5.9 12.6 or 16/10 -11.3 
aaaanti4.2 18.2 16.817.6 10 -11.3/5.9 12.6 or 16/10 -11.3 
aaaaanti3.7 21.4 12.617.6/3.7 10 -11.3/5.9 12.6 or 20/10 -11.3 
aaaaanti4.2 22.4 2117.6 10-11.3/5.9 12.6 or 16/10 -11.3 
_a3.7 10.3 16 10 -11.3/5.9 16/10 -11.3 
_a4.2 9.8 8.017.4 10 -11.3/5.9 10 -11.3/8.0 
__ :>1:./\ None None 20/5.9 10.5 
__ :iA 
None None 5.9 7.0 
a-gene analysis: a+-thalassaemia Gap-PeR 
A Gap PCR method was developed for the detection of the two 
common forms of a+-thalassaemia, _a3.7 and _a4.2 (See figure 2.2). The 
primers for the detection of a+- and aO-thalassaemia were designed by Mr 
Y.T.Liu and the details have been published (Liu et al., 2000). Alternate 
primers published at the same time were also optimised (Chong et al., 2000 
a). The primer sequences are detailed in Table 2.2 and the location of these 
primers in relation to the a-genes with the relevant deletions are shown in 
Figure 2.2. 
The buffer conditions were optimised for a total reaction volume of 
25f.l1 with 100ng target template in Buffer A (Table 2.15). Products were 
separated on a 1 % agarose gel after amplification with the following 
cycling conditions; 72°C-IO' Xl 
64°C - I '30" X30 
72°C - I '30" 
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Table 2.2 a-gene Gap-PeR primers 
Mutation Oligonucleotide sequence GenBank Product size c: 
(bp) Co-ordinates 0 .'" 
Z8472 I c 
*Z69706 E 8'-.c c::::;: 
_a3.7 multiplex 
_a3.7 F (Liu et al) AAGTCCACCCCTTCCTTCCTCACC 32755-32778 0.3 aa 2217 
36309-36332 aa 2213 _a3.7 R I (Liu et al) ATGAGAGAAATGTTCTGGCACCTGCACTTG 34942-34971 0.1 _a3.' 30685-30714 1963 
_a3.' R2 (Liu et al) TCCATCCCCTCCTCCCGCCCCTGCCTTTTC 38492-38521 0.1 aaa"lII i3.' 2440 
_a3.' F(Chong et al ) CCCCTCGCCAAGTCCACCC 32746-32764 0.4 _a3.' 2020 
_a3.' RI(Chong et al ) AAAGCACTCTAGGGTCCAGCG 38562-38582 0.4 aa 1800 
_a3.' R2(Chong et al ) AGACCAGGAAGGGCCGGTG 34530-34548 0.1 
_a42 multiplex 
_a42 F (Liu et al) TCCTGATCTTTGAATGAAGTCCGAGTAGGC 30283-30312 0.8 aa 1510 
_a4.2 R I (Liu et al) TGGGGGTGGGTGTGAGGAGACAGGAAAGAGAGA 31760-31789 0.4 _a4.2 1725 
_a4.2 R2 (Liu et al) ATCACTGATAAGTCATTTCCTGGGGGTCTG 36176-36205 0.4 
_a4.2 F(Chong et al ) GTTTACCCATGTGGTGCCTC 30132-30 lSI 0.4 _a4.2 1628 
_a4.2 R(Chong et al ) CCCGTTGGATCTTCTCATTTCCC 35983-36005 0.6 
a O multiplex 
a SEA F CTCTGTGTTCTCAGTATTGGAGGGAAGGAG 26129-26158 0.4 an 1010 
aR TGAAGAGCCTGCAGGACCAGGTCAGTGACCG 27108-27138 0.4 a SEA 660 
a SEA R ATATATGGGTCTGGAAGTGTATCCCTCCCA 3148-3177* 0.4 
a FI L F AAGAGAATAAACCACCCAATnlTAAATGGGCA 12283-12315 0.4 a
FI L 550 
a FIL R GAGATAATAACCTTTATCTGCCACATGTAGCAA 544-576" 0.4 
a THAI F CACGAGTAAAACATCAAGTACACTCCAGCC 10364-10393 0.2 a
THAI 411 
a THAI R TGGATCTGCACCTCTGGGTAGGTTCTGTACC 1241-1271 * 0.2 
Figure 2.2 Schematic to highlight the location of the primers to detect 0.+-
thalassaemia by Gap-PeR 
5' ____ ________ ______ 
X2 
CJ 
_0.-1.2 
Y2 Z2 X I YI ZI 
[II I c=J 0 LI __ ----J 
+ RI 
+ R2 
+ RI _0.3.7 
+ 1'2 + 
RI 
... _0.-1 .2 Primers (Chong et al. , 2000a) 
... _0.-1.2 Primers (Liu et aI. , 2000) 
... _0.3.7 Primers (Chong et al. , 2000a) 
... _0.3.7 Primers (Liu et aI. , 2000) 
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a-gene analysis: o!-thalassaemia Gap-PCR 
Assays for the detection of the deletions (--SEA,_JIL and _ THAI) were 
successful under the conditions stated in the paper (Liu et al., 2000) and 
also using alternative buffer conditions, DNA polymerases and PCR 
machines. The primer sequences are detailed in Table 2.2 and the location 
of these primers on the a-cluster depicted in Figure 2.3. 
Figure 2.3 Schematic to highlight the location of the primers to detect 0.0_ 
5' 
thalassaemia by Gap-peR 
inrer- HVR 
t \jIa2 
V 
----. a THAI F 
----. a'" F 
.--a R 
THA I 
III 
I Okb markers 
3' HVR 
v 3' 
t 
V V 
SEA 
Products were separated on a 1.5% agarose gel after amplification with the 
following cycling conditions; 95°e - 3' XI 95°e - I' noe - 10' XI 
64°e - 1'30" X30 
noe - ]'30" 
a-gene analysis: ARMS-PCR 
Candidates were screened for specific mutations in either a-gene by 
allele specific primers (Table 2.3). The amp I ification of these primer sets to 
detect a mutation depended upon the careful design of these mismatched 
primers using the guidelines in CUlTent Protocols in Molecular Biology 
(2000) and also on the buffer system used for the PCR conditions. Buffer A 
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(Table 2.15) was used with 51lM of each ARMS primer and its associated 
second primer (Table 2.3). 
Table 2.3 ARMS primers for the detection of mutations in the al or a2 gene 
Mutation Oligonucleotide sequence (5'-73') GenBank 
Co-ordinates .... G 0 '-' 
" Z84721 "C OIl 3P- c:: _ 
'"t:l "- .. 01 . .c:: " " 0 § « £ 
HbEvanston GCCAGCGTGCGCGCCGACCTTACCCTT 37622-37648 Al 58 
TCTTGGTGGTGGGGAAGGACAGGAACATAT 37791-37820 Al 58 
Hb Sun Prairie GTGCACGCCTCCCTGGACAAGTTCCTAC 34398-34425 A3 58 
HbKoyaDora AGCACCGTGCTGACCTCCAAATACCGTCC 34434-34462 A3 58 
Poly A Tail GCACCGGCCCTTCCTGGTCTTTGAATTG 34529-34556 A3 58 
) 
HbQ-India CACGTGCGCCACGGCGTTGGTCAGCGCGAG 37168-37198 Al 60 
HbQ-India Normal GGCCCCAAGGGGCAAGAAGCAT 38293-38313 Al 60 
5'a Exon 1 (A4) GTCAAGGCCGCCTGGGGTAAGGTC al: 37160-37633 AS 58 
a2: 33806-33829 
3'a Exon 2 (AS) GTGCGCGTGCAGGTCGCTCAG al: 37549-37568 
az: 33745-33264 
5' a common (AI) CTGGTCCCCACAGACTCAGA al: 37549-37568 A2 
a2: 33745-33264 
3'azURR (A3) TTTATTCAAAGACCAGGAAG 34538-34557 
Each pnmer set included extra primer(s) to act as a control to 
demonstrate that the individual samples could be amplified. The mutations 
Hb Evanston and IVSI-117 (G-tA) required a multiplex of 3 primers. A 
common primer in a-promoter (AI), a control primer (3'a Exon 1) (408 bp) 
and the mutation specific primer. The mutations Hb Sun Prairie, Hb Koya 
Dora, Poly A Tail (AATAAA-tAATA-> and Hb Q-India required a 
multiplex of 4 primers. Two primers (5'a Exon 1 and 3'a Exon 1) were 
included to give a control band. 
a-gene analysis: sequence analysis 
Amplification of the a-genes was made after the design of 
oligonucleotides to allow independent amplification of either the aI- or the 
az-gene. The sequence of these primers (AI, A2 and A3) as well as the 
annealing temperatures are shown in Table 2.4 and were published after 
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"V; 
U ;:; 
Q::e 
409 
581 
358 
323 
229 
370 
765 
408 
766 
studying Thai patients with suspected Hb Constant Spring (Viprakasit et al., 
2002). The PCR amplification conditions were different from those stated 
in the paper. Products were separated on a 1 % agarose gel after 
amplification with the following cycling conditions; 
95°C - 3' Xl 95°C -1' 72°C-IO' Xl 
XOC - 1 '30" X30 
noc - 1 '30" 
Table 2.4 Amplification and sequence primers for analysis of al and a2 genes 
Primer Oligonucleotide sequence (5'---t3') GenBank G .... Co-ordinates .., 0 8 ';) 
Z8472 1 "C OIlS c.. .5 1i '" 
'8 til .... t) § ::I 0 "" ..-. cte til <:2 
Amplification 
5' (X common CTGGTCCCCACAGACTCAGA (Xl: 37549-37568 
(AI) (X2: 33745-33264 
3'(X1URR (A2) ACGGGGGTACGGGTGCAGGAAG 38334-38355 Al 157 1406 J 
3'(X2URR (A3) TTTATTCAAAGACCAGGAAG 34538-34557 Al 158 I 1327 I 
Sequence 
161:CI (AS1) TGGAGGGTGGAGACGTCCTG (X2: 33537-33556 
(XI: 37341-37360 
278: 3'aD3 CCAGCTGCAGAGAGGTTCTAGCC (XI: 38460-38482 
279: 5'aSOI GAGAACCCACCATGGTGCTGT (X2: 33765-33785 
(Xl: 37569-37589 
280:3'(XC3B ATTCCGGGACAGAGAGAACCC (X2: 34588-34608 
281:3'(XClO ACGGTTGAGGGTGGCCTGT (X2: 33921-33939 
(Xl: 37725-37743 
282:5'(XC7 TCGACCTGAGCCACGGCTCTG (X2: 34032-34052 
(Xl: 37836-37856 
285:3'(XC5 GCGGACAGCGCGTTGGGCATG (X2: 34120-34140 
(Xl: 37924-37944 
286:5'(XC6 AGGCGGCGGCTGCGGGCCTGG CXz: 34287-34307 
(Xl: 38091-38111 
Amplicons were cleaned up using exclusion chromatography and 
cycle sequencing outlined in 2.4 and 2.5. The only deviation was that 2111 
5M betaine was substituted into the reaction for an equal volume of water. 
The sequencing primers used was previously published (Dode et al., 1993) 
and their locations in relationship to the a-genes shown in Figure 2.4. 
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Figure 2.4 Schematic of the a-genes to show the location of the amplification 
and sequence primers 
Exon 1 
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analysis: haplotype analysis 
The a-haplotype assays were used as published (Miles et al., 2001). 
peR conditions were changed to use Buffer A (Table 2.15). The primer 
sequences, annealing temperatures and fragment patterns are given in Table 
2.5. 
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Table 2.5 Alpha haplotype oligonucleotides 
Primer Oligonucleotide sequence GenBank Fragment sizes (bp) 
0) 
Co-ordinates b03 I::: ... 
Z84721 . - os co ... 
0) 0) C 0.. ___ 
I::: S U « 0) 0 ... '--" 
XbaIF CTCAACAGATGCCAGCCAAACAGAC 5108-5132 60 - 932 
XbaIR GAACCATTACACCAAGTGAAGGACG 6016-6040 + 6431289 
Sac IF AAGATGGAGAAGGAAGGATGACTGC 18710-18734 60 - 560 
SacIR GAGAGCAAGCCGATGTGGTAGAATG 19246-19270 + 4321128 
IZBglIF CCAGGACACAGATGGAGGCTAATGT 20503-20527 60 S- 876-768 
IZBglIR TTGGGGTTGGGTGCATGAGGC 21985-22005 S+ 664-544/224 
M- 2136-1812 
M+ 1922-1588/224 
L- 2748-2424 
L+ 2588-2200/224 
PZ/ZF GGGTGGGCAGAAGGGGAGAC 23745-23764 65 PZ 1137 
PZ/ZR GATCCCAGATGCTGGGACTTTAGAGGCTGT 24853-24882 Z 758 
AccIF AGGCATGGGCCGCCATTCCTGG 28964-28985 65 - 855 
AccIR CTTGATCTGGGCTGAGCC 29802-29819 + 519/336 
RsaIF GCACCTCCCACCCTCCCCCTC 32731-32751 65 - 819 
RsaIR GTCTCCACCCTCCACCCGCCACTC 33527-33550 + 466/305/48 
UPS! IF GGTfGAATGCTCCAGCCGGITCCAGCTATTGC 36626-36657 60 - 926 
UPS! IR CCAGAAGAGTGCCGGGCC 37535-37552 + 581/345 
e Pst IF ACGGTGTCTTCGTTATTTCATCAGG 39341-39365 60 - 884 
e Pst IR TCAGTGCTTCATTTCTTTTTGTGGC 40201-40225 + 569/315 
P.globin gene analysis: ARMS-peR 
Candidates were screened for specific mutations in the f3-gene by 
allele specific primers (Table 2.6) in a total reaction volume of 25111. 1111 of 
each mutation specific primer and a second primer, all at a concentration of 
10D26O"ml (-5IlM), were added to Buffer D (Table 2.15) with 0.51lg 
genomic DNA. Control primers were added to each assay to assess for 
amplification failure. Control set C+D was used in all assays except for 
IVSII-745 that used E+F. The PCR conditions and most of the 
primers had been previously published (Old, 1996). 
If a patient was positive for a specific mutation, normal sequence 
was assessed by allele specific primers to test for homozygosity (Table 
2.7). Similar amplification conditions were employed as for the mutation 
specific primers. All amplicons were separated on a 3.0% (Nusieve: 
Seakem GTG) agarose gel after 1 hour of electrophoresis at 100v and 
visualised on a transilluminator after staining with ethidium bromide. 
56 
Table 2.6 Primers for the detection of mutations by ARMS-peR 
Mutation Oligonucleotide sequence (5'-t3') GenBank ,..., 
Co-ordinates .... u 
UOl317 S e..., u .., N .;:: 
CD 3 ·iil 0. c: U "Q :a e! c: ::I 
§ "Q '""' o 0. 
en p.':;e 
-28 (A-tG) AGGGAGGGCAGGAGCCAGGGCTGGGCITAG 62080-62109 A 65 624 
CAP+l (A-tC) ATAAGTCAGGGCAGAGCCATCTATTGGTTC 62108-62137 A 65 597 
CDS (-CT) TCAAACAGACACCATGGTGCACCTGAGTCG 62174-62204 A 65 528 
CD8/9 (+G) CCTTGCCCCACAGGGCAGTAACGGCACACC 62212-62241 B 65 225 
CDl5 (G-tA) TGAGGAGAAGTCTGCCGTTACTGCCCAGTA 62204-62233 A 65 500 
CD15 (-T) CTGAGGAGAAGTCTGCCGTTACTGCCCTAG 62230-62260 A 65 498 
CDl6 (-C) TCACCACCAACTTCATCCACGTTCACGTTC 62236-62266 B 65 238 
CD30 (G-tC) TAAACCTGTCTTGTAACCTTGATACCTACG 62278-62307 B 65 279 
IVSI-l (G-tA) TTAAACCTGTCTTGTAACCTTGATACCGAT 62279-62308 B 65 281 
IVSI-I (G-tT) TTAAACCTGTCTTGTAACCTTGATACCGAAA 62279-62308 B 65 281 
IVSI-5 (G-tC) CTCCTTAAACCTGTCTTGTAACCTTGITAG 62283-62312 B 65 285 
IVSI-6 (T-tC) TCTCCTTAAACCTGTCTTGTAACCITCA TG 62284-62313 B 65 286 
IVSI-IIO (G-tA) ACCAGCAGCCTAAGGGTGGGAAAATAGAGT 62387-62416 B 65 419 
CD39 (C-tT) CAGATCCCCAAAGGACTCAAAGAACCTGTA 62433-62462 B 65 436 
CD41142 (-TCTT) GAGTGGACAGATCCCCAAAGGACTCAACCT 62437-62470 B 65 439 
IVSII-l (G-tA) AAGAAAACATCAAGGGTCCCATAGACTGAT 62621-62650 B 65 634 
IVSII-745 (C-tG) TCATATTGCTAATAGCAGCTACAATCGAGG 63347-63376 D 65 738 
deletion CTCTGGGTCCAAGGGTAGACCACCAGCATA 62384-62438 B 65 445 
619 bp deletion Control primers D+E 65 242 
jis:CD6(G-tT) CCCACAGGGCAGTAACGGCAGACITCTGCA 62236-62235 B 65 207 
f3E:CD26(G-tA) TAACCTTGATACCAACCTGCCCAGGGCGTT 62265-62294 B 65 236 
A: 3'lnt-2 CCCCTTCCTATGACATGAACTTAA 62680-62703 
B:5'URR ACCTCACCCTGTGGAGCCAC 62028-62047 
C:3'URR GAGTCAAGGCTGAGAGATGCAGGA 64061-64084 C+D 65 861 
D: 5'lnt-2 CAATGTA TCATGCCTCTTTGCACC 63224-63247 
E 5' GY-Hind III AGTGCTGCAAGAAGAACAACTACC 35677-35700 E+F 326 
F 3' uy-Hind III CTCTGCATCATGGGCAGTGAGCTC 35981-36004 
Table 2.7 Primers for the detection of normal DNA sequence by ARMS-peR 
Mutation Oligonucleotide sequence (5'-t3') GenBank .., 
Co-ordinates :f2 '""' ... 0. 
UOl317 -g .... <II 0.0 ::1 ___ 
o "Q <I) ih:: =SU o N .., 0 p.':; .-en 0. ... --- tI) • 
CD8/9 (+G) CCTTGCCCCACAGGGCAGTAACGGCACACT 62212-62241 B 65 225 
CDl5 (G-tA) TGAGGAGAAGTCTGCCGTTACTGCCCAGTA 62204-62233 A 65 500 
CD41142 (-TCTT) GAGTGGACAGATCCCCAAAGGACTCAAAGA 62441-62470 B 65 439 
IVSI-l (G-tA) TTAAACCTGTCTTGTAACCTTGATACCCAC 62279-62308 B 65 281 
IVSI-l (G-tT) GATGAAGTTGGTGGTGAGGCCCTGGGTAGG 62279-62308 A 65 455 
IVSI-5 (G-tC) CTCCTTAAACCTGTCTTGTAACCTTGTTAC 62283-62312 B 65 285 
j3E:CD26 (G-tA) TAACCTTGATACCAACCTGCCCAGGGCGTC 62265-62294 B 65 236 
NB: The second primer A and B refers to Table 2.6 
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p.gene analysis: RFLP analysis 
peR fragments were amplified across known polymorphisms, 
associated with a restriction enzyme site, and assessed by digestion with 
the relevant restriction enzyme. The fragments were amplified under the 
same peR conditions as the ARMS-peR for the f3-gene mutations using 
the amplification primers shown in Table 2.8. The cycling conditions were 
also the same except 30 cycles of amplification were used and the 
annealing temperatures highlighted in Table 2.8 (Old, 1996). 
Table 2.8 f3-haplotype oligonucleotides 
RFLP Oligonucleotide sequence GenBank 4) Fragment 
F: = Forward Co-ordinates -u] sizes os 
R: = Reverse U01317 ::Ie (bp) "0 4) o N ::: d:: "1il 
Hind II /e F: TCTCTGTITGATGACAAATTC 18652-18672 760 55 -/- 760 
R:AGTCATTGGTCAAGGCTGACC 19391-19411 +1+ 445+315 
Xmn I lOy F: AACTGTTGCTITATAGGATTTT 33862-33883 657 55 -1- 657 
R:AGGAGCTTATTGATAACCTCAGAC 34495-34518 +/+ 455+202 
Hind ill lOy F:AGTGCTGCAAGAAGAACAACTACC 35677-35700 326 65 -1- 326 
R:CTCTGCATCATGGGCAGTGAGCTC 35981-36004 +1+ 235+91 
Hind ill lAy F:ATGCTGCTAATGCTTCATTAC 40357-40377 635 65 -/- 635 
R:TCATGTGTGATCTCTCAGCAG 40971-40991 +1+ 327+308 
Hind IT 15'\jf/3 FTCCTATCCATTACTGTTCCTTGAA 46686-46709 795 65 -/- 795 
R:ATTGTCTTATTCTAGAGACGATTT 47457-47480 +1+ 691+104 
Hind II 13'\jff3 FGTACTCATACTTTAAGTCCTAACT 49559-49582 913 55 -1- 913 
R:TAAGCAAGATTATTTCTGGTCTCT 50448-50471 +/+ 479+434 
Ava II 1/3 F:GTGGTCTACCCTTGGACCCAGAGG 62416-62439 328 65 -1- 328 
R:TTCGTCTGTTTCCCATTCTAAACT 62720-62743 +/+ 228+100 
HinfIl/3 F: GGAGGTTAAAGTTTTGCTATGCTGTAT 63974-64001 474 55 -/- 320+154 
GGGCCTATGATAGGGTAAT 64429-64447 +/+ 213+154+107 
Dde 1//3 F: ACCTCACCCTGTGGAGCCAC 62028-62047 443 65 HbSfS 760 
R:GAGTGGACAGATCCCCAAAGGACTC 62441-62471 HbNA 445+315 
AAGGA IVSI-130 268+175 
Bgi I //3 N 443 
CDI5(-T) 237+205 
Pst I //3 N 443 
CDI6(-C) 237+205 
EcoR 1/13 F:CAATGTATCATGCCTCTITGCACC 63224-63247 861 65 HbDID 760 
R:GAGTCAAGGCTGAGAGATGCAG 64061-64085 HbNA 445+315 
GA 
Mwo 1/f3 F: AGACTCITGGGTITCTGATAGG 62345-62366 189 65 N 760 
R: T AAAGGCACCGAGCACTTTCTT 62512-62534 CD55(-A) 445+315 
Additional RFLP assays were designed to confmn the presence of 
some mutations that were either new or that did not have an ARMS-PCR 
assay for mutation detection. The same PCR and cycling conditions were 
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used as in all these RFLP assays using the annealing temperatures outlined 
in Table 2.8. The expected fragment patterns are given in the same table. 
f3-gene analysis: sequence analysis 
sequence analysis used previously described primers (Thein 
& Hinton, 1991). Amplification of the was made using the 
oligonucleotides 5' and 3' in Buffer E (Table 2.15) in a total 
volume of IOOI-,d. The nucleotide sequence of these primers and the 
annealing temperatures are shown in Table 2.9. Amplicons were cleaned up 
using exclusion chromatography and cycle sequencing as outlined (See 
section 2.4 and 2.5). 
Table 2.9 Amplification and sequence primers for analysis of the t3 gene 
Primer Oligonucleotide sequence GenBank " Co-ordinates 0 '.::I ';;l 
U01317 g g .. " 
is 'C d:e cno. 
Amplification 
CGATCTTCAATATGCTTAC 61831-61849 3'/338 58 2617 
3'/338 GGGCCTATGATAGGG 64434-64448 
5'j3URR TTCCCCTCCTACCCCTACTTTCTA 61224-61247 3' j3URR 163 901 
3'JiURR GCTCTGCCCTGACTTTTATGC 62104-62124 
Sequence 
Exl.lL GAGCCAAGGACAGGTACGG 61996-62014 
3'/32 CAAAGGACTCAAAGAACCTC 62437-62456 
Ex2.1L AGACTCTTGGGTTTCTGA 62346-62363 
Ex2,IR TAAAGGCACCGAGCACTT 62517-62535 Ex2.lL 158 189 I 
3'/39 CATTCGTCTGTTTCCCATTCTA 62725-62746 
IMO#15 CAATGTATCATGCCTCTTTGCACC 63225-63248 
3'138 GCAGCCTCACCTTCTTTCATGG 63869-63890 
5' j3URR-l GTTTCCCAAAACCTAATA 61440-61457 
3'/3URR-l TGGATCTCTTCCTGCGTCTC 61718-61737 
i'gene analysis: Southern blot 
Southern blot analysis was performed in an identical manner to that 
described earlier in a-gene analysis. The differences were that the genomic 
DNA was digested with either Bam HI or Hind III and then subsequently 
hybridised with a previously published y-probe (Jeffreys, 1979). 
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Table 2.10 Fragment sizes observed by Southern blot analysis with normal y-
gene arrangements 
y Allele Restriction digest and hybridisation probe 
BamH I-V Hind III - V 
15.3/512.7 7.3 or 6.5+0.8 / 3.3 or 2.7+0.6 
15.3/5 3.3 or 2.7+0.6 
Gy_ 512.7 7.3 or 6.5+0.8 
'}4Gene analysis: sequence analysis and RFLP 
Amplification of the y-genes was made after the design of 
oligonucleotides to allow independent amplification of the Gy_ or "r-gene. 
The sequences of these primers as well as the annealing temperatures are 
shown in Table 2.11 or have been published (Bayoumi et ai., 1999). 
Table 2.11 Amplification and sequence primers for analysis of the y genes 
Primer 
Amplification 
3'A.y 
5'1-467 
5'y-265 
5'y-Cap 
5'Y-1 
3'y-IVsn 
5)':IVsn 
Oligonucleotide sequence (5'-""73') GenBank 
Co-ordinates 
U01317 
TTACTGCGCTGAAACTGTGGTCTT 38783-38806 
ITT ACTGCTTTT A TTTGCTCATCA 41119-41142 
TGTTGCTIT ATAGGA TTTTTCACT 33865-33888 
AGA TITCTCCTGCACCITIT ACT 36270-36292 
3'A.y 
AAATCCTGGACCTATGCCTA A.y :38947-38966 Gy:34011-34030 
TGACTGAATCGGAACAAGG A.y :39149-39167 GY:34213-34231 
AGCACCCTTCAGCAGTTCC Ay :39393-39411 GY:34457-34475 
GGAITTGTGGCACCTTCTGACTG Ay :39632-39654 GY:34696-34718 
CTCCCAACCCCAGTATCT A.y :40002-40019 Gy:35066-35084 
TGGGTTCATCTTTATTGTC A.y:40734-40752 GY:35818-35836 
HFE gene analysis 
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154 
2359 
2427 
The primers and conditions for the analysis of HFE gene containing 
the H63D and C282Y mutations were described previously (Merryweather-
Clarke et ai., 1997). The PCR conditions were optimised in buffer G (Table 
2.15) using primers from Table 2.12. The amplicons for the mutation 
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C282Y was digested with Rsa I and H63D was digested with Mbo I as per 
manufacturer's instructions. 
Table 2.12 RFLP primers to detect HFE gene mutations 
RFLP Oligonucleotide sequence GenBank 
(5'-73') Co-ordinates c Co 0 c e 292910 ';::J os .g U J:l t) .. c 
"'8'""' ::I ell ::s "8c: 
<.l '-" Cl 0. 
C282YF CAAGTGCCTCCTTTGGTGAAGGTGACACAT 6490-6519 0.4!IM 343 N:2031l40 
C282YR CTCAGGCACTCCTCTCAACC 6843-6862 O.4lJM M:203/111129 
H63DF ACATGGTTAAGGCCTGTTGC 4621-4640 0.4J.lM 294 N:237/57 
H63DR CTTGCTGTGGTTGTGATTTTCC 4894-4915 O.4jJM M: 138/99/57 
G-6-PD gene analysis 
The primers for the RFLP were already published (Kaeda et ai., 
1995). The conditions for amplification used Buffer F (Table 2.15) in a 
final reaction volume of 25JlI with 30 rounds of amplification, Products 
were separated on a 3% agarose gel after amplification with the following 
cycling conditions; 
95°C - 3' Xl 95°C -1' 72°C-lO' Xl 
65°C - 1 '30" X30 
72°C - 1 '30" 
The amplicons for the mutation G-6-PD Med was digested with Mbo II, 
1311 TIC was digested with Bel I and G-6-PD Orissa with Rae III as per 
manufacturer's instructions. 
Table 2.13 RFLP primers to detect G-6-PD mutations 
Mutation Oligonucleotide sequence GenBank 8 Co-ordinates .", 
229527 "d .. jg '.;:l (J .. C ell ::s 
u "8 .-.. 
.. 0. .t: Cl o.e r;;, c:>. 
5'Med ACTCCCCGAAGAGGGGTTCAAGG 14596-14978 3'Med 65 N:3811l19 
3'Med CCAGCCTCCCAGGAGAGAGGAAG 15478-15500 M:3811l19/I00 
S'1311T/C TGTTCTTCAACCCCGAGGAGT 16880-16701 3'131lT/C 65 N:386 
3'1311T/C AAGACGTCCAGGATGAGGTGATC 17065-17087 M:363/23 
5'Orissa CAGCCACTTCTAACCACACACCT 13288-13310 3'Orissa 65 N: 107175166/48/45110 
3'Orissa CCGAAGTTGGCCATGCTGGG 13620-13639 M: 123/107/66145110 
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UGTIA promoter analysis 
The primers for the amplification and the nested primer used as a 
sequence primer (Table 2.14) were already published (Beutler et aI, 1998). 
The conditions for amplification used Buffer E (Table 2.15) in 25Jll. 
Table 2.14 Amplification and sequence primers for analysis of the UGT1A 
promoter 
Primer Oligonucleotide sequence GenBank: = Co-ordinates 0 ""' (5'-t3') '::l c..... .s .c D87674 8 '-' = 
'J:: 1:l 
Q.. 8 ] u .. 
8 
" Cf.I 
Amplification 
5'UGTlA GCCAGTTCAACTGTTGTTGCC 2983-3003 3' UGTIA 4 314 
3'UGTlA CCACTGGGATCAACAGTATCT 3273-3297 I 4 
5'UGTlA AGAAACCT AATAAAGCTCCACC I 3009-3030 J 10.2 
Products were separated on a 1 % agarose gel after amplification with 
the following cycling conditions; 
95DC - 3 ' Xl 95DC - I ' 
2.5 Common methods 
Reagents 
60DC - I '30" X30 
72DC - I ' 30" 
72DC-IO' Xl 
Chemicals used were of analytical grade or higher and were 
purchased from more than one supplier that included Sigma-Aldrich 
Company Ltd, Merck Ltd, Life Technologies and Applied Biosciences. 
Oligonucleotides were manufactured by Os wei DNA Services. 
Hybridization probes were made by GenSet. Restriction enzymes were 
purchased from New England Biolabs. Radiochemicals were supplied by 
Amersham International and all Lightcycler kits were supplied by Roche 
Diagnostics. 
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Genomic DNA extraction 
DNA was prepared from either fresh or frozen whole blood by a 
standard phenol chloroform method (Old & Higgs, 1983). Fresh whole 
blood was washed with at least two volumes of reticulocyte saline (0. 13M 
NaCI, 5mM KCI, 7.4mM MgCh) and the red cells lysed with 25mllysis 
solution (0.77M NH4CI, 0.046M KHC03). The 'buffy coat' was then re-
suspended in 5ml lysing solution (IOOmM NaCI, 25mM EDTA). 0.5m1 
10% SDS and 20JlI 20Jlg/ml proteinase K was added and the mixture was 
incubated overnight at 37°C. Proteins and other impurities were removed 
by extracting twice with an equal volume of O.lM Tris (pH 8) saturated 
phenol and then chloroform. DNA was precipitated out of solution by the 
addition of one tenth volume 7.5M ammonium acetate and 2-3 volumes of 
absolute ethanol. The DNA was washed in 70% ethanol and then re-
suspended in double distilled water. Frozen blood was placed straight into 
the lysing solution with 2-3 times more 20Jlg/ml proteinase K with an extra 
phenol extraction step. 
Polymerase chain reactions 
All PCR reactions were optimised on an Eppendorf gradient 
thermocyc1er but most subsequent reactions were carried out on Biometra 
thermocyc1ers. Buffers for PCR were made up as per Table 2.15. AmpliTaq 
and AmpliTaq Gold were products of Applied Biosciences and Platinum 
Taq was a product of Life Technologies. 
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Table 2.15 peR conditions 
Reagent A B C D E F G 
Applied Bio. Buffer IV * Xl Xl - - Xl Xl -
Biosystems Buffer I ** - - Xl Xl - - Xl 
Dinucleotide triphosphates 0.2J..LM 0.2uM 0.21JM 0.2J..LM O.2J.LM 
MgClz 1.5mM 1.5mM - - 2mM 1.5mM 1.5mM 
Betaine 0.75M 0.75M 0.75M - - -
Dimetbylsulphoxide 5% 10% 5% - - -
Gelatin - - - 100llglml - -
- - - 0.8mM - -
Platinum Taq O.5U - - - 2U - -
Am..£liTaq - O.5U - O.05U O.5U O.5U 
AmpliTaq Gold 
*AppIied Biotechnologies 
Buffer IV (XIO) Cat No AB-029 
-
Tris-HCI 7S0mM (PH 9.0 @ 2SCQ) 
(NHchS04 200mM 
Tween 0.1 % (w/v) 
Electrophoresis 
- 1.25 - - -
Buffer I (XIO) Cat No AB-0242 
Tris-HCI 100mM (PH 8.3 @ 2SCO) 
KCI SOOmM 
MgCI ISmM 
All agarose based gel electrophoresis used either Seakem GTG or a 
mixture of Nusieve agarose and Seakem GTG. Products to be 
electrophoresed were combined with one-sixth volume of 6X Loading 
buffer (Xylene cyanol FF and Bromophenol blue in a 15% solution of 
PicoU). Electrophoresis was performed at 100v for 1 hour, gels were 
stained with ethidium bromide, washed and then photographed using a 
Biorad Gel Documentation System. 
Template preparation/or sequencing 
PCR reactions that amplified more than one band were separated by 
electrophoresis and visualised by staining with ethidium bromide and 
viewing on a long wavelength UV transilluminator. The amplicon of 
interest was isolated by excision out of the gel and cleaning up using a kit 
(Bio 101, Anachem (UK) Ltd) as per manufacturer's instructions. 
PCR reactions that produced a single amplicon were cleaned up and 
concentrated using a Microcon-100 centrifugal filtration device supplied by 
Whatman (UK) Ltd as per manufacturer's instructions. 
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Sequencing 
Cycle sequence reactions were performed using a big dye terminator 
kit purchased from Applied Biosystems, Warrington (UK) Ltd. As per the 
manufacturer's instructions unless stated. The extension products were 
separated from the unincorporated dyes by ethanol precipitation. These 
products were then resuspended in 12.5Jll template suppression reagent and 
electrophoresed through an ABI 310 Genetic Analyser to separate the 
extension products as per the manufacturer's protocols (Applied 
Biosystems, Warrington (UK) Ltd). 
Computer analysis 
DNA analysis was performed on new sequence variations. Mutations 
were analyzed to compare the restriction enzyme pattern against the nonna! 
consensus sequence using a DNA computer program (DNA Star Inc., 
Wisconsin, USA). 
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Chapter 3 a-globin gene arrangement 
The objective of the study was to ascertain the spectrum and 
frequency of the molecular lesions that cause a-thalassaemia and other a-
gene arrangements in the population of Sri Lanka using Southern blot 
analysis. The subsequent phase was to develop simple robust PCR based 
methods to speed up the process and also use less starting material. The 
clinical significance of these genetic variations could be examined and 
their incidence compared against other world populations. 
3.1 a-Gene deletions and insertions 
In every population studied the most prevalent form of a-
thalassaemia is caused by deletions removing 3.7kb DNA (_0.3.7) that 
result in the expression of one a-gene only, as a wild type fusion protein 
(See section 1.2.2.2). Its counterpart is a single a-gene insertion that is 
found at much lower frequencies. Deletions that remove both a-genes 
from a single chromosome, although less common, have a greater clinical 
problem as couples that are both carriers for this molecular lesion would 
be at risk of producing a baby unable to produce adult a-globin chains 
that result in haemoglobin Bart's hydrops fetalis syndrome. 
Hospital based patients 
The a-gene cluster was investigated in a cohort of transfusion 
dependent patients attending five different clinics around the island; 
Anuradhapura, Badulla, Chilaw, Colombo and Kurunegala (See section 
2.2). Some relatives from Anuradhapura were included in the analysis. 
The a-genotype was mainly determined by Southern blot analysis as 
described previously (See section 2.4). The a-gene allele frequency in the 
patients is shown in Table 3.1. 
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0'1 
Table 3.1 a-globin gene frequency of patients and some parents attending five thalassaemia clinics in Sri Lanka 
Anuradhapura* Badulla Chilaw Colombo Kurunegala 
Allele Frequency Allele Frequency Allele Frequency Allele Frequency Allele Frequency 
a-Gene No. (%) No. (%) No. (%) No. (%) No. (%) 
alleles 
0.0. 275 87.6 119 93 14 87.5 48 92.3 363 91.2 
I _0.3.7 26 8.3 7 5.5 2 12.5 4 7.7 20 5.0 
_ci·2 8 2.5 0 0 0 0 0 0 2 0.5 
0.0.0. 5 1.6 2 1.5 0 0 0 0 11 2.8 
auuu 0 0 0 0 0 0 0 0 2 0.5 
Total 314 100 128 100 16 100 52 100 398 100 
*Includes parental a-genotypes 
Total 
Allele Frequency 
No. (%) 
819 90.2 
59 6.5 
10 1.1 
18 2 
2 0.2 
908 100 
Only five forms of a-gene arrangement were revealed. The majority 
of chromosomes appeared to be wild type (aa). Two single a-gene 
deletions (_a3,7 and _a4,2 at 6.5% and 1.1 % respectively) and two extra a-
gene arrangements (aaa and aaaa at 2% and 0.2% respectively) were 
observed. These a-gene rearrangements could be discerned after digestion 
of genomic DNA with Bam HI and hybridisation with an a-probe (Figure 
3.1). The _a3,7 and _a4,2 gene deletions were indicated by fragment sizes of 
10.2kb and 9.8kb, respectively. Extra a-genes were indicated by larger 
fragment sizes of 18kb and 22kb for the triple a- and quadruple a-gene 
arrangement, respectively. Confirmation of these gene arrangements and 
distinction between aaaanti3,7 and aaaanti4,2 was determined after digestion 
with the restriction enzyme Bgl II and probing with a S probe and then 
subsequently with an a probe. The fragment sizes are shown in Table 2.1. 
Figure 3.1 Composite autoradiograph to highlight the fragment pattern 
associated with different a-gene arrangements after digestion with 
Bam H I and hybridisation with an a-probe 
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The frequency of the a-gene arrangements was consistently high in all 
regions around the island. The _a3,7 deletion was found with an overall 
allele frequency of 6.5%, ranging between 5 and 12.5%. The highest 
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frequency was observed in Chilaw but coincided with the smallest study 
group and may have been a sampling anomaly. The _a4.2 gene deletion was 
much less common and only found in Anuradhapura and Kurunegala at an 
overall frequency of 1.1% (0.5% and 2.5% respectively). Again, this 
mutation may not have been observed in Badulla, Chilaw or Colombo 
because of the lower number of patients from these clinics and its lower 
incidence in the popUlation. The overall observed allele frequencies with 
extra a-genes were high at 2% and 0.2% for aaa and aaaa gene 
arrangement, respectively but were not observed in Chilaw or Colombo. 
The a-genotype frequency in this cohort demonstrated a nonna! 
distribution for a recessive disorder (Table 3.2). Not all patients revealed a 
full genotype but still allowed one chromosome to be typed. Amongst 
these were some surprising observations. 
Table 3.2 Observed genotype frequency of a-thalassaemia in Sri Lanka 
Genotype Individuals Frequency (%) 
aaJaa 356 81.7 
_a3.7/aa 53 12.2 
_a3.7/_a3.7 0 0 
_a4.2/aa 7 1.6 
_a4.1'/_a4.2 1 0.2 
_a3.7/_a4 .1. 1 0.2 
aaaJaa 16 3.7 
aaaaJaa 0 0 
aaaJaaa 1 0.2 
aaaaJaaaa 1 0.2 
Total 436 100 
No individuals homozygous for the single a-gene deletion, _0.3.7, 
were found. In contrast, from a smaller group of carriers for extra a-genes a 
single case homozygous for the aaa gene arrangement was found and the 
fIrst case homozygous for the aaaa arrangement was observed. Further 
investigation revealed that the parents of the patient homozygous for the 
aaaa.-gene arrangement were fIrst cousins. 
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The overall allele frequencies (908 alleles from Table 3.1) were used 
to confmn the genotype frequency using the Hardy-Weinberg equation 
(See Appendix 1). The genotype frequencies were determined for the 
combined single a-gene deletions (_a3.7 and _a4.2) and the chromosomes 
with extra a-genes independently. These were then compared with the 
observed frequencies (436 genotypes from Table 3.2) in this cohort of 
patients (Table 3.3). 
Table 3.3 Predicted genotype frequency of a-genotypes using the Hardy-
Weinberg equation 
Genotype Expected Observed 
Single a-gene deletion aa/aa 85.4 85.8 
-a/aa 14 13.8 
-aI-a 0.6 0.4 
Extra a-genes aa/aa 95.6 95.9 
aaaJoo or aooaJoo 4.3 3.7 
aaa/ooa or aaaa/aaaa 0.1 0.4 
A X2 test to determine the fit between the observed and the expected 
a-genotype showed an exceedingly high level of significance with a 
probability of 0.995>p>0.975 @ 2df using Microsoft Excel statistics (See 
Appendix 1). 
Gap PeR/or the detection of a+- and d-thalassaemia 
A peR based method was designed to speed up the analysis for the 
single a-gene deletions. Even though a O -thalassaemia was not observed in 
this cohort a method to detect these deletions was prudent as they are found 
at high frequencies in SE Asia and have greater clinical ramifications. Mr 
Y. T. Liu was responsible for the design of the oligonucleotides used in 
these assays. The conditions were tested using an ammonium sulphate or a 
potassium chloride buffer system with different DNA polymerase enzymes 
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and peR additives. The annealing temperature was optimised on a gradient 
thermocycler. 
a+ -thalassaemia 
A Gap-PCR method to screen for the two common a+-thalassaemia 
gene deletions (_a3.7 and the _a4.2) was developed (See 2.4). These 
mutations are deletions between homologous G-C rich regions around the 
a-genes. The primers were deliberately kept long (30mers) to allow high 
annealing temperatures and located in the non-homologous regions 
flanking the breakpoints. 
The PCR assay was performed on patients that had been previously 
characterised by Southern blot analysis. All a-genotypes were identical and 
included in the publication (Liu et a!., 2000). Further analysis of over 50 
more patients revealed a disturbingly high error rate (8%). All errors were 
due to normal allele dropout with a carrier for the _a4.2 gene deletion and 
three heterozygous for the _a3.7 gene deletion typed as homozygous for this 
deletion. Further optimisation helped but failed to consistently resolve this 
problem. Alternative oligonucleotides (Chong et al., 2000a) were 
substituted into the assay using the same buffer conditions and the errors 
were eliminated, as shown in Figure 3.2. 
Figure 3.2 a+-thalassaemia peR to detect the _a3.7 and the _a4.2 deletion 
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d -thalassaemia 
A multiplex Gap-PCR designed to detect the common aD -deletions 
included those found in SE Asia ( __ SEA, _fIL and _JHAI) plus two found 
around the Mediterranean ( __ Med and _(aiD.5). The PCR conditions used to 
amplify products across the breakpoints were similar to those established 
for the detection of a+ -deletions. The design of the primers to detect these 
large deletions is easier as many of the highly replicated areas are located 
within the deletion (See section 2.4). Typical results using previously 
characterised controls are shown in Figure 3.3. Out of 1046 alleles tested 
no cases of aD-thalassaemia were identified. 
Figure 3.3 o •• SEA THAI FIL MED ex -Thalassaenua peR multiplex to detect the -- , -- , -- , --
and - (ex)20.5 deletions 
..: 
r.l 
CI) tS tS J tS I tS tS tS tS J.. .... ""- Q""-"1' tS ....... tS ..; ..: 
t-- tS r.l tS N r--....... ..... -a CI) CI) -a .... ... tS .... >< I I I I I - >< .a- tS I I tS I I I I .a-
1187 .. 
1010 .. 
875 .. 
660 .. 
550 .. 
411 .. 
Hb Bart's and the incidence of a-thalassaemia 
Further investigations of the a-genes were conducted on sequential 
neonates born at the delivery units in Kurunegala and Chilaw to check 
against selection bias. These cord blood samples became available late in 
this study so protocols were established on cord blood from the UK. Prior 
to DNA analysis, population screens to detect a-thalassaemia were 
performed by ascertaining the proportion of neonatal samples with elevated 
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levels of Hb Bart's (See section 1.2.1). Hb Bart's becomes elevated with a 
greater chain imbalance where > a chains. 
Detection of Hb Bart's 
Estimations of Hb Bart's levels were assessed by comparison of 
three protein separation techniques; IEF, CAE and CE-HPLC (See section 
2.3). IEF and CAE were labour intensive so only 20 and 10 samples were 
tested by each method, respectively. They needed to be performed in small 
batches but gave a clear resolution of the Hb Bart's protein. A crude visual 
grading of relative proportions of haemoglobins was possible at high levels 
but remained inaccurate at low levels. The third method, CE-HPLC, 
employed the use of different cation exchangers; the a-thalassaemia short 
program, the short program and the sickle cell short 
program. This was a semi-automated method that allowed evaluation of 96 
samples in a single run that gave evaluations at both high and low levels. 
Comparison of HPLC columns 
The short program IS similar to the sickle cell 
screening program but elutes the proteins off the cation exchanger over half 
the time period. The a-thalassaemia short program is a column specifically 
designed to measure Hb Bart's or HbH that elute early with all other 
haemoglobins eluting later at the same retention time. Hb Bart's levels 
were evaluated on 168 cord blood samples using the a-thalassaemia short 
program and the {3-thalassaemia short program (Figure 3.4). 
The majority of the samples (57.7%) demonstrated an almost 
identical level of Hb Bart's. Most of the rest (overall 38.7%) showed a 
similar expression pattern with 20.8% and 17.9% having a modest change 
either greater or lower on the compared with the a-
thalassaemia column, respectively. The only large discrepancy was seen in 
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3.6% of samples that showed a much greater (-2 times) level on the B-
thalassaemia column compared to the a-thalassaemia column. These 
samples were re-assessed visually using rEF and CAE that suggested the a-
thalassaemia short column gave a more accurate determination of the level 
ofHb Bart's. 
Figure 3.4 
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Chart to show the Hb Bart's levels in cord blood collected in Sri 
Lanka and compared in pair wise fashion as measured on two 
different HPLC cation exchangers 
• Alpha-thalassaemia short column 
• 8eta-thalassaemia short column 
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Individual cord bloods 
Hackney study 
Over 150 cord blood sampJes were collected from the Homerton 
Hospital (London) and the Hb Bart ' s levels measured shortly after delivery 
using a sickle cell thalassaemia neonataJ screen program on the Biorad 
Variant Analyser. This was performed and assessed by Dr R. Amos such 
that enough samples with a wide range ofHb Bart's could be collected and 
transported to Oxford for DNA analysis. Southern blot analysis was 
performed and the a-genotype successfully assessed on 103 of these 
samples, by Miss M. Rugless. The results were plotted in increasing 
ascendancy ofHb Bart's levels (Figure 3.5). 
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Figure 3.5 Graph to show the correlation between the level of Hb Bart's and 
the a-genotype in cord blood samples from the Homerton Hospital 
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Hb Bart's was observed in all cord blood samples and a clear tri-
modal distribution was observed over this range, 0.5-11.9% and was 
summarised in Table 3.4. 
Table 3.4 Correlation of a-gene status with Hb Bart's levels 
Hb Batt ' s level (%) n a-Gene number a-Genotype 
0.5-1.4 25 4 aaiaa 
1.5-5.7 9 4 aaiaa 
41 3 -aiaa 
1 3 _aNew/aa 
1 2 -ai- a 
6.1-11.9 26 2 -ai-a or --faa 
The increasing level of Hb Bart' s appeared to correlate with an 
increasing level of a-gene deletion. An Hb Bart' s level less than 1.4% 
invariably resulted in a normal a-genotype. Between 1.5 and 5.7% most 
samples were linked with a single a-gene deletion. All cord blood samples 
with Hb Bart's above 6.1 and up to 11.9% had two missing a-genes either 
as --faa or -a/-a. A notable exception was observed in the middle group 
where -20% (11/52) of these samples did not appear to have a single a-
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gene deletion. Nine appeared to have a normal a-genotype (aaJaa), one 
was homozygous for a single a-gene deletion and one case gave new band 
patterns that needed further characterisation as summarised in Table 3.4. 
Sri Lankan cord blood study 
Cord blood samples were collected from two hospitals In Sri Lanka 
(Kuru neg ala Teaching Hospital and the Base Hospital in Chilaw), frozen 
and transported to the UK under the direction of Miss S. Rajapakshe. In 
Oxford, the level of Hb Bart' s was estimated by cation exchange CE-HPLC 
using the f}-thalassaemia short program. The a-thalassaemia column was 
deemed too expensive and was only used on a part of the Sri Lankan cord 
blood cohort. The frequency distribution of Hb Bart's was plotted (Fig 3.6) 
and an estimate for the incidence of a-thalassaemia made using cut off 
points determined from the Hackney study. 
Figure 3.6 Distribution of Hb Bart's in Kurunegala (. ) and Chilaw (. ) 
measured by HPLC using the /3-thalassaemia short program 
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The two study centres showed a divergence in the predicted a-
genotype frequencies compared with the transfusion dependent patients 
earlier. Amazingly, the overall genotype frequency of a-thalassaemia 
predicted from the level of Hb Bart's was almost identical to that observed 
in the transfusion dependent patients. Single a-gene deletions and two a-
gene deletions were predicted in 13.6% and 0.3% of samples (Table 3.5). 
The previous assessment on the incidence of a-thalassaemia in Kurunegala 
was similar but was much lower in Chilaw, more consistent with that of 
nearby Kurunegala. 
Table 3.5 
Level of 
Predicted incidence of a-thalassaemia in Sri Lanka from Hb Bart's 
levels found in cord blood 
Kurunegala Chilaw Combined 
Hb Bart's (%) Number Frequency Number Frequency Number Frequency 
0.5-1.4 229 85.1 44 91.7 273 86.1 
1.5-5.7 39 14.5 4 8.3 43 13.6 
6.1-11.9 1 0.4 0 0 1 0.3 
Total 269 100 48 100 317 100 
DNA from 75 cord blood samples were extracted and the a-genotype 
analysed by Gap-PCR or Southern blot analysis (Table 3.6). A much less 
clearly defined genotype distribution pattern was observed over the 
observed range of Hb Bart's levels (0.5-10.3%) compared to the Hackney 
study. Using the established cut off points almost one third (22175) of the 
samples did not conform to a predicted phenotype/genotype prediction. 
Four samples had low Hb Bart's level and were expected to correlate with a 
normal a-genotype but revealed a single a-gene deletion (_a3.7), five had a 
borderline level of Hb Bart's with a nonnal a-genotype and the remainder 
had elevated levels ofHb Bart's with a normal a-genotype. 
77 
Table 3.6 Correlation between the Hb Bart's level in cord blood and the a-
gene arrangement in samples collected in Sri Lanka 
Hb Bart's level (%) n Patient a-gene a-Genotype 
number 
0.5-1.4 42 4 aaJaa 
4 3 -aJaa 
1.5-5.7 18 4 aaJaa 
10 3 -aJaa 
6.1-11.9 1 2 -aJ-a 
Further analysis of these samples assessed by CE-HPLC using the a-
thalassaemia short program showed that all four samples with a lower level 
of Hb Bart's than expected when in association with a single a-gene 
deletion were low using either column. Half of the samples (9/18) with a 
nonnal a-genotype and an elevated Hb Bart's level now demonstrated a 
lower level of Hb Bart's more consistent with their revealed a-genotype. 
The other half still appeared to be raised. This unreliability was probably 
due to a logistical problem. The processing of the samples (freeze-storage) 
prior to analysis may form protein agglutinates and alter the true expression 
pattern. 
The spectrum of mutations observed was similar to those determined 
earlier in the transfusion dependent cohort. Eleven cases were found to be 
carriers for the _a3.7 allele, two cases for the _a4.2 allele and two cases 
homozygous for the _a3.7 allele were found. 
3.2. Non-Deletion a-thalassaemia 
Non-deletion <x-thalassaemia has been found in all nearly all regions 
of the world and in combination with aO-thalassaemia results in HbH 
disease (See section 1.2.2.2). However, its incidence has been hard to 
establish due to the difficult technical problems associated with reliable 
detection within the a-globin cluster. This form of a-thalassaemia has been 
reported in India and together with the preponderance of samples with an 
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unaccountably high level of Hb Bart's using the a-thalassaemia short 
program an analysis of the a-genes was considered necessary. The goal 
was to develop a more robust strategy of analysis for mutations in and 
around the a-genes on strong candidates referred to the NHRL. Candidates 
for this form of a-thalassaemia from many popUlations, especially India, 
were included so that any mutations found in the Sri Lankan population 
could then be compared and an indication of the origin of these mutations 
could be postulated. 
Patients for a-gene analysis 
Patients referred to the NHRL (See section 2.2) that were microcytic 
and hypochromic that was not due to iron deficiency or deletion forms of 
a-thalassaemia became candidates for non-deletion a-thalassaemia. In Sri 
Lanka studies were initiated to investigate transfusion dependent patients 
so good candidates for non-deletion a-thalassaemia were unavailable. 
Therefore, a random screen for non-deletion a-thalassaemia was performed 
on transfusion dependent patients and their relatives attending a clinic at 
Anuradhapura. However, the cord blood studies, in Hackney and Sri 
Lanka, with unexplained elevated Hb Bart's levels provided better 
candidates for further investigation. 
Indian a-ARMS and RFLP Screen 
Assays were developed for six mutations [Hb Evanston: al codon 14 
(TGG-7CGG); al IVSI-117 (G-7A); Hb Sun Prairie: a2 codon 130 
(GCT-7CCT); Hb Koya Dora: a2 termination codon (TAA-7TCA); Hb 
Constant Spring: a2 termination codon (T AA -7CAA) and a2 
polyadenylation signal (AATAAA-7AATA_)] reported in patients 
originating from the Indian subcontinent. All ARMS primers were 
designed with two mismatched nucleotides, one strong and the other weak, 
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within the last four nucleotides (3') of the primer. Hb Constant Spring 
detected by RFLP analysis as the mutation removes a restriction enzyme 
site (Mse l) but could be confused with the other mutations that remove the 
restriction enzyme motif (Viprakasit et al., 2002). The primers and 
conditions are shown in section 2.4 and a typical positive result highlighted 
in Figure 3.7. These assays were performed on all the aT candidates and the 
results are shown in Table 3.7. 
Figure 3.7 ARMS assay for the detection of Hb Sun Prairie 
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Table 3.7 Non-deletion a-thalassaemia determined by ARMSIRFLP analysis 
for the six known mutations described in Indian patients 
Origin Number of a-gene status Number of 
IndividuaJs IndividuaJs 
screened 
Sri Lanka 190 Wild type 190 
Indian Subcontinent 39 Poly A tail 5 
(AATAAA ) 
Hb Sun Prairie 1 
Wild type 33 
Europe 40 Wild type 40 
Africa 9 Poly A tail 1 
(AATAAA ) 
Wild type 8 
Middle East 25 Poly A tail 2 
(AATAAA ) 
Wild type 23 
SE Asia 12 Hb Constant SQring 4 
Wild type 8 
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In a limited screen of patients and their relatives from Anuradhapura 
all were found to be negative for these mutations. In the group of patients 
referred to the NHRL 131125 were positive for the Indian a-ARMS and 
RFLP Screen found with three of these mutations (poly A tail 
(AATAAA __ ), Hb Sun Prairie and Hb Constant Spring). 
Un surprisingly, six of the patients originated from the Indian subcontinent 
but the remainder originated from Africa, the Middle East and SE Asia. 
Sequence analysis strategy 
Amplification oligonucleotides were designed and buffer conditions 
optimised for the investigation of both the al- and a2-gene independently 
(See section 2.4). These buffers, like those used in Gap-PCR and ARMS of 
the a-genes, were reliant on the inclusion of the organic denaturant betaine. 
Its subsequent inclusion in the cycle sequence reaction also changed a poor 
sequence reaction into a fair to good sequence reaction for these G/e rich 
templates. A full sequence analysis stretching from Cap-I50 to 150 
nucleotides beyond the poly A tail was obtained on both the al- and a2-
gene using a modified big dye terminator strategy. 
Hackney cord blood a-gene sequence 
The methodology was tested on candidates from the Hackney cord 
blood study as these had been assessed and needed further characterisation 
to identify reasons for elevated Hb Bart's in these samples. Seven cord 
blood samples with elevated Hb Bart's levels (1.8-5.7%) that appeared to 
have a normal a-gene status (aa/aa) and four samples with Hb Bart's 
levels above 10% samples were investigated by sequence analysis of both 
the al- and arglobin genes (Table 3.8). 
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Table 3.8 a-gene sequence analysis of Hackney cord bloods with possible a.T 
Hb Bart's a-genotype 
Cord level (%) 
blood Southern blot Sequence Sequence variation 
No analysis analysis 
34 1.8 aaJaa aaJaa Normal consensus 
39 2.1 aa/aa aTaT/aaor (Xl: IVSI-39(C-tT) Heterozygous 
a.aT/aTa (X2:IVSII-llS( -7bp) Heterozygous 
54 3.3 aaJaa aaJaa Normal consensus 
55 3.3 aaJaa aaT/aa al:Hb Evanston Heterozygous 
67 3.8 aaJaa aaJaa Normal consensus 
76 5.6 aaJaa aaJaa Normal consensus 
77 5.7 aaJaa aTaJaa 0.2: Hb Sallanches Heterozygous 
100 10.7 _0.3.7/_0.3.7 _0.3.7/_0.3.7 Normal consensus 
101 11.7 _0.3.7/_0.3.7 _a3.7(f)/_a3.7 a2:NSn -55(G-t T) Heterozygous 
102 11.7 _0.3.7/_0.3.7 _a3.7/_a'J·7 Normal consensus 
103 11.9 _0.3.7/_0.3.7 _0.3.7/_0.3.7 Normal consensus 
Seven of these samples (34, 54, 67, 76, 100, 102 and 103) 
demonstrated a nonna! consensus sequence. Further investigation to 
examine red cell indices in these families would confrrm their phenotypic 
status but require ethical permission to proceed. Four samples showed 
sequence variations that were confrrmed by reverse strand sequence 
analysis and where possible by RFLP. 
Two cord blood samples were found to be heterozygous for 
previously described point mutations in the a-genes. The fITst was a cord 
blood sample (77) with an Hb Bart's level of 5.7%. Sequence analysis 
identified a single nucleotide substitution at codon 104 (TGC-4TAC) of the 
a,2-gene (Figure 3.8) that encodes for the amino acid change cysteine to 
tyrosine. The mutation, Hb Sallanches, was previously described in a 
French individual (MorIe et ai., 1995). 
The second mutation was found in a cord blood (55) with a small 
elevation in Hb Bart's level to 3.3%. A single nucleotide substitution at 
codon 14 (TGG-4CGG) in the (Xl gene (Figure 3.8) encodes for a change in 
amino acids from tryptophan to arginine. This amino acid substitution, Hb 
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Evanston codon 14 (TGG---'7AGG), was previously described in a patient of 
African origin (Honig et al., 1984). This patient was of Indian origin with 
the same amino acid substitution but with a different base change at codon 
14 (TGG---'7CGG). A similar case was described in a meeting abstract 
(Huisman et al., 1997). 
Two cord blood samples were found to be heterozygous for new 
mutations in the a-genes. The first was found in the cord blood sample (39) 
associated with an Hb Bart's level of 2.1 %. The mutation, a heterozygous 
base substitution in the at gene, changed a cytosine to a thymidine at 
position 39 of the first intron (Figure 3.8). This putative new splice variant 
does not create a motif similar to any globin acceptor or donor site and 
requires further examination by RNA analysis. In the same individual 
another heterozygous change was found in the second intron of the ar 
gene. A small deletion that removed seven nucleotides in the second intron 
(IVSII-115 (-GGCCCTC» was identified (Figure 3.8). This deletion 
changes the sequence so that it is the same as the al intron 2 consensus 
sequence and probably constitutes a polymorphism. In the last case, 
another CXI---'7CXZ base substitution was found at nucleotide 55 (G---'7T) in the 
second intron in the heterozygous condition (Figure 3.8) in a sample with 
two a-genes deleted. The level of Hb Bart's in this cord blood was 11.7% 
and is consistent with a silent polymorphism. 
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Figure 3.8 Mutations in and around the at and a2 genes found in cord 
bloods with elevated Hb Bart's levels from the Hackney study 
Heterozygous 
Hb Evanston Trait 
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_ _ , 
Normal . 
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Hb Sallanches Trait 
codon 104 
5' -GCCACTGCCTGCTGGTGA-3' 
5' -GCCACTA CCTGCTGGTGA-3' 
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a-gene analysis of patients from the subcontinent of India 
Thirty-nine patients were investigated by complete sequence analysis 
of the al and <X2 genes. Mutations were found in 22 cases but the remaining 
17 cases presented with only consensus normal sequence (Table 3.9). 
Table 3.9 Sequence variation in individuals originating from the Indian 
Subcontinent 
Gene Cases 
Codon42 (TTC---7TTG); Hb Hirosaki (Xl 1 
Codon 38/39 (-ACC); Hb Taybe (Xl 1 
Codon 38/39 (-ACC); Hb Taybe & (Xl 1 
Codon 113 (CTC---7CTG) 
CD130 (GCT ---7CCT); Hb Sun Prairie (X2 1 
Cap+ 14 (C---7G) a2 1 
IVSII-55 (T ---7G) a2 4 
IVSII-55 (T---7G)+IVSII-115 (+7bp) a2 1 
IVSII-115 (-7bp) (XI 1 
Poly A Tail (AATAAA ---7AATA ) (X2 5 
Poly A Tail +7 (G---7T) <XI 1 
CD124 (TCC---7TTC) <X2 
(C---7G) +IVSII-115+ 7bp <X2 1 
IVSI-39 (C---7Gl <X2 1 
Cap+14 (C---7G)+IVSII-70 (T---7G) (X2 1 
Codon59 (GGC---7CGC) (X2 1 
IVSII-51 (C---7G) a2 1 
No mutations observed Nonnal 17 
Total 39 
Nine patients were found to have four previously described 
mutations (Figure 3.9). Two cases of Hb Taybe were found as reported in 
subjects from the Middle East (Pobedimskaya et ai., 1994). The third was 
an a-chain variant, Hb Hirosaki, described in a Japanese family (Huisman 
& Carver, 1998). 
The fourth was heterozygous for Hb Sun Prairie and five patients 
were found to be heterozygous for the polyadenylation signal mutation 
(a2:AATAAA __ ). Both mutations were previously reported in 
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Indian patients (Harkness et ai., 1990; Harteveld et at., 1994) that validated 
the ARMS-PCR method. 
A further seven patients had mutations that have been previously 
described as neutral polymorphisms. A mutation was found in the cap 
sequence (Cap+14 (C-70» in a single case that had been previously 
observed (Harteveld et ai., 1996). A point substitution described earlier 
(IVSII-55 (T -70» was found in 4 individuals and one individual was 
found with the same 7bp deletion in the second intron (IVSII -115 (-
OGCCCTC». The final case was doubly heterozygous with two mutations 
in the second intron, IVSII-55 (T-70) and IVSII-1l5 (+OOCCCTC). 
Six individuals were found to carry mutations that have not been 
described before as shown in Figure 3.10. The frrst individual had a single 
heterozygous base change in the (Xl-gene (Poly A Tail +7 (O-7T» found in 
conjunction with a single heterozygous base change in the a2-gene (CD124 
(TCC-7TTC). In the thalassaemias no base substitutions have been 
described after the polyadenylation signal only deletions that extend 
beyond it (Weatherall & Clegg, 2001). The base change at codon 124 
would change a serine to a phenylalanine that may disrupt the al:132 contact 
point. This individual demonstrated a very mild to borderline set of red cell 
indices (Hb 11.8g/dl; MCV 83.6ft; MCH 25.7pg and HbA2 2.7%). 
The second individual originated from Pakistan and was found to 
have two mutations in the u2-gene, cap-4 (C-70) and IVSII-115 (+7bp) but 
presented with normal red cell indices suggesting the mutation(s) appeared 
to be clinically mild or of little significance. 
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CTGAGTCTGTGGGACCAGAAG GGGCCTGGGCCGCACTGACCCTCTTCTC 
Figure 3.9 Sequence chromatograms of sequence variation - . -
Normal 
found in individuals originating from India 
GACAAGTTCCTGCCTICTGTGAGC 
GACAAGTTCCTGGCTTCTGTGAGC 
A mutation in the cap region of the uTgene (Cap+ 14 (C---tG)) was 
found in the third patient with borderline/nonna! indices. This mutation 
was also found in combination with a second mutation located in intron-2 
(IVSII -70 (T ---to)) and presented with a more severe red cell index. 
Previously described mutations in the cap region of the f)-globin gene have 
all been associated with an extremely mild phenotype (Huisman et ai., 
1997) and this mutation has been previously described as a polymorphism 
(Hartveld et ai., 1996). The mutation in intron-2 was not similar to any of 
the observed globin donor or acceptor motifs and needed further 
characterisation. 
The fourth patient presented with moderately reduced red cell indices 
(Hb 11g/dl; MCV 60.3ft and MCH 20pg) and was found to have a single 
heterozygous nucleotide substitution in the first intron of the a2-gene 
(IVSI-39 (C---tG)). This is the same mutation described in the Hackney 
study except that was observed in the aI-gene. This mutation may create a 
new splice site to allow premature splicing but is unlike any of the 
observed globin donor or acceptor motifs. 
The fifth case presented with mildly reduced red cell indices. A 
single heterozygous point mutation (codon 59 (OGC-tCGC)) was found in 
the second exon of the a2-gene. This base change would alter the amino 
acid from a glycine to an arginine that may result in a nonsense or unstable 
protein that cannot form part of a stable haemoglobin tetramer. 
The final case presented with near normal indices but was found to 
have a heterozygous change (IVSII-51 (C---tG)) in the a2-gene but is unlike 
any of the observed globin donor or acceptor motifs. 
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Figure 3.10 New sequence variations in the a-gene(s) found in 
patients originating from India 
Normal 
TCTTTGAATAAAGTCTGATTG 
TCTTTGAATAAAGTCTGAGTG 
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AGAAGAGTGCCCGGCCGCG GGGCCACCGCAAGAAGG CGCCTTCCTGGACAAGTTCCTGG 
AGAAGAGTGCCGGGCCGCG 
TCCTCGCGCGCCCGGA 
TCCTCGCCCGCCCGGA 
TTGCTCTCAGGGC 
TTCCTCTCAGGGC 
Sri Lanka: a-gene sequence 
Southern blot and sequence analysis was performed on 19 cord blood 
samples that exhibited a wide range of Hb Bart's level. The majority 
exhibited a normal consensus sequence. 
Three samples showed sequence divergence with the normal 
consensus a-gene sequence. The first (K83) was found to have the same 
heterozygous point mutation (Cap+14 (C-tG» in both the al and a2-gene 
(Figure 3.9). This was associated with an Hb Bart's level of 2.0%. The 
second and third individuals (K93 and K4) were found to have the same 
heterozygous mutation (Cap-4 (C-tG», except the former was identified in 
the aI-gene and the latter in the a2-gene (Figure 3.10). The Hb Bart's level 
found in these cord bloods was 1.2% and 2.2%. This same mutation was 
described in a patient from the Indian subcontinent earlier. The Hb Bart's 
level indicates that this degree of chain imbalance would most likely be 
associated with a mild phenotype or a polymorphism. 
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3.3 Discussion 
Many surveys have been undertaken to evaluate the incidence of a-
thalassaemia in different populations based on the quantification of Hb 
Bart's levels in cord bloods (reviewed in Weatherall & Clegg, 2001). These 
were considered crude as estimates for Hb Bart's are technically difficult 
and subsequent correlation with the a-genotype was inconsistent. The 
advent of DNA analysis allowed a much more definitive assessment and 
became the most widely used method but screens mainly for known forms 
of a-thalassaemia. a-gene deletions are common across many tropical and 
sub-tropical regions. Characterisation of the prevalence of these forms 
would allow a greater understanding of the subsequent health risks. 
Technical developments 
Hb Bart's quantification 
An accurate determination of Hb Bart's levels is critical for its 
subsequent correlation with a-thalassaemia, especially at low levels «2%). 
CE-HPLC was the most efficient method tested. The sensitivity was good 
as all samples analysed showed some Hb Bart's ranging from as little as 
0.5% of total haemoglobins. Previous studies reported using CAE included 
many samples with no Hb Bart's (Pembrey et aZ., 1975; Higgs et ai., 1982; 
Lie-Injo etaZ., 1982). 
The a-thalassaemia short program and the short 
program yielded similar evaluations for Hb Bart's, in most cases, but a 
small number of samples (3.6%) gave values for the level of Hb Bart's 
higher by a factor of two. Further examination using IEF and CAE showed 
a better correlation with the a-thalassaemia short program. HPLC analysis 
could be related to other methods even if the estimations were different. 
Hence, a system of calibration was required to relate the level of Hb Bart's 
with the a-gene status (Papassotiriou et ai., 1999). 
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In the Hackney cord blood study a tri-modal distribution was 
observed with a good correlation between the level of Hb Bart's and the 
degree of a-gene disruption and subsequent expression. Below 1.5% all 
samples demonstrated a normal a-gene arrangement. All other previous 
studies showed that the assessment of Hb Bart's at low levels was 
inadequate to define the aaJaa and -aJaa genotype using CAE (Higgs et 
al., 1982; Lie-Injo et al., 1982). At the cut off point (1.5%) both genotypes 
were observed and so formed a point of overlap. 
The second cut off point was more distinct as no cord bloods were 
found with Hb Bart's levels above 5.7% or below 6.1 %. Within the first 
and second anti-nodes cord bloods were associated with a single a-gene 
deletion. However, over one fifth of the cases within this category did not 
show a single a-gene deletion and required further investigation. Further 
investigation of the seven available samples with a putative aaJaa 
genotype revealed two known non-deletion a-thalassaemia and one with a 
putative new non-deletion a-thalassaemia. However, four cases still 
appeared to have nonna! consensus sequence. All samples with Hb Bart's 
levels above 5.9% and up to 11.9% correlated with a-gene arrangements 
possessing just two genes. A distinction between -ai-a and --faa could not 
be made. These observations were in line with previous studies (Higgs et 
ai., 1982; Lie-Injo etaZ., 1982). 
Analysis of Hb Bart's in fresh cord bloods appeared to represent an 
extremely efficient and accurate indicator of the incidence of u-
thalassaemia without the need to perform DNA analysis. The cut off values 
to distinguish different a-thalassaemia groups matched a previous study 
observed using CAE analysis (Pembrey et ai., 1975). However, DNA 
analysis of a selection of frozen cord bloods from Sri Lanka only showed a 
rough agreement with this categorisation. Any discrepancy may have been 
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due to an unusual gene arrangement in either the a- or y-genes but was, 
more likely, due to an artefact of the process of freezing the sample prior to 
analysis. Unfortunately, a haemoglobin analyser was not available on the 
island as the cost of the machine to the Health Service or to research groups 
was deemed prohibitive. Hence, the only way to analyse these samples was 
to transport them on ice whenever they were collected or to transport them 
as batches of frozen lysates. 
DNA analysis 
Many groups have designed PCR based methods for the detection of 
the common a+-gene deletions (Dode et ai., 1993; Baysal & Huisman, 
1994; Bowie et ai., 1994; Chang et al., 1994; Smetanina & Huisman, 1996; 
Galenello et ai., 1998; Oron-Karni et ai., 1998; Chong et ai., 2000a and band 
Shaji et aI., 2000). PCR assays have also been developed for the detection 
of aO-gene deletions (Chang et al., 1991; Bowden et al., 1992; Ko et al., 
1992; Bowie etai., 1994; Winchagoon etaZ., 1995; Chong etat., 2000a and b 
and Eng et at., 2000). All methods have needed to overcome the high G-C 
content and the duplicated nature of the region but the earlier protocols 
suffered from a lack of reproducibility in other laboratories. The 0.0 -gene 
deletion assays have been more successful probably as greater areas of 
sequence homology are deleted. 
Amplification of the a-gene and the development of a specific 
mutation detection system for a-gene mutations are subject to the same 
problems. They have been overcome in three ways. The first was by 
amplification of small segments to build a jigsaw puzzle (Hsia et aZ., 1989; 
Kropp et al., 1989; Hartveld et ai., 1996). The second was by using multiple 
rounds ofPCR using nested primers (Do de etal., 1990; Yuregir etaZ., 1992) 
and the third was to use additives to enhance amplification (Dode et ai., 
1990). Many reagents have been included in an attempt to increase 
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amplification efficiencies (Bachmann et ai., 1990; Rees et al., 1993; 
Varadaraj & Skinner, 1994; Henke etaZ., 1997). 
New oligonucleotide primers for Gap-PeR and amplification of the 
a-genes were designed but the most important improvement for all these 
protocols was the enhancement of the PCR buffer conditions. For all sets of 
oligonucleotides the addition of betaine, DMSO and Tween 20 in an 
buffer with the use of hot start conditions greatly improved the 
amplification ofPCR within the G-C rich a-cluster. This also applied to the 
cycle sequence extensions and for ARMS-PCR to directly detect specific 
mutations. In fact, some previous studies may tum out to be useful if 
optimised using the new buffer systems. All peR strategies require the 
primary DNA sequence at the primer annealing sites to remain unchanged 
so that amplification is not hindered. 
Clinical consequences of a-thalassaemia 
The estimated a-genotype frequency in a cohort of transfusion 
dependent patients and by measurement of the level of Hb Bart's was 
remarkably similar. Single a-gene and double a-gene deletions were 
observed at 13.8 and 0.4%, respectively. Hence, in a population of 18.6 
million the approximate incidence of heterozygous and homozygous a+-
thalassaemia would be predicted to be 2.6 million and 56 thousand, 
respectively. Generally, these mutations would be associated with a normal 
phenotype and would pose no notable health problems (See section 1.2.2.2) 
but reach these tremendously high levels because of their selective 
advantages. 
Transfusion dependent {3-thalassaemia patients have severely 
defective {3-globin chain production that results in an excess of a-chains. 
Any factor that modifies the magnitude of this surfeit should have an 
important effect on their phenotype (Ratip et aZ., 1997; Weatherall, 2001). 
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This study group could be directly compared with cord blood samples from 
a maternity unit that should have consisted of individuals with a nonna! 
incidence of haemoglobinopathies on the island. However, as samples from 
the two study groups gave almost identical results any modifying effects 
from a-thalassaemia was probably coincidental. 
No evidence of aO -thalassaemia was found on the island and as a 
consequence Hb Bart's hydrops fetalis or HbH were not observed. Cord 
blood analysis did not reveal many candidates for non-deletion a-
thalassaemia. Limited sequence analysis on these individuals was 
uninformative. 
Evolutionary aspects 
Incidence of different forms of a-gene deletions and insertions 
Past studies on Indian tribal groups showed high carrier frequencies 
of a-thalassaemia ranging from 50% up to 80% (Brittenham et ai., 1980; 
Kulozik et ai., 1988; Gupta et ai., 1991; Modiano et al., 1991). By contrast, 
the carrier frequency in the non-tribal population had been found to be 
much lower ranging between 4-15% (Hassall et ai., 1988; Misra et ai., 1991; 
Desai et ai., 1997). The high frequency of a-thalassaemia in the tribal 
groups was probably due to the manner in which these communities have 
remained closed. The genetic pool becomes limited and some traits can 
become greatly amplified. The incidence of a-thalassaemia observed in Sri 
Lanka was similar to the non-tribal groups of India but is also in keeping 
with populations from many tropical and sub-tropical zones. The 
indigenous population of Sri Lanka, the Veddah, have never been tested for 
the incidence of a-thalassaemia but probably align more closely with tribal 
popUlations of India. 
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In Sri Lanka only two types of a-thalassaemia were observed, _a3.7 
and _a4.2, that had allele frequencies of 6.5% and 1.1 %, respectively. This 
occurrence was observed all round the island in the transfusion dependent 
patients and also in the cord blood study. Only when the number of patients 
in a study group was small, were the relative frequencies notably different. 
However, the most northerly centre studied with a reasonably large number 
of alleles, Anuradhapura, had a higher allele frequency for both these single 
a-gene deletions of 10.8%. Towards the lower middle of the country the 
combined allele frequency for Badulla, Colombo and Kurunegala was 
almost half this value at 5.7%. 
The bottom left hand comer of the island, extending just above 
Colombo and across to Ratnapura and Matara, is thought to constitute the 
wet zone. The number of breeding grounds for the different Anopheles 
species (pools on the beds of rivers and streams) depends on the pattern of 
rainfall. In the wet zone abundant rainfall throughout the year maintains a 
constant flow in the rivers. In the dry zone of the country, where malaria 
was endemic large numbers of surface pools provide ideal breeding 
grounds for the insect (van der Hoek et al., 1997). The higher incidence of 
a-thalassaemia in the north may correlate with the greater exposure to 
malaria. 
In comparison, the spectrum of a-thalassaemia mutations reported 
on the Indian subcontinent showed the same predominant molecular 
lesions. Approximately 80% of the mutations seen were the _a3.7 allele and 
most of the rest were the _a4.2 allele (Kulozik et ai., 1988; Hassall et ai., 
1988). The _a3.7 allele is found in nearly all populations but the _a4.2 allele 
is found at higher frequencies in SE Asia. 
Even though no a O -thalassaemia alleles were found in our study a 
single case of HbH disease has previously been reported (de Tissera et al., 
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1988). Its clinical significance on the island is low as its incidence probably 
only occurs in isolated families similar to India (Drysdale & Higgs, 1988). 
The spectrum and frequency of a-gene arrangements in Sri Lanka and 
India was more consistent with a shared genetic history or the same 
environmental influence between these two countries. 
In Sri Lanka, two forms of extra a-genes were observed, aaaanti3.7 
and aaaaanti3.7, at frequencies of 2% and 0.2%, respectively. In this 
popUlation this high incidence would give a predicted carrier frequency of 
0.76 million people with extra a-genes. Extra a-genes, without any other 
haemoglobinopathy, are asymptotic but in combination with f3-thalassaemia 
can deleteriously exacerbate that condition (Discussed in Chapter 6). 
Interestingly, the aanti3.7 gene insertion is the counterpart of the a3.7 gene 
deletion and when a cross over event has occurred both alleles exist in the 
progeny. Successive progeny should have an equal chance of passing on 
the two different gene arrangements. This was obviously not the case and 
was further support for the positive selection for a-thalassaemia. 
The distribution pattern for extra a-genes is anecdotal. Patients with 
extra a-genes have been described at low levels in most popUlations 
studied from Africa, around the Mediterranean, in the Middle East and in 
India (reviewed in Weatherall & Clegg, 2001). In fact, a population study 
on natives from the Punjab demonstrated a single a-gene deletion of 10% 
and a single a-gene insertion of 5% (Garewal et al., 1994). Any link 
between populations required further studies to evaluate the level of extra 
a-genes in India to make a rational comparison. 
Incidence of different forms of non-deletion a-thalassaemia 
The global incidence of non-deletion a-thalassaemia is not known 
but as the a-gene is thought to be older than the gene (Czelusniak 
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et al., 1982) and is duplicated a greater possibility of mutations should have 
occurred. Previous cord blood on Greek and Middle Eastern populations 
have indicated that the number of samples with elevated Hb Bart's not due 
to a-gene deletions is variable between populations and lies between 1 and 
10% (Kyriacou et al., 2000). However, the underlying cause for the chain 
imbalance has not always been identified and many cases remain an 
enigma. 
A similar fraction of cord blood specimens from the Hackney study 
(-10% of total) also exhibited raised Hb Bart's levels that were probably 
not due to deletion of the a-globin gene. In Sri Lanka cord blood 
specimens confrrmed the same level of a-thalassaemia in the general 
popUlation (Table 3.5) as observed in the transfusion dependent 13-
thalassaemia major and HbE/I3-thalassaemia patients (Table 3.1). Thus, the 
incidence of non-deletion a-thalassaemia in Sri Lanka would appear to be 
non-existent. However, 22175 of these cord blood samples (Table 3.6) did 
not agree with the predicted genotype associated with the estimated level of 
Hb Bart's after DNA analysis. This would imply that either the estimation 
of Hb Bart's may have been flawed or that different forms of a-
thalassaemia may be found on the island that was not revealed in the 
transfusion dependent l3-thalassaemia major and HbElI3-thalassaemia 
patients investigated. Southern blot analysis of these cord blood samples 
indicated that the a-globin gene clusters appeared nonnal. a-globin 
sequence analysis was perfonned on a cross section exhibiting different 
levels of Hb Bart's. 
In Sri Lanka, only two sequence variations were revealed from 19 
cord blood samples analysed. A point substitution in the promoter region 
(Cap-4 and a point substitution in the cap region (Cap+ 14 
that were both associated with modestly elevated Hb Bart's levels. Further 
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regional cord blood analysis within Sri Lanka needs to be performed to 
identify a larger cohort of candidates that may have non-deletion (X-
thalassaemia. The latter mutation has been observed in many world 
populations but the former was only observed in a patient from Pakistan 
and link these two populations. Only more intensive studies of individuals 
from Sri Lanka and the Indian subcontinent will the significance of these 
mutations be determined. 
In conclusion 
Deletion forms of (X- thalassaemia were found to be common in Sri 
Lanka as was that of extra (X-genes that is common for a population that 
have been exposed to malaria for a long period of time. However, no 
evidence was observed for the presence of a O -thalassaemia and probably 
the only variation in the normal consensus sequence was due to 
polymorphisms. These a-gene arrangements are both consistent with a 
tropical popUlation but more specifically are in keeping with the notion that 
this population is closely linked to that of some populations within the 
Indian subcontinent. The advancement of methods to screen for these 
various molecular lesions by either biochemical analysis or by DNA 
analysis will allow much more accurate determinations on their frequency 
and spectrum. Indeed, micro-mapping may reveal groups within this 
popUlation that are prone to specific forms of these gene arrangements that 
may well exist in isolated communities. Their identification may infer 
genetic ties with other populations but more importantly could improve the 
course of management of some forms of thalassaemia to result in enhanced 
health care and better quality of life. 
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Chapter 4 !i-Thalassaemia 
The objective of the study was to gain an assessment of the spectrum 
and frequency of a-thalassaemia and a-chain variants in Sri Lanka. The 
clinical importance, in combination with each other, assessed and a 
comparison of their incidence made with other populations around the 
world, especially against groups within the subcontinent of India. 
4.1.. Schoolchildren survey 
Over 1600 blood samples were collected from 18 schools in 15 
districts and haemoglobins analysed by CE-HPLC in Oxford. No sample 
collection was undertaken from the Northern Province due to the ongoing 
civil war. Haemoglobin variants can be detected by protein separation 
techniques and the incidence of a-thalassaemia estimated by measuring the 
amount of HbA2• CE-HPLC is a powerful technique to identify Hb variants 
and to assess the level of haemoglobins HbF and HbA2• However, the 
elution profile time from CE-HPLC is small and Hb variants may be 
obscured by co-elution, particularly with HbA. 
After developmental switching to the adult forms of haemoglobins a 
small amount of HbAz is seen in all individuals (See section 1.2.1). A 
distribution plot of HbA2 values up to 10% combining all the regions on the 
island is shown in Figure 4.1. Five distinct groups were interpreted as 
correlating with different globin genotype states. 
(i) A very low HbA2 level < 1.5% may be due to a-thalassaemia or 0-
thalassaemia and can also be due to iron deficiency. preferentially 
form tetramers with the a.-chains. If the latter are scarce, the formation of 
HbA2 is also reduced as with any reduction in the level of O-chain 
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production. A frequency of 6.2% was observed which is about half the 
carrier frequency for a-thalassaemia observed on the island. 
Figure 4.1 Distribution of blood Hb A2 levels in Sri Lankan schoolchildren 
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(ii) A normal distribution range for HbA2 showed values between 1.5% 
and 3.4%. A high proportion of the schoolchildren (90.9%) fell into this 
group. 
(iii) Individuals with HbA2 between 3.4 and 4% were in the 'borderline 
raised group'. These cases may have been part of the high end of the 
normal spectrum or due to a very mild form of f3-thalassaemia. f3-
thalassaemia has a paucity of available f3-chains and a concomitant excess 
of a-chains that form tetramers with the available 8-chains. Only a few 
individuals, 0.2%, were observed in this group. 
(iv) Individuals with an elevated level of HbA2, 4 to 8%, were thought to 
have f3-thalassaemia in a slightly more severe fashion (moderate to no 
expression of the f3-chains) but may have been due to f3-gene deletions. 
Again HbA2 forms due to the lack of f3-chains. The incidence on the island 
in this cohort of schoolchildren was 2.1 %. 
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(v) Individuals with a highly elevated HbA2 level, above 8%, probably 
possess a haemoglobin variant or may have a gene deletion, even 
though these forms of thalassaemia are extremely rare. In the population of 
Sri Lanka HbE was a good candidate has been previously reported in this 
population and is known to co-elute with HbA2• 
Developmental switching of haemoglobins around birth results in the 
expression of HbA instead of HbF, but a residual level of HbF is often 
observed in many individuals (See section 1.2.1). A distribution plot of 
HbF values up to 10% combining all the regions on the island is shown in 
Figure 4.2. The presence of two distinct groups suggested different 
haemoglobinopathy states. 
,---------------- ------------------, 
Figure 4.2 Distribution of blood Hb F levels in Sri Lankan schoolchildren 
........ 600 VJ ...... 
0; c--i 
::I 'D II 
"0 u.. 0;; 500 & :.a c:: IS'< 
'D ..... 400 IS'< ex[ 0 M 
0 V M 1\ 6 u.. 
:>... 300 u = (\) 
:::I 
0"' 200 
100 
0 If) "")N"")M "")c;o "")0) \1")0 
0 r- oo 
0; ...... 
N 
HbF Level (%) 
(i) Individuals with an HbF level less than 3% were classed as 'normal'. 
All populations show this range but the cut-off value is not so high. The 
majority of the schoolchildren (96.9%) demonstrated an HbF level in this 
group. 
(ii) Moderately elevated levels of HbF between 3.8 and 6.0% could have 
been caused by a number of factors. The HbF level evaluation by HPLC 
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needed to be assessed critically as another haemoglobin fraction (HbA1c; 
glycated haemoglobin observed in all patients but elevated in individuals 
with diabetes) elutes very shortly after HbF and may be confused with it. 
Any modest increase in the HbF level could indicate non-deletion HPFH or 
BJ3-thalassaemia. These mutations ablate the expression from one J3-g1obin 
gene but often involve the deletion of the nearby B-gene so that a 
concomitant increase in the level of HbA2 cannot occur. About 3.1 % of the 
schoolchildren were in this group but could not be investigated further. 
All centres demonstrated small variations in the level of J3-
thalassaemia (1-5%) and HbE trait (0-2%) (Table 4.1). This was possibly 
due to random sampling inconsistencies. These could be confirmed by 
increasing the number of samples tested at each location. 
Table 4.1 Incidence of and haemoglobin variants in Sri Lanka 
Province District Population Number f3Tr HbE HbS 
Screened 
Northern laffna 129,000 - - - -
North Anuradhapura 763,000 100 2 1 0 
Central Polannaruwa 340,000 100 0 1 0 
North Kurunegala 1,498,000 200 5 3 0 
Western Puttlam 636,000 100 4 0 0 
Eastern Trincomalee 331,000 100 5 0 1 
Central Kandy 1,306,000 100 4 0 0 
Matale 440,000 100 3 0 0 
Western Colombo 1,967,000 138 1 2 0 
Gampaha 1,582,000 100 1 1 0 
Kalutara 979,000 100 2 0 0 
Ne...&ambo 50-100,000 70 0 0 0 
Sabaragamuwa Kegalle 770,000 100 2 1 0 
Ratnapura 942,000 - - - -
UVA Badulla 748,000 100 4 0 0 
Monoragala 373,000 - - - -
Kataramagama t <10,000 100 0 0 1 
Southern Galle 906,000 - - - -
Hambantota 544,000 100 4 0 0 
Matara 822,000 100 0 0 0 
NB: t The samples from Kataramagama were shIpped as drIed blood spots on filter paper and upon 
analysis all samples appeared to have elevated HbF levels. It was concluded that these samples were 
badly degraded and should be omitted from the study. 
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Overall, 0.8% of the individuals tested presented with obvious 
haemoglobin variants. Only three structural variants were implicated; HbD, 
HbE and HbS. HbD and HbS were only found in 3 individuals and 
represented rare alleles on the island. HbE co-eluted with HbAz and needed 
closer scrutiny. Most samples with elevated HbAz or Hb variants were 
investigated further by DNA analysis. The estimate of B-thalassaemia at 
every site around the island ranged from 0-4% of the schoolchildren tested. 
Fifteen blood capillary blood samples were also made available from a 
group of the original island inhabitants, the Veddahs. Three of these had 
elevated HbAz levels consistent with B-thalassaemia one of which was 
detennined to be IVSI-5 by ARMS-PCR. However, the 
relationship between these individuals was not recorded. 
DNA was also extracted from 42 blood samples collected in the 
schoolchildren survey that exhibited an elevated level of HbAz or a 
haemoglobin variant. These DNA samples were used to confinn some of 
the common B-thalassaemia mutations identified in the hospital patients 
using ARMS assays. Sixteen children were found to be carriers for IVSI-5 
(G----+C), three for JVSJ-l four for HbE and one for HbD. The 
mutation was not identified in twelve of the remaining cases and the DNA 
from six individuals would not amplify. 
Assuming a Hardy-Weinberg distribution and an estimate for the 
population of Sri Lanka number as 18.4 X 106 then estimates of affected 
individuals can be made. The number of individuals homozygous for B-
thalassaemia would be 2650 and the number of individuals with 
thalassaemia would be 956 people. The current birth rate is about 367,000 
live births per annum that would add a further 52 B-thalassaemia major 
infants and 20 HbE/B-thalassaemia every year. 
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4.2 The molecular basis of l3-thalassaemia 
The molecular characterisation of the cases with was 
studied to ascertain the range and frequency of the mutations present within 
the population. This would give the necessary information about the 
disease severity associated with the mutations and suggest the possible 
origins of these mutations. 
Nine major centres took part in this study as outlined in Figure 2.1. 
In all but two of these centres, Galle and Ragama, genomic DNA was 
extracted (See section 2.4). 703 patients who were receiving regular or 
intermittent blood transfusions were studied to define different types of 
thalassaemia and their associated mutations in the patient population (Table 
4.2). Overall, the pattern of haemoglobinopathies was similar in each 
centre. The majority of patients were homozygous (40.4%) or compound 
heterozygotes (21.6%) for gene mutations. HbE was found in 
almost a quarter (176 cases out of 703) of the symptomatic patients. In the 
hospitals with the largest number of patients (>40 patients) the proportion 
of those with HbElI3-thalassaemia ranged from 16-31% (Mean=25%). In 
Anuradhapura, Badulla Chilaw and Kandy the proportion with HbElI3-
thalassaemia was between 16.9-18.6% but in Kurunegala this disorder 
represented 31.9% of the total cases. Seven patients with HbS (1 %; 7 
cases) and two with HbD (0.3%; 2 cases) were encountered in four out of 
the nine centres. 
Using the prevalence of from the Indian subcontinent 
as a guide, a screening strategy was applied to the first batches of patients 
from Sri Lanka (-100 cases from Anuradhapura and 200 cases from 
Kurunegala). Thirteen gene mutations CD5 (-
CT); CD8/9(+G); CD15 CD16 (-C); CD30 IVSI-l 
IVSI-5 CD41142 (-TCTT); 619bp Del.; HbS; HbD and 
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HbE) were screened for using ARMS-PCR or RFLP-PCR (Tables 2.6, 2.7 
and 2.8). The screen included the haemoglobin variants as they needed 
confmnation or may have been masked by blood transfusions. As the 
Portuguese were in control of the island (See section 1.1.1) and also have a 
high prevalence of J3-thalassaemia, mutations common in that community 
were also assessed (IVSI-l IVSI-6 IVSI-IlO and 
CD39 (Tables 2.6). Subsequent batches of samples were screened 
for the mutations already identified and the remainder sequenced. 
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Table 4.2 Distribution of haemoglobinopathies in patients treated for thalassaemia in nine hospitals in Sri Lanka 
Hospital Anuradhapura Badulla Chilaw 
f3-thalassaemia major 
Homozygote 62 49 17 
(45.6) (64.5) (32.7) 
Compound 37 9 17 
heterozgote (27.2) (11.8) (32.7) 
. Unknown 12 4 8 
(8.9) (5.3) (15.4) 
f3 Varianttf3-thalassaemia 
HbFlf3-thalassaemia 23 14 9 
(16.9) (18.4) (17.3) 
HbS/f3-thalassaemia 1 0 1 
(0.7) (0) (1.9) 
HbD/f3-thalassaemia 1 0 0 
(0.7) (0) (0) 
Total 136 76 52 
-
(100.0) 
-
,--000.0) (100.0) 
Figures in brackets represent the frequency as a percentage 
NA= not available 
(5 
-..l 
Colombo 
19 
(57.6) 
7 
(21.1) 
6 
08.2) 
1 
(3.0) 
0 
(0) 
0 
(0) 
33 
(100.0) 
Galle Kandy KurunegaJa Negambo Ragama 
2 23 112 NA NA 
(10.0) (53.5) (35.3) 
0 8 74 NA NA 
(0) (18.6) (23.4) 
8 4 28 3 9 
(40.0) (9.3) (8.8) (21.4) (75.0) 
6 8 101 11 3 
(30.0) (18.6) (31.9) (78.6) (25.0) 
3 0 2 0 0 
(15.0) (0) (0.6) (0) (0) 
1 0 0 0 0 
(5.0) (0) (0) (0) (0) 
20 43 317 14 12 
OOQ.Qt Sto()·O) iU)9·0} _ (100.0) (100.0) 
Total 
284 
(40.4) 
152 I 
(21.6) I 
82 
, 
(11.7) 
176 
(25.0) 
7 
(1.0) 
2 
(0.3) 
703 
(100.0) 
Table 4.3 Frequency of the f3-globin gene mutations found in hospital patients 
being treated for thalassaemia 
Method Anuradhapura Badulla Chilaw Colombo 
Mutation of Allele Allele 
Allele Allele 
analysis No. 
(%) No. (%) No. 
(%) No. (%) 
IVSI-5 (G-+C) ARMS 161 64.4 108 71.1 48 54.6 36 52.9 
IVSI-J (G-+A) ARMS 29 11.6 4 2.6 10 11.4 14 
20.7 
CD26 (G-+A) HbE ARMS 23 9.2 13 8.6 9 10.2 1 1.5 
CD41142 (-TCIT) ARMS 1 0.4 2 1.3 5 5.7 2 2.9 
CDl5 (-T) Sequence 6 2.4 10 6.6 2 2.3 2 
2.9 
CDl6 (-C) ARMS 2 0.8 0 0 4 4.5 0 
0 
RFLP 
CD8/9 (+G) ARMS 8 3.2 0 0 2 2.3 0 
0 
CD30 (G-+C) ARMS 4 1.6 0 0 0 0 0 
0 
IVSJ-130 (G-+C) 
Sequence 2 0.8 0 0 2 2.3 1 
1.5 
RFLP 
CDJ5 (G-+A) ARMS 0 0 0 0 0 0 1 
1.5 
Poly A Tail (T-+C) 
Sequence 3 1.2 0 0 0 0 2 2.9 
ARMS 
CD55 (-A) Sequence 0 0 4 2.6 0 0 0 
0 
RFLP 
CD6 (A-+T) HbS 
RFLP 1 0.4 0 0 1 1.1 0 0 
ARMS 
IVSI-J (G-T) 
Sequence 0 0 0 0 0 0 4 
5.9 
ARMS 
IVSII-I (G-tA) 
Sequence 0 0 1 0.7 1 1.1 0 
0 
ARMS 
IVSI-I29 (A-+C) 
Sequence 0 0 0 0 0 0 
0 0 
RFLP 
IVSI-130 (G-+A) 
Sequence 2 0.8 0 0 0 0 
0 0 
RFLP 
-28 (A-+G) 
Sequence 0 0 2 1.3 0 0 0 
0 
ARMS 
25 bp Deletion 
Sequence 0 0 2 1.3 0 0 0 
0 
RFLP 
IVSII-745 (C-+G) 
Sequence 0 0 0 0 0 0 2 
2.9 
ARMS 
CD5 (-CT) 
Sequence 0 0 0 0 1 1.1 
0 0 
ARMS 
CD6ICDIO (-I3bp) Sequence 0 0 0 0 0 0 
0 0 
CDl2I(G-+C) HbD 
Sequence 0 0 0 0 0 0 
0 0 
RFLP 
619 bp deletion 
Gap- 1 0.4 0 0 0 0 
0 0 
peR 
Unknown Sequence 7 2.8 6 3.9 
3 3.4 1 2.9 
Total 250 100 152 100 
88 100 66 100 
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Table 4.3 cont'd 
Galle Kandy Kurunegala Negambo Total 
Mutation Allele Allele Allele AIIele Allele 
No. (%) No. 
(%) No. (%) No. 
(%) No. (%) 
IVSI-S (G-+C) 5 62.5 48 60 284 49.0 7 43.8 697 56.2 
IVSI-I 1 12.5 8 10 123 21.2 0 0 189 15.2 
CD26 HbE 0 0 8 10 101 17.4 7 43.8 162 13.1 
CD41142 (-TCTT) 0 0 10 12.5 18 3.1 0 0 38 3.1 
COIS (-T) 0 0 2 2.5 5 0.9 0 0 27 
2.2 
CDI6 (-C) 0 0 0 0 14 2.4 1 6.2 21 1.6 
C0819 (+0) 0 0 0 0 6 1.0 0 0 16 
1.3 
0 0 0 0 7 1.2 0 0 11 0.9 
IVSI-130 0 0 0 0 4 0.7 0 0 9 
0.7 
COl5 0 0 1 1.25 5 0.9 1 6.2 8 
0.6 
Poly A Tail (T 0 0 0 0 2 0.3 0 0 
7 0.6 
C055 (-A) 0 0 0 0 1 0.2 0 0 5 
0.4 
CD6 HbS 1 12.5 0 0 2 0.3 0 0 5 
0.4 
IVSI-I (G-T) 0 0 0 0 0 0 0 0 
4 0.3 
IVSII-I 0 0 0 0 2 0.3 0 0 
4 0.3 
IVSI-129 (A-+C) 0 0 2 2.5 1 0.2 0 
0 3 0.2 
IVSI-130 (G-+A) 0 0 0 0 1 0.2 0 
0 3 0.2 
-28 (A-+G) 0 0 0 0 0 0 0 
0 2 0.2 
2S bp Deletion 0 0 0 0 0 0 0 
0 2 0.2 
IVSII-745 (C-+G) 0 0 0 0 0 0 0 
0 2 0.2 
C05 (-CT) 0 0 0 0 0 0 0 
0 1 0.1 
CD6ICDIO (-13bp) 0 0 I 1.25 0 0 0 
0 1 0.1 
CD121(G-+C) HbD 1 12.5 0 0 0 0 0 
0 1 0.1 
619 bpdeletion 0 0 0 0 0 0 0 
0 1 0.1 
Unknown 0 0 0 0 4 0.7 
0 0 21 1.7 
Total 8 100 80 100 580 100 
16 100 1240 100 
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DNA analysis was completed on 620 of these patients to reveal the 
spectrum of mutations that exist in the population of Sri 
Lanka (Table 4.3). The mutations (Cap+l IVSI-6 IVSI-
110 and CD39 were not found in any patients examined 
and appeared to be absent from the island. Cap+l and IVSI-6 
(T in combination with a -thalassaemia would probably be 
associated with intermedia phenotype and hence would not 
present at clinic. 
The haemoglobin variants HbE, HbD and HbS were confirmed and 8 
different mutations (lVSI-5 IVSI-l 
CD8/9(+G), CD30 CD41142(-TCTT), CD16 (-C), CD15 
and the 619bp deletion mutation) were identified using ARMS and RFLP 
analysis. The IVSI-5 mutation was found to be the most common 
mutation in all the communities studied. The second most prevalent 
thalassaemia mutation overall was IVSI-l The remaining 6 
mutations identified by ARMS-PCR were all found at a low frequency in 
the population of Sri Lanka. These 8 thalassaemia mutations, and the 
haemoglobin variants, accounted for 92.5% of the thalassaemia mutations. 
DNA sequencing of the remaining unidentified alleles revealed a 
further 14 mutations. Eleven of these mutations -28 CD15 (-T), 
IVSI-130 IVSI-130 25bp deletion, IVSII-l CD5 
(-CT), CDI0 IVSI-l IVSII-745 and the 
polyadenylation signal mutation (T have all been described previously 
(reviewed in Weatherall & Clegg, 2001). These were confirmed by ARMS-
PCR. Upon further examination the mutation CDI0 and a second 
mutation CD 16 (-C) appeared to be present on the same allele. 
Four individuals were sequenced to reveal the mutation 
CD16 (-C). In each case the mutation CDI0 appears to be 
llO 
invariably linked to this BO-thalassaemia mutation. The change in sequence 
at codon 10 creates a new Pst I restriction enzyme site. Fifteen carriers for 
the CD 16 ( -C) mutation and one homozygote were screened by 
amplification of the first exon and subsequent Pst I digestion. All the 
alleles carrying the BO CD 16 (-C) frameshift mutation were associated with 
the W· CDI0 mutation (Old et aI., 2001). The existence of either 
mutation on its own has not been established. The cryptic splice site 
mutation at codon 10 would splice out the second mutation, CD16 (-C). 
Further RNA analysis was required to establish the effect of these changes. 
The other four mutations identified by DNA sequencing were new 
(Figure 4.3). All these mutations were confirmed by sequence analysis in 
both directions. A 13bp deletion that removed nucleotides between CD6 to 
CDI0 was found in a Sinhalese patient who was doubly heterozygous for 
IVSI-5 4.3). This patient is transfusion dependent. The 
mutation IVSI-129 as well the mutations IVSI-130 IVSI-
130 were confirmed by RFLP analysis and digestion with the 
restriction enzyme Dde I as the mutation results in the loss of the Dde I 
recognition site and a new RFLP pattern (Figure 4.4). 
The new splice site mutation IVSI-129 (Figure 4.3) was 
found in just one Sinhalese patient who was a compound heterozygote for 
this mutation and for the mutation IVSI-5 The resultant phenotype 
was that of (3-thalassaemia major such that the mutation should be 
classified as (30- or severe (3+ -thalassaemia. 
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Figure 4.3 Chromatograms showing the new l3-globin gene mutations 
Codon 6-10 (I 3bp Deletion) Heterozygous Cap+ 1544 (G-A) Heterozygous 
Normal 
CCACAGGGCAGTAACTCAGGAGTCAGATGCACCATGGTGTCTGT 
Deletion 
....... 
CTACTAAACTGGGAGATATTATGAA 
CTACTAAACTGGGGGATATTATGAA 
." i " PolyA Cap 1 Exon2 Exon3 tail 
. .............................. 
Normal 
ACCACCAGCAGCCGAAGGGTGGGAAAA 
ACCACCAGCAGCCTAAGGGTGGGAAAA 
. ...................... .. 
ACTCCTGATGCTGTTATGGGCAACCCTAA 
Deletion 
Figure 4.4 PCR-RFLP analysis for the detection of HbS, IVSI-130 (G---7A), 
IVSI-130 (G---7C) and the new mutation IVSI-129 (A---7C) through 
the loss of a Dde I restriction enzyme sites 
.- 603bp 
376bp 
.- 3 JObp .- 281/27 1bp .- 234bp 
175bp .- 194bp 
.- 11 8bp 
Normal 
443bp 
175 i 201 i 67 
Normal + Polymorphism 27i* i 201 i 67 153 HbS/S 
i 376 67 rvSI-129 or IVSI-130 
175 i 268 
Dde II F 
5' --+ D 3' 
Exon 1 Exon2 
Dde R 
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The third new mutation was codon 55 (-A) (Figure 4.3) a frameshift 
mutation that was found in four patients. Two patients were compound 
heterozygotes for this mutation and for the mutation IVSI-5 (G-7C), 
another patient was a compound heterozygote for this mutation and for the 
mutation CD15 (-T). The last patient was homozygous for the CD55 (-A) 
mutation. All these individuals were treated as transfusion dependent 
patients and the new mutation CD55 (-A) was classified as 0° or severe 0+. 
CD55 (-A) was confirmed by RFLP analysis as this mutation creates an 
Mwo I recognition site (Figure 4.5). A PCR product containing exon 2 
using the primers outlined in Table 2.8 was digested with the restriction 
enzyme Mwo I and run out on a 3% agarose gel. 
Figure 4.5 RFLP analysis to demonstrate the introduction of an Mwo I site 
associated with the mutation codon 55 (-A) 
"<t 
X 
>9< 
50bp 
Mwo I /f3Forward 
-+-
-" c 
< c:a. -... < c:a. 
.D :r:: 
138bp 
() 
"0 
00 
'" N 0 ... 
'" oJ
:r: 
1: 
< <n c:a. V"l -... < c c:a. 0 
.D -0 0 :r:: u 
189bp 
'" "0 0 
00 bJl 
'" '" N N 0 0 
t) . Ei 
oJ 0 :r: :c 
i 
<n V"l "<t 
II"l 
V"l r--
c c ..... 0 C -0 :x: -0 0 >9< 0 u u 
t 50bp Mwo 1113 Reverse 
One individual from Colombo was found to have a single 
heterozygous change in the 3'URR at Cap+1544 (G-tA) (Figure 4.3) and 
no other mutation on the other allele. This patient was not included in the 
study as the family presented with another haematological disorder, 
congenital dyserythropoietic anaemia (CDA). Mutations in this region of 
the f3-globin gene are normally associated with a very mild phenotype and 
so the thalassaemia status requires further investigation. 
Twenty-one alleles failed to show any difference compared to the 
normal DNA consensus sequence of the complete f3-globin gene and its 
surrounding DNA sequence and thus remain uncharacterised after 
sequencing. Family studies were performed on all four patients centred in 
Kurunegala as the remaining families from the other centres were 
unavailable for further studies. 
Disease in two of these patients appeared to be associated with an 
increased level of HbF in at least one of their parents (family DM and 
KRC55). In family DM the mother had a raised HbA2 (4.7%) and was 
found to be a carrier for the f30 -thalassaemia mutation, CD 16 (-C) that was 
also found in linkage with the base change at CDI0 (C-tA). The father had 
a raised HbF (20.3%) but a normal HbAz and was found to have a normal 
f3-gene after DNA sequencing. As the propositus appeared to be 
homozygous for the mother's mutation the father must have had a deletion 
and only his single normal allele could be observed. Haplotype markers 
along the f3-cluster were examined but did not help to map the extent of the 
deletion. In family KHC55 the mother was found to have a raised HbF 
level of 19.6% but a normal HbA2 level and appeared to have a normal f3-
gene after DNA sequencing. Again, the propositus was seen to be 
homozygous for the severe f3+-thalassaemia mutation, IVSI-5 (G-tC), so 
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again another or the same deletion, as in family DM, that removes the {3-
gene must be present in this family. These two families were screened for 
two deletions, the Indian inversion deletion and HPFH-3 both found on the 
Indian subcontinent, but were found to be negative. Southern blot analysis 
on both families was unsuccessful and further analysis. 
The other two patients had a {3-gene mutation identified on one allele 
and the other allele was observed to have a normal consensus sequence. (1-
gene analysis showed that these patients had inherited extra a-genes that 
were interacting with the {3-thalassaemia to exacerbate the chain imbalance 
and result in a more severe phenotype (See Chapter 6). 
Of the 24 different {3-thalassaemia alleles revealed in this study three 
mutations accounted for 84.5% and would result in a large number of 
homozygotes for the same mutation. This was confirmed in Table 4.2 that 
assigned the affected patient's genotypes after DNA analysis. Almost two 
thirds of the patients (65.1 %) with {3-thalassaemia major were found to be 
homozygous for the same mutation. As family studies were not performed 
routinely any index case observed to be homozygous could have had a 
deletion of the {3-gene. 
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4.3 Discussion 
Many surveys have been undertaken to evaluate the incidence of 
thalassaemia in different populations based on the elevation of HbAz levels 
above 3.4% in adult blood samples (reviewed in Weatherall and Clegg, 
2001). mutations are common across many tropical and sub-tropical 
regions in individuals that present with varying degrees of anaemia. The 
prevalence of like that of a-thalassaemia, would be 
maintained by positive selective advantage against infectious disease, 
especially in childhood (See Table 1.3 and section 1.2.2.2). As these 
infectious diseases have probably been present on the island for many 
generations the predicted level of would be high. 
Characterisation of the molecular lesions allows a greater understanding of 
the subsequent health risks. 
Clinical consequences and spectrum of pglobin mutations 
The carrier frequency for and for HbE in Sri Lanka 
was determined at 2.3% and 0.6% respectively. These were consistent with 
a reported estimate for Sri Lanka of 3.5%, combined trait 
and HbE trait, (WHO, 1994) even though the previous method of data 
collection appeared anecdotal. The schoolchildren survey was a crude 
estimate of more than 1600 individuals, <0.01% of the Sri Lankan 
population. This elevated level of perturbation is indicative of 
selective pressures to maintain these mutations in the popUlation. The 
incidence of haemoglobinopathies observed in the different study centres 
was extremely diverse between 0 and 5%. The reason is not clear but may 
reflect variable exposure to malaria in the past, some degree of 
consanguinity, founder effects, genetic drift or sampling inadequacies. If 
the overall estimates are closer to 0% then the clinical consequences are 
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relatively insignificant but if they are closer to 5% then the predicted health 
burden on the island population will be great. 
Four educational institutions in the schoolchildren survey were 
deemed within the wet/intermediate zone (Colombo, Kalutara, Kegalle and 
Matara). The rest were located in the dry zone. The incidence of 
haemoglobinopathies (combined trait and HbE trait) in the 
wet/intermediate zone and the dry zone were 1.8% and 3.2%, respectively. 
This supports the hypothesis that they have arisen due to selective 
advantage to protect individuals against malaria. 
Local dogma suggested that the level of haemoglobinopathies in the 
Kurunegala region was higher than any other part of the island 
(Wickremasinghe et ai., 1963; Nagaratnam, 1989). This was not born out by 
the schoolchildren survey. However, the Kurunegala Teaching Hospital is a 
centre of excellence to treat these patients and hence it has a greater 
hospital patient load compared to other regions. As the hospital has a good 
reputation to treat transfusion dependent patients, families outside this 
region also attend the thalassaemia clinic. The hospital study at this centre 
was notably different to other regions due to its greater preponderance for 
patients. In Kurunegala 31.9% of the 317 patients 
studied had compared with all the other study centres 
combined where 19.4% of the 386 patients had this form of the disease. 
This variation in this relatively small population shows the need to assess 
large numbers of individuals to gain accurate estimations and also 
highlights the need for accurate details of the sample populations are 
recorded so that a reasonable cross section of the population can be 
assessed. This was not performed in Sri Lanka due to logistical problems. 
If the Kurunegala district is analysed independently the predicted 
gene frequency for and HbE would be 0.0125 and 0.0075. 
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Assuming a regional population of about 1.5 million and a Hardy-
Weinberg distribution the predicted number of patients homozygous for p-
thalassaemia and HbE/f3-thalassaemia would be 220 and 260, respectively 
(de Silva et al., 2000). The number of patients currently receiving 
transfusions for these two disorders is 214 and 101 (Table 4.2). Hence, 
whereas the patients homozygous for (3-thalassaemia are well represented 
there appears to be a shortage of patients with HbE/(3-thalassaemia. This 
shortfall may be due to the under diagnosis of this disorder or that a group 
of these patients never present with the disease as they have very mild 
symptoms. 
Using the schoolchildren survey, the number of individuals on the 
island predicted to have (3-thalassaemia major or HbEl(3-thalassaemia was 
2650 and 956, respectively. This estimation did not account for the 
predicted length of time each of these individuals may live compared 
against the rest of the population. Severely affected individuals have a 
reduced life expectancy. On the other hand, the rate of population growth is 
still on the increase and the management of patients is continually 
improving which results in longer life expectancies and the consequent 
increase in the number of patients with these conditions. Currently, the 
anticipated number of new patients born annually would be 52 and 20 for 
(3-thalassaemia major and HbE/(3-thalassaemia, respectively. 
The hospital based study group consisted of 620 transfusion 
dependent patients representing about 1I6th of the total predicted number of 
thalassaemia patients on the island estimated from the schoolchildren 
survey. This gave a heavy bias towards revealing mutations associated with 
no or very low (3-chain expression that probably occurred because all the 
patients were transfusion dependent. Hence, only a handful of patients had 
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mutations associated with a mild phenotype (promoter and polyadenylation 
signal mutations). In contrast, HbE was found to be common. In the 
homozygous state (HbEIE) , the mutation is only associated with a mild 
anaemia. However, in combination with the patients have 
an extremely variable phenotypic outcome from asymptotic to transfusion 
dependent. The difference between these outcomes needs to be investigated 
further as the consequences for the patient and for health planning are 
tremendous. 
The frequencies of the common mutations were similar between the 
different study centres. Analysis for the three most common gene 
mutations (IVSI-5 (G-tC), IVSI-1 (G-tA) and HbE) would provide the 
basis of a genotype service that would identify 84.1 % of the mutations. 
However, in a Pre-natal Diagnostic Service about 25% of cases would 
remain unresolved by analysis for these three molecular lesions. To provide 
a reasonably comprehensive service (>95% of successful diagnosis) over 
20 of the gene mutations (top 20 mutations listed in Table 4.3) 
would have to be tested for. The earlier an infant is diagnosed with a severe 
fonn of haemoglobinopathy the sooner an effective form of management 
can be implemented. A pre-natal diagnostic service is unlikely to be 
established at present due to religious convictions of the majority of the 
popUlation. The official religion of Sri Lanka is Buddhism and the 
orthodox view is against any fonn of abortion. However, other Buddhist 
countries have implemented the use of PND and Sri Lanka may one day 
follow suit. 
It has been estimated that the cost of treating 2000 patients may have 
been between 3-5% of the annual expenditure on health in Sri Lanka for 
1996 (de Silva et ai., 2000). If the number of patients increases then greater 
pressure will be placed on these finances and difficult moral decisions 
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about the efficacy of who and how to treat them will become extremely 
difficult. 
New p-thalassaemia mutations 
Currently, 198 different forms of non-deletion l3-thalassaemia have 
been described (reviewed in Weatherall & Clegg, 2001). In this study, three 
new f30 -thalassaemia mutations were identified; two in the coding regions 
and one in intron 1. These are IVSI-129 (A---7C), CD6110 (-13) and CD55 
(-A). This represents an increase in the number of non-deletion type 13-
thalassaemia mutations by 1.5% from a very smaIl population. 
The intronic base substitution introduces a consensus splice site 
mutation in the first intron, IVSI-129 (A---7C), that is similar to IVSI-130 
(G---7A) or IVSI-130 (G---7C). Another mutation in the same nucleotide has 
been identified in a German patient, IVSI-129 (A---7G) (Vetter et al., 1997). 
Other mutations occur at this consensus splice site (IVSI -130) all of which 
fail to produce l3-globin chains. The first exonic mutation was a small 
deletion of 13 base pairs starting in codon 6 and extending to codon 10 that 
shifts the reading frame and results in a premature stop at codon 14. The 
last mutation was a single nucleotide deletion at CD55 (-A) that causes a 
frameshift and should result in a premature stop at codon 60 in a similar 
manner to a previously reported mutation at codon 54 (-T) (Huisman et al., 
1997). These three new mutations may have arisen independently as they 
have not been observed in any other populations. 
Evolutionary aspects 
All new variations start as a mutation that may alter the expression or 
activity of the resultant protein. The subsequent frequency of this change 
will depend upon its selective advantage or disadvantage and also the 
successful expansion of its host. DNA analysis has been performed on 
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many populations to examine the spectrum and frequency of individual 
mutations (reviewed in Weatherall & Clegg, 2001). In every population 
with high frequencies of haemoglobinopathies two or three f3-globin gene 
mutations have been found to be present at high frequencies with a larger 
number of rare mutations. confers a selective advantage 
against malaria. Mutations that arose earlier in a population's history will 
be present at higher frequencies. Interaction between populations with the 
same selective pressure may result in the spread of these mutations and 
hence reduce the selective pressure on these individuals. Analysis of these 
mutations may indicate some interaction between populations. 
The spectrum of molecular lesions was determined in the hospital 
based patients and confmned in a small number of individuals in the 
schoolchildren survey (See section 4.1.1). Twenty-four gene 
mutations were identified from screening 620 hospital patients being 
treated for thalassaemia. Three mutations accounted for 84.4% of the 1240 
alleles: IVSI-5 56.1 %; IVSI-I 15.2% and haemoglobin E 
a structural variant with a mild f3-thalassaemia phenotype, 
13.1 %. The distribution of these common mutations in the different 
provinces was fairly uniform. A big difference was observed with the 
spectrum of rare mutations. As well as many individuals with HbE, two 
more haemoglobin variants were observed in the population, a few with 
HbS and a single case consistent with HbD-Punjab. All of these structural 
variants have been reported in India. 
As Sri Lanka has close historical connections with India and 
Portugal (See section 1.1.1) the molecular lesions revealed were compared 
between these populations. Many studies to investigate the incidence of f3-
thalassaemia on the Indian subcontinent and in Portugal have been reported 
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and the combined results are shown in Table 4.4. The mutations observed 
in the population of Sri Lanka are very similar to that of India, especially in 
the North East. 
Table 4.4 
Mutation 
Cases analySed 
References 
NSI-5(G-C) 
619bpDel. 
CD8/9(+G) 
NSI-I(G-T) 
CD4 114 I( -TC'IT) 
CD I 5(G-Al 
CD30(G-C) 
CD I 6(-q 
CD5(-CT) 
Cap+l(A-C) 
CD30(G-A) 
-88(C-T) 
NSI-I(G-A) 
NSll-1(G-A) 
CD47/48(+ATCT) 
NSll-837(T-G) 
C08(-AA) 
25bp del 
C039(C-T) 
C088(+T) 
C0121 (G-T) 
CD4/C05ICD6 
-28(A-G) 
C08(A-G) 
COI3/CD261CD27 
CD15(-T) 
NSI-II O(G-A) 
NSI-l30(G-C) 
NSI(3')(T-G) 
CD44(-C) 
COSS(+A) 
C057/58(+C) 
NSll-848(C-A) 
CDI26-131(-17bp) 
NSI-6(T-C) 
-90(C-T) 
HbE 
HbO 
HbS 
Uocbaracterised 
Other 
Frequency of f3-globin mutations found on the Indian subcontinent, 
Portugal and Sri Lanka 
Indian North West North North Central South Pakistan Sri Lanka 
subcontinent India India East India India 
India 
n=6742 n-1003 0-1112 n-688 o 394 n-254 n=2752 0-620 
1-14 1,3-6, 1,6,9,1 9,12,14 12 11,12,1 1,2,5,8,9, 
11,12,14 1,12,14 4 11,14 
40.95 56.72 25.27 51.59 60.14 80.31 32.58 56.2 
14.16 13.56 30.75 1.03 2.54 0.79 13.7 0.1 
13.37 3.29 11.96 2.33 5.08 2.76 23.22 1.3 
8.92 7.28 18.08 0 1.52 0 10.07 0.3 
6.48 6.58 7.73 2.33 11.17 8.27 6 3.1 
3 5.78 0.27 1.89 3.55 3.15 3.2 0.6 
1.75 1.4 0.18 3.2 3.3 0 2.14 0.9 
1.47 0.4 1.17 0.15 3.3 I.18 2.22 1.6 
1.22 0.7 0.27 0 1.02 0 2.03 0.1 
1.16 0 2.07 0.58 1.78 0 1.09 0 
0.42 0.3 0.09 0.29 0 0 0.47 0 
0.34 0 0.81 0.29 1.02 0 0.18 0 
0.3 0.4 0 0 0.51 0 0.44 15.2 
0.25 0.2 0.09 0 0 0 0.51 0.3 
0.22 0 0.09 0 0.51 0 0.4 0 
0.18 0.3 0 0 0 1.97 0 0 
0.16 0 0 0 0 0 0.36 0 
0.09 0.4 0 0 0 0 0.D7 0.2 
0.03 0 0 0 0 0 0.07 0 
0.03 0 0 0 0 0 0.04 0 
0.03 0 0 0 0 0 0 0 
om 0 0 0 0.25 0 0 0 
om 0 0 0 0 0 0 0.2 
om 0 0 0 0.25 0 0 0 
0.01 0 0 0 0.25 0 0 0 
0.01 0 0 0 0 0 0.04 2.2 
0.01 0 0 0 0 0 0 0 
0.01 0 0 0 0 0 0 0.7 
0.01 0 0.09 0 0 0 0 0 
om 0.1 0 0 0 0 0 0 
0.01 0.1 0 0 0 0 0 0 
om 0 0 0 0 0 0 0 
om 0 0 0 0 0 0.04 0 
0.01 0 0 0 0 0 0.04 0 
0 0 0 0 0 0 0 0 
0 0 0 00 0 0 0 0 
3.13 0.1 0.09 26.15 1.27 0 0.58 13.1 
0.07 0 0 0 0 0 0 0.1 
0.06 0 0 0 0 0 0 0.4 
2.08 2.39 0.99 10.17 2.54 1.57 0.51 1.7 
0 0 0 0 0 0 0 1.7 
I.Agarwal et aI., (2000); 2.Abmed et aI., (1996); 3.Bandyopadhyaya et aI., (1999),4 DastJdar el al., (1994),5 el-Kalla & 
Mathews (1997); 6.Garewal et aI., (1994); 7.Gorakshakar et aI., (1999); 8.Khan & Riazuddin (1998); 9.Parikh et aL, 
(1990); 10.Thein et al., (1988); 11.Varawalla el al., (1991a); 12.Vaz et aI., (2000); 13.Venkatesan et aI., (1992) ; 
14.Vermaetal., (1997); 15. Faustino etal., (1992); 16. Gomes et aI., (1988) 
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Portugal 
D-252 
15,16 
0 
0 
0 
0 
0 
7.9 
0 
0 
0 
0 
0 
0 
21 
0 
0 
0 
0 
0 
37.3 
0 
0.4 
0 
0 
0 
0 
0 
I1.5 
0.8 
0 
0 
0 
0 
0 
0 
19 
1.2 
0 
0 
0 
0.4 
0 
The point mutation IVSI-5 is the most common {3-
thalassaemia mutation not only in Sri Lanka but globally. It is found at high 
frequencies in S.B. Asia and the subcontinent of India and occurs in the 
Middle East and Europe but not in Portugal (reviewed in Weatherall & 
Clegg, 2001). 
The second most common mutation on the island was also a 
consensus splice site point mutation IVSI-l This mutation occurs 
at high frequencies around the Mediterranean basin and is centred round 
Spain and Portugal (reviewed in Weatherall & Clegg, 2001). Isolated cases 
have been reported in North India (Varawalla et al., 1991b) and Central 
America (Villalobos-Arambula et ai., 1997) in descendants from Spain. 
Hence, this mutation appears to be more closely implicated with a 
European origin. This would be consistent with the island history as 25 
generations previously the Portuguese held dominion over the island for 
over a century (See Chapter 1.1). 
The third most common allele HbE, is found at its highest 
frequencies in S.E Asia and can be found at polymorphic frequencies in the 
popUlations around the Thail Cambodia! Vietnamese border (reviewed in 
Weatherall & Clegg, 2001). The frequency of HbE diminishes in 
populations that are further away from this region. HbE is known to exist in 
Bangladesh and North East India at high frequencies but has only been 
described in a few cases from North and North West India (Garewal et at., 
1994; Ahmed et at., 1996) and has not been described in South India 
(Verma et ai, 1997). Hence, its occurrence in Sri Lanka may seem unusual. 
However, a connection between North India and Sri Lanka has been well 
recorded, albeit in legend or religious documentation (See section 1.1). The 
occurrence of this allele would appear to support the link between the 
popUlations. 
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All the other mutations were found at frequencies less than 3% and 
may be considered as rare alleles. Fifteen of these alleles [-28 
CDS (-CT); CD6 HbS; CDS/9 (+0); CD15 CD15 (-T); 
CD16 (-C); CD30 IVSI-l IVSI-130 CD41142 (-
TCTT); IVSII-l CD121 HbD; 2Sbp deletion and 
the 619bp deletion] have been reported in populations from the 
subcontinent of India (Table 4.4). In fact, the nine most common mutations 
found in India have also been found in Sri Lanka demonstrating their close 
genetic links. In contrast, only two of the eight mutations described in 
Portugal (about 30% of the alleles shown in Table 4.4) have been found in 
Sri Lanka. 
Three previously reported mutations were found on the island that 
had not been described in India; two consensus splice site and one 
polyadenylation signal mutation. The first splice site mutation, IVS 1-130 
was located just before the second exon and had been reported in 
Japanese, Egyptian and Turkish patients (Deidda et ai., 1990; Oner et aI., 
1990). The second splice mutation (IVSII-74S was located in the 
second intron prior to the third exon and had been previously reported on a 
patient from the Mediterranean region (Orkin et al., 1982b). The 
polyadenylation signal mutation (Poly A tail (AATAAA AACAAA» 
was previously reported in Turkish and Black patients (Orkin et al., 1985). 
Two of these mutations (IVSl-130 and Poly A tail (AATAAA 
AACAAA» were also found in individuals originating from India within 
the NHRL (personal communication from Dr J. Old). These rare mutations 
may indicate a connection between North Africa and Sri Lanka. 
The observation that the same molecular lesions observed in Sri 
Lanka have already been reported in many other populations, both near and 
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far, prompted further investigation of these genes in the context of their 
surrounding DNA (Chapter 5). The primary structure of DNA is not static 
and the patterns observed form a record that can infer the age of the 
alterations and the likely relationship between individuals or populations. 
Haplotype analysis could allow an assessment of the connection between 
populations to demonstrate possible close genetic ties or to implicate that 
the same mutations have arisen on more than one occasion. 
Notably, after an extensive examination of patients, all molecular 
lesions were accounted for in the Kurunegala Teaching Hospital. Many 
studies reveal 1-3% of individuals in a population screen, with unexplained 
causes for the tJ-thalassaemia. tJ-thalassaemia that does not involve a 
mutation in or around the tJ-gene is incredibly rare and every study may 
require lengthy investigation to unravel the molecular lesions involved. 
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Chapter 5 Haplotype Analysis 
The aim was to compare haplotype arrangements at more than one 
locus within the population of Sri Lanka and then to compare these against 
populations of other countries. These DNA arrangements may be linked 
with a phenotype and used as markers for a disease assessment. 
Comparison of genetic material between populations may help to track the 
flow of genes or polymorphisms and possibly infer their age. 
5.1 a-globin baplotypes 
Normal chromosomes 
A selection of patients and their parents from Anuradhapura were 
chosen with a normal a-genotype (aaJaa) to ascertain the common a-
cluster haplotypes in the population. The same nine polymorphisms were 
examined as outlined earlier (See section 1.2.2.2). Eighteen families were 
studied but only 14 families yielded informative haplotype data (Table 5.1). 
The genotypes at the haplotype loci were obtained by PCR analysis, mostly 
by RFLP (See section 2.4). 
Table 5.1 Distribution of normal a-globin gene baplotypes in Sri Lanka 
Haplotype RFLP* Sri Lanka 
n % 
Ia ++ -MPZ++ -- 6 43 
IIi -++MPZ+ --- I 7.1 
rna - - +M Z - - -- 2 14.3 
IIIb + -+MZ - - -- 3 21.4 
un -++ M PZ - - -- 1 7.1 
VIla - +- M PZ+ - -- 1 7.1 
Chromosome Number 14 100 
* A + denotes the presence of a restrIction enzyme sIte and a - its absence. The 
inter-l; fragment could be assessed as small (s) medium (m) or large depending on the 
size of the amplicon and the l; (Z) or (PZ) by the size of that amplicon. 
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Three haplotypes CIa; nla and nIb) accounted for 78.4% of the 
chromosomes studied whilst a further three rare haplotypes accounted for 
the remaining chromosomes. Of the nine sites chosen to construct the a-
globin haplotype three sites showed no variation. A greater number of 
alleles in all the island popUlation ethnic groups need to be typed to be sure 
of the distribution and identify less common haplotypes. 
5.2 Ii-cluster bapJotypes 
Normal chromosomes 
Seven polymorphisms as outlined earlier (See section 1.2.2.2) were 
investigated in the parents and relatives of transfusion dependent patients to 
determine the normal range of haplotypes found on the island. The 
polymorphisms were analysed by RFLP-PCR analysis using the conditions 
described (See section 2.4). Indeed, family studies helped to assign each 
polymorphism to a particular haplotype but many remained uninformative. 
118 normal chromosomes were successfully haplotyped and their 
frequencies shown in Table 5.2. The haplotypes are given using the usual 
Orkin scheme (Orkin & Kazazian, 1984) and also the Shimuzu 
designations (Shimuzu et al., 2001) as these had a much greater number of 
different haplotype arrangements. 
In Sri Lanka, 23 different haplotypes were identified. Only two 
haplotypes (1 and 3) were observed at frequencies above 10% yet 
accounted for less than 50% of the chromosomes typed. The remainder 
appeared to be present in a small number of individuals and represented 
rare alleles in the population. 
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Table 5.2 Distribution of normal gene baplotypes in Sri Lanka 
Haplotypes n Frequency 
Orkin Shimuzu RFLP* (%) 
I 1 +---- ++ 22 18.6 
V 2 +---- +- 9 7.6 
VIT 3 +---- -+ 31 26.3 
IX 5 -+-++++ 5 4.3 
ill 6 -+-+++- 3 2.5 
IV 7 -+-++-+ 5 4.3 
IT 8 -++-+++ 4 3.4 
9 -++-++- 5 4.3 
10 -++-+-+ 10 8.5 
18 ---++++ 3 2.5 
19 ---++-+ 1 0.8 
21 -----++ 1 0.8 
26 -++--++ 1 0.8 
38 +---+-+ 3 2.5 
41 ++-+++- 1 0.8 
43 ++---++ 2 1.7 
44 ++----+ 2 1.7 
Other --+-+-+ 3 2.5 
--+-+++ 3 2.5 
----+-+ 1 0.8 
-++++-+ 1 0.8 
++-++-+ 1 0.8 
++---+- 1 0.8 
Chromosomes studied 118 100 
* A + denotes the presence of a restriction enzyme site and a - its absence (See 1.2.2.2). 
fJ-thalassaemia associated chromosomes 
The haplotypes were ascertained in 401 of the hospital transfusion 
dependent patients after mutation identification. Less than half the 
chromosomes analysed (156 patients) gave informative haplotypes (Table 
5.3). Sixteen different {3-thalassaemia mutations were all found at low 
frequencies on 10 different haplotypes. Over half (63.5%) of the assigned 
haplotypes were found on the most common background haplotype (Vil or 
3) due largely to the two most common (3-thalassaemia mutations (IVSI-I 
and IVSI-5 but also with IVSI-130 and 619bp 
129 
a 
deletion. A further 3.8% haplotypes were found on the second most 
common haplotype and was associated with 4 different 
mutations (CD8/9 (+0), CD15 (-T), IVSI-5 and IVSI-130 
Table 5.3 Haplotypes associated with different f3-globin mutations 
f3-Genotype Haplotype Designation 
Shimizu groups 1 8 6 7 2 28 3 29 5 25 Other 
Orkin groups I IT ITI IV V VI VII VITI IX X 
Anuradhapura 
HbS 1 
CD8/9(+G) 2 
CD15(-T) 2 
HbE 3 4 
3 
21 
1 3 67 10 12 
IVSI-130(G-+A) 1 1 
rvSI-130(G-+C) 1 
Poly A tail 1 
(AATAAA4AACAAA) 
619bp Deletion 1 
Badulla 
CD15(-n 4 
HbE 3 
2 42 6 
CD55(-A) 2 
Kurunegala 
HbS 2 
CD15(G4A) 1 
CD15(-n 2 
CD 1 6(-C) 2 
HbE 9 21 7 
rvSI-1(G-+A) 35 
rvSI-5(G-+C) 7 30 
IVSI-129(A-+C) 1 
rvSI-130(G-+C) 1 
CD41/42(-TCIT) 1 
Mutation Total 12 O· 14 15 32 0 198 0 3 16 22 
Frequency (%) 3.8 0 4.5 4.7 10.3 0 63.5 0 1 5.1 7.1 
11 of the 16 mutations assigned haplotypes were on more unusual 
backgrounds (HbS, CD15 (G-A), CD16 (-C), HbE, CD30 IVSI-5 
IVSI-129 IVSI-130 CD41142 (-TCTT), CD55 (-
130 
A), and Poly A Tail Twelve mutations were 
associated with a single type of haplotype (HbS, CDS/9 (+0), CD15 (-T), 
CDl5 (G-A), CDl6 (-C), CD30 IVSI-I IVSI-129 
(A-7C), CD41/42 (-TCTT) , CD55 (-A), Poly A tail 
and 619 bp deletion). However, six of these 
mutations (HbS, CD15 (O-A), IVSI-129 CD41142 (-TCIT), Poly 
A tail and 619 bp deletion) only had one 
infonnative chromosome. 
Seven different thalassaemia mutations (CD8/9 (+G), CD15 (-T), 
CD30 IVSI-l IVSI-130 CD55 (-A) and CD16 (-
C» were each linked to their own distinct haplotype. Four mutations (HbS, 
HbE, IVSI-5 (G-7C) and IVSI-130 (O-7A» were found on more than one 
haplotype but in each case had a common and rare form. The common 
mutations were observed on more than one haplotype except for IVSI-l 
that was found associated with a single haplotype on 56 alleles. No 
major regional variations were observed between the centres of 
Anuradhapura, Badulla and Kurunegala. 
Table 5.4 Unusual baplotypes associated with mutations 
HllIJlot)'pes (RFLP) I n 
Shimuzu 1 Orkin I 
Poly A tail (AA 
44 1 * I ++--- -+ 1 1 
HbE 
9 1 X I -++-+-+ I 6 
New I ---+++- 1 1 
* Not reported by Orkin & Kazazlan, 1984 
Seven mutations were found on very rare haplotypes (Table 5.4). 
One haplotype was associated with the mutation Poly A tail 
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in a single individual and HbE was found on four 
different haplotypes that included a new arrangement along the p-cluster in 
a single individual. 
Further investigations were undertaken to examine the different 
possible origins of the individuals. Haplotypes were determined in 
individuals that were carriers for HbE originating from the subcontinent of 
India. Fifty families that had been referred to the National 
Haemoglobinopathy Reference Service for mutation identification to 
distinguish between HbEIE and HbE/p-thalassaemia were included but less 
than half revealed informative haplotypes (Table 5.5). 
TableS.S HbE haplotype associations in populations from the 
Subcontinent of India 
Haplotypes (RFLP) Frequency Origin 
n % 
1 +---- ++ 1 4.8 Bengal 
2 +---- +- 12 56.8 BangladeshlBeI!8'al 
3 +---- -+ 2 9.6 BangladeshIBengal 
5 -+-++++ 1 4.8 Bengal 
14 -+-++-- 1 4.8 Bengal 
37 +---+++ 2 9.6 Benga1/Natal 
New -+++-+- 2 9.6 Pakistan 
Total 21 100 
Surprisingly, in only 21 informative alleles seven different haplotype 
were revealed. Over half (56.8%) of the alleles determined were found 
associated with the most common haplotype (Shimuzu 2 or Orkin V). The 
rest were fairly evenly distributed among 5 haplotypes (Shimuzu 1,3,5, 14 
and 37 or Orkin I, VIT, IX, not described and not described) with one new 
haplotype in two individuals from Pakistan that were unrelated. None of 
these haplotypes were found in Sri Lanka. 
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3' P.haplotype 
The B-cluster on chromosome 11 spans over 70 kilobases and 
includes a region that has a high mutation rate for chromosomal 
rearrangement. This hotspot is located downstream of the cpB-gene and 
upstream of the Hence, the haplotype can be analysed 
according to a 5' and 3' section either side of the 'hotspot'. One of the two 
polymorphisms in the 3' section is in the second intron of the B-gene and 
the second is downstream of the B-gene. Therefore, mutations in the 
tend to be tightly linked to the 3' haplotype (Table 5.6). This association 
may further indicate the genetic relationship with other populations. 
Not all the permutations were observed as no alleles were revealed 
with a -/- configuration. The most common configuration was -/+ which 
was identified in over 50% of the normal chromosomes. Unsurprisingly, 
over 80% of the mutations overall were found on this background. The 
remaining mutations were found split between the configurations +/+ and 
+/-. Anaradhapura and Badulla appeared very similar but patients from 
Kurunegala had a great preponderance for the +/- configuration. This 
contrasted quite dramatically with the normal chromosomes investigated 
from Anuradhapura that had a far greater proportion with the +1+ 
configuration. 
Two mutations were found on more than one 3' haplotype. IVSI-5 
was found almost exclusively on the -1+ configuration but in a 
single individual was found in the +1+ configuration. The mutation IVSI-
130 was only seen in two individuals and was found in two 
different configurations +/+ and +/-. 
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Table 5.6 Association between the 3' p-haplotype and P-globin sequenee 
3' gene haplotype (Ava II and Hinl l) 
+1+ +1- -1+ -1-
Anuradhapura 
CD8/9(+G) 2 
CD I 5(-T) 4 
HbE 7 
3 
IVSI-I(G-A) 36 
IVSI-5(G-C) I 129 
IVSI-130(G-A) 1 I 
IVSI-13O(G-C) 1 
Poly A tail 2 
(AA TAAA-AACAAA) 
619bp Deletion 1 
Mutation Total Jl(5.901o) 8(4.3%) 169(89.8) 0 
Nonnal 30(37.5%) 8(10%) 42(52.5%) 0 
Badulla 
CD 15(-T) 4 
HbE 3 
IVSI-5(G-C) 50 
CD55(-A) 2 
Mutation Total 4(6.8%) 5(8.5%) 50(84.7%) 0 
KuruneEala 
CD I 5(G-A) 1 
CDI5(-T) 2 
CDI6(-C) 2 
HbE 37 
IVSI-l(G-A) 35 
IVSI-5(G-C) 37 
IVSI-129(A-C) I 
IVSI-130(G-C) I 
CD41142(TCTT) I 
Mutation Total 2(1.7%) 39(33.3%) 76(65%) 0 
Overall Mutation Total 17(4.7%) 52(14.3%) 295(81%) 0 
Overall Total 47(10.6%) 60(13.5%) 337(75.9010) 0 
Xmn-I G y-gene polymorphism 
The Xmn-I polymorphism is linked to HbF levels and may be under 
greater selective control. The (+) configuration is associated with elevated 
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TableS.7 Frequency of the Xmn I polymorphism associated with different 13-
globin genotypes 
f3-genotype I Xmn-/ status I n Frequency (%) 
Anuradhapura 
f3-thalassaemia major +1+ 1 1.4 
+1- 11 15.3 
-1- 60 83.3 
HbE/ l3-thalassaemia +1+ 0 0 
+1- 12 85.7 
-1- 2 14.3 
f3 Tr +1+ 1 0.9 
+1- 25 23.4 
-1- 81 75.7 
HbAIE +1+ 3 37.5 
+1- 4 50 
-I- I 12.5 
Badulla 
l3-thalassaemia major +f+ 1 2 
+f- 12 24.5 
-/- 36 73.5 
HbE/ l3-thalassaemia +1+ 0 0 
+/- 7 100 
-f- 0 0 
Colombo 
l3-thalassaemia major +1+ 4. 18.75 
+1- 2 6.25 
-l- IS 75 
HbFJ f3-thalassaemia +f+ 1 100 
+1- 0 0 
-1- 0 0 
Kurune2ala 
f3-thalassaemia major +1+ 3 2.3 
+/- 25 19.2 
-1- 102 7S.5 
HbE/ f3-thalassaemia +1+ 10 10 
+1- 70 70 
-f- 20 20 
Total 
f3-thalassaemia major +1+ 9 3.3 
+1- 50 18.2 
-1- 216 78.5 
HbFJ f3-thalassaemia +1+ 11 9 
+/- 89 73 
-1- 22 IS 
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levels of HbF. The locus was examined by RFLP analysis (See 2.4) in a 
large proportion of the patients and relatives from four centres on the 
island: Anuradhapura; Badulla; Colombo and Kurunegala. An assessment 
was then made to ascertain if there was an association between the Xmn-/ 
status with different haemoglobinopathy groups (Table 5.7). 
The Xmn-/ (-) configuration was the most prevalent found on 
78.1 % of the chromosomes. This high frequency should mean that every 
globin gene grouping should have a high preponderance for the (-/-) 
configuration. This was the position in patients with major 
(78.5%) and relatives with trait (75.7%). However, patients 
with HbE/I3-thalassaemia and relatives with HbAIE had a larger proportion 
with the (+1-)(73%) and the (+1+)(18%) status. This tum around may result 
in a greater level of HbF in patients with chromosomes containing HbE. 
Three J3-globin gene mutations were also found in associated with an 
Xmn-/ (+) configuration. CD30 (G-7C) and CDl5 (G-7A) are rare 
mutations in Sri Lanka and hence could only be demonstrated in a few 
families. The (+) configuration was found in a small subset of patients with 
the mutation IVSI-5 (G-7C) but the majority of these patients 
were associated with the (-) configuration. 
Although only a few cases were infonnative only four J3-globin 
cluster haplotypes have been found with the (+) status. CD30 (G-7C) was 
found on Orkin haplotype IX, CD15 (G-7A) on haplotype IV and HbE on 
haplotypes III and V. Three of these Orkin haplotypes (m, IV and IX) 
share the same 5' haplotype ( -+-++ ), upstream of the hotspot for 
rearrangement, and were found in about 10% of the normal chromosomes 
described earlier (Table 5.2). The 5' haplotype and not just the Xmn-/ 
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polymorphism still holds the key to dissect its association with elevated 
HbF levels but the Xmn-l. 
BP-l fJ-gene promoter polymorphism 
The aim of this study was to investigate the heterogeneity of a 
repeated purine-pyrimidine sequence motif approximately 500bp upstream 
of the p-gene. This marker may be a possible indicator for disease severity 
by regulation of the level of HbF. 
Hospital based patients and their relatives from Kurunegala were 
investigated by peR sequence analysis (See section 2.4) using the 
amplification primers 5' pURR against 3' (3URR and sequencing with 
primers 5'I3URRI and 3'(3URRI outlined in Table 2.9. The different 
isoforms were assessed and their frequency determined (Table 5.8). 
Table 5.8 Incidence of different BP-l motif observed in individuals from Sri 
Lanka 
Repeat configuration Frequency 
n % 
(ATMT)9 1 1.2 
(ATh(T)7 25 29.4 
(AT)s(T)s 13 15.3 
(AT)s(T)6 1 1.2 
(AT)g(T)7 5 5.9 
(AT)s(T)9 2 2.4 
(ATMT)3 16 18.8 
(ATMT)5 13 15.3 
(ATMT)7 7 8.1 
(AT)ll(T)l 1 1.2 
(AT)II(Th 1 1.2 
Total 85 100 
Amazingly, eleven different arrangements of this motif were 
observed with four common types accounting for 78.8% of the 
chromosomes studied but the pattern of the motifs did not appear to follow 
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a normal distribution pattern around a hypothetical average pattern 
(AT)s(T)s). Also a subset of these individuals (15) examined, were part of a 
group with that had been studied more intensively. An 
extremely crude attempt to correlate the 5' URR motif with the level of 
HbF (total haemoglobin concentration or relative proportion) was made on 
these patients but no correlation was observed. 
138 
5.3 Discussion 
Phylogenetic analysis indicates that (l- and genes were 
formed by duplication of a common ancestor -450 Mya (Burmester el al., 
2002). The process of duplication and divergence of the (l- and t3-genes has 
continued to generate the current gene clusters. Hence, a large degree of 
sequence homology can be observed. The genes and the control mechanism 
for globin expression are found in the same overall arrangement in 
mammalian species. The t3-globin gene cluster extends over 70 kilobases 
and the genes embedded in this sequence are highly conserved between 
individuals and across species. The embryonic and adult genes are most 
highly conserved across species as seen in Figure 5.1. 
Regions around genes and upstream in the LCR are essential for 
regulation of gene expression and are also conserved. However, the more 
closely sequence throughout the t3 globin cluster is examined in different 
populations the greater the degree of sequence heterogeneity. This is not 
greatly surprising as these gene duplication events took place millions of 
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years ago and hence has allowed a large expanse of time for change to occur. 
Any polymorphism that has different configurations in different groups of 
people can be useful and many have been proposed as important in the 
regulation of the globins process (Labie & Elion, 1996; Zago et ai., 2000). 
Patients that are able to maintain a relatively normal concentration of 
haemoglobin by maintaining high levels of HbF may have a milder clinical 
phenotype (Weatherall, 2001). The Xmn-/ polymorphism (+) configuration 
has been associated with higher HbF levels and can be used as a prognostic 
marker. However, the polymorphism has never been proven to be directly 
involved in the regulatory process (Labie & Elion, 1996). 
The majority of chromosomes in the population of Sri Lanka are on 
the Xmn-/ (-) configuration similar to other populations (Thein et ai., 1988; 
Lie-Injo et ai., 1989). This is somewhat surprising, as selective advantage 
may have predisposed towards allowing the rescue of individuals from 
anaemia by switching to HbF production. This may suggest that conditions 
for anaemia may have been of prime importance. An attempt was made to 
eradicate malaria on the island in the 1960s that may have changed the 
selective advantage away from anaemia. The genetic outcome may only 
become apparent after many more generations. 
If this trait has a great selective advantage its incidence and 
consequently that of the linked p-gene mutation HbE should expand to a 
larger part of the population increasing the prevalence of HbE/P-
thalassaemia. The predominant haplotype shared the same 5' portion with a 
(-+-++) configuration. Part of this 5' haplotype is shared with the Asian 
Indian haplotype associated with higher levels of HbF in patients with sickle 
cell disease (++-++) (Wood, 1993). The y-genes and their surrounding DNA 
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need to be more closely scrutinized in individuals with a high and low HbF 
level. The Xmn-J polymorphism may be linked to another mutation that 
could be responsible for the regulation of HbF expression. The HbS Asian 
Indian haplotype is also associated with a longer version ((AT)9T5) of the 
simple repeat element upstream of the B-gene that binds to a nuclear binding 
protein (BP-I)(Labie and Elion , 1996). 
The connection between Sri Lanka and the rest of the world 
Previously described polymorphisms on both the a- and B-globin 
clusters were analysed and the normal haplotypes were compared against 
other world populations (Table 5.9 and 5.10). 
Table 5.9 Comparison of normal a-globin gene baplotypes in world populations 
Haplotype RFLP Mediterranean S.E. Asian Asian Indian Sri Lanka 
Ref. ! Ref.! Ref. ! Ref. 2 Ref. ! Present 
study 
% % % % % % 
Ia ++ -M PZ++ -- 56 28.6 54.2 41.1 25 43 
Ib -+-MPZ++ -- 6 1.9 0 2.2 3.6 0 
lla -+-LPZ+--- 20 24.8 16.7 23.2 35.7 0 
lli - ++M PZ + - -- 0 0 0 0 0 7.1 
rna - - +M Z - - -- 6 8.3 6.3 6.6 21.4 14.3 
llIb + -+MZ - - -- 0 0 2.1 1.3 3.6 21.4 
me -+-LZ---- 4 1.1 2.1 0 3.6 0 
nTh +++M Z - - -- 0 1.1 0 0 7.1 0 
Illi -++MPZ---- 0 0 0 0 0 7.1 
Vlla - +- M PZ+ - -- 0 0 0 0 0 7.1 
Other 8 34.2 18.6 25.6 0 0 
Chromosome Number 50 266 48 151 28 14 
References. 1. FlInt eraZ., (1993) 2.Martmson eraZ., (1995) 
A complex pattern for the global distribution of a-globin haplotypes 
was observed (Table 5.9). Two a-globin haplotypes (Ia and IIa) were 
common to all populations reported and were generally found at high 
incidence levels. Three other a-globin haplotypes (lb, lIla and lITe) were 
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Combined 
% 
31 
2.4 
23.7 
2.4 
19 
9.5 
2.4 
4.8 
2.4 
2.4 
0 
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widely distributed but generally at a low incidence. The population of Sri 
Lanka demonstrated a different distribution pattern of haplotypes compared 
to other populations. a-globin haplotype IlIa was found at a high frequency 
in Sri Lanka but had a higher incidence in Asian populations. a-globin 
haplotype IIlb had a high incidence in Sri Lanka and has only been reported 
in Asian Indians, at a low frequency. a-globin haplotypes IIii and IIIi were 
only found on the island. The other a-globin haplotype only reported in Sri 
Lanka was VIla but has been previously described in people of West African 
origin (Flint et al., 1993). A connection between these groups is not 
postulated. 
The results from the previous study on individuals from Sri Lanka and 
the current study were widely different. In part, this was due to the low 
number of haplotypes assessed. However, some large differences still need 
to be explained and probably reflect groups of different ethnic origin or 
smaller isolated communities. 
The global distribution pattern of (3-globin haplotypes is just as 
complex (Table 5.10). Seven (3-globin haplotypes were common to all 
popUlations studied. Three (1, 2 and 5) were generally found at high and four 
(3, 5, 6 and 8) at a low level of incidence. (3-globin haplotype 3 was found at 
a higher incidence in populations from the East and haplotype 5 was higher 
in populations from the West. The population of Sri Lanka revealed its own 
pattern of haplotypes. f3-globin haplotypes 18 and 38 were only revealed in 
people from Sri Lanka. However, a larger sample size is required in all the 
populations to be more confident about these popUlation differences. 
142 
Table S.10 Distribution of normal f3-globin gene baplotypes in world populations 
P<>pulations 
Cyprus" Algeria" Asian Thailand" Cambodia" South Japan" 
* ** RFLP Indian" Otina" 
1 I +---- ++ 50 43.1 25 16.9 12.3 20.4 13.9 
2 V +---- +- 10.5 15.4 9 49.2 26.2 24.2 18.4 
3 VII +---- -+ 5.3 19.1 24.6 41.5 35.1 41.1 
4 +---- -- I 
5 IX -+-++++ 26.3 13.9 13.9 1.5 6.2 2.4 5.1 
6 III -+-+++- 9.2 1.5 1.5 3.1 1.4 1.3 
7 IV -+-++-+ 6.8 4.6 4.7 5.1 
8 II -++-+++ 2.6 9.2 9.9 1.5 2.8 3.2 
9 -++-++- 2.5 3.1 1 1.9 
10 B3 -++-+-+ 5.6 1.5 1.5 4.3 1.3 
11 -+--+++ 0.3 0.6 
12 -+--++- 0.3 
13 i -+--+-+ 0.3 1.5 3.1 0.6 
14 -+-++-- 0.6 
16 ----++- 4.6 
18 ---++++ 
19 ---++-+ 1.9 1.9 
21 B4 -----++ 1.5 0.3 
23 ------+ 0.6 
24 -+---++ 1.3 
26 -++--++ 0.9 
27 -++--+- 0.6 
28 VI -++---+ 5.3 3.1 0.3 
29 VIII -+-+-+- 0.6 
35 +--++-+ 1 
38 +---+-+ 
39 +-+---+ 1.3 
40 ++-++++ 1.2 
41 ++-+++- 1.2 
43 ++---++ 0.6 
44 ++----+ 1.3 
45 +++-+++ 0.6 
Other 
Chromosomes studied 38 65 324 65 65 211 158 
Reference: '" Shmllzu etal., (2001) .'" Orkin & Kazazlan (1984) 
At both the u- and [3-globin cluster the incidence of different 
haplotypes in Sri Lanka was more similar to other populations of the Far 
East than in populations around the Mediterranean. The people of Sri Lanka 
and those from the subcontinent of India appear to share a close genetic 
history. This ties in closely with history of the country (See section 1.1.1) 
and the population migrations that have been recorded over thousands of 
years, mainly from neighbouring India. 
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Sri Lanka 
18.6 
7.6 
26.3 
4.2 
2.5 
4.2 
3.4 
4.2 
8.5 
2.5 
0.8 
0.8 
0.8 
2.5 
0.8 
1.7 
1.7 
8.5 
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Origin of mutations 
Haplotype analysis was found to be useful to study f3-globin 
haplotypes linked with f3-thalassaemia mutations. Unsurprisingly, 77.6% of 
the assigned haplotypes were found on the three common background 
haplotypes (Shimizu groups 1, 2 and 3; Orkin I, V and VII). Previously 
reported haplotype mutation associations from other populations were 
compared against those assigned in the population of Sri Lanka (Table 5.11). 
Table 5.11 A comparison of haplotype associated with different beta globin 
mutations in different populations of the world 
B-genotype Sri Lanka Mediterranean Middle East Indian South East Asia 
(Ref 1, 13) (Ref 3, 4, 5) Subcontinent (Ref 1,6,7, 8,9, 
(Ref 1, 2, 13) 10, 11, 12, 13) 
CD6(GAG-tGTG) 2,41 2,41 
HbS 
CD8/9 (+G) 1 1,7 1, 5,8 
CDI5 (G-tA) 7 8 1,5,7,8 
CD16 (-C) 2 2 
CD26(G-tA) HbE 2,6 1,2,3,5,6,7,8, 
9, 12 
CD30 (G-tC) 5 1 1 
IVSI-l (G-tA) 3 1,2,5,6,21 2 
IVSI-5 (G-tC) 1,3,7 1,3 1,3, 7, 10, 13, + 1,3,5,21,37 
CD41142 (-TCTT) 7 1 ,5,6,2,41 1,3 
619 bp Deletion - 3 3 
1 Orkin & Kazazlan, (1984) 7 Chan etal. ,(1987) 13 Kazazlan etal. ,(1984) 
2 Thein etal. , (1988) 8 Antonarikis etal. , (1982) 
3 Old I.M. Personal communication 9 Yongvanit etal. , (1989) 
4 Filon etal. , (1994) 10 Brown etal. ,(1992) 
5 Novellettoetal. , (1990) 11 Hundreiseretal.,(1988) 
6 Lie Injo etal., (1989) 12 Fuchaeron etal. ,(1990) 
Six of these mutations (HbS, CDS/9 (+G), CD15 CDI6 (-C), 
IVSI-5 and the 619 bp .1) showed the same haplotypes as those 
observed in India. The simplest connection would be due to a population 
migration from India but they also occur on common background haplotype 
so a multicentric origin for this mutation, although unlikely, remains a 
possibility. 
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Four mutations showed an association with a haplotype not described on 
the Indian subcontinent. The relatively rare mutations CD30 (G--"7C) and 
CD41!42(-TCTT) were found on Shimizu haplotypes 5 and 7 respectively. 
Both of these haplotypes constituted less than 5% of the normal background 
haplotype and have not been reported with these haplotypes in any other 
population. However, the 3' {3-globin haplotype associated with the mutation 
CD30 (G--"7C) is always ++. Any change upstream of the recombination 
hotspot would generate other haplotypes but may still be consistent with a 
common origin for the mutation. In contrast, the 3' (3-globin haplotype 
associated with the mutation CD41142( -TCTT) was found in Sri Lanka on a 
-+ configuration. The most commonly reported association for this mutation 
was on the +- configuration but it has also been reported on a ++ 
configuration and is suggestive that this mutation may have arisen 
independently in the island population. Three other different thalassaemia 
mutations (CDI5 (-T), IVSI-130 (G---7C) and CD55 (-A» were each linked 
to their own distinct haplotype. Information on their haplotype associations 
in other popUlations has not been reported. 
The three most common mutations on the island also yielded the largest 
number of informative haplotypes. The single base substitution IVSI-5 
(G-7C) is the most prevalent mutation, in Sri Lanka and globally, and is 
probably the oldest {3-thalassaemia mutation (reviewed in Weatherall & 
Clegg, 2001). The mutation was found on four different background 
haplotypes (Shimizu 1, 3, 7 and 25; Orkin I, VII, IV and X respectively) that 
possibly denotes that the mutation has been in existence long enough for 
chromosomal rearrangements to have occurred. Closer examination of the 
haplotype showed that the 3' haplotype was almost exclusively due to one 
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from -/+ with a single individual showing +/+. This would strongly indicate 
that the mutation has probably only arisen once a long time ago and that 
different 5' haplotypes have occurred due to the hotspot for gene 
arrangements just upstream of the p-gene. 
IVSI-l has been reported as an extremely rare mutation in north 
India (Varawalla et aI., 1991b). The mutation is common in countries 
surrounding the Mediterranean reaching very high frequencies in Spain and 
Portugal. The mutation observed in Sri Lanka was linked exclusively to 
Shimizu haplotype 3. In the Mediterranean populations the mutation was 
linked to haplotype 1,2,5, 6 and 21 in Portugal and North Africa (Faustino 
etaZ., 1992; Pachecho etaZ., 1996) but never to haplotype 3. In particular, the 
3' haplotypes from these distinct regions are informative. In Sri Lanka a -/+ 
arrangement is found compared to either a +/+ or +/- arrangement around the 
Mediterranean. The chances of some form of recombination are 
exceptionally slim especially from the +/- configuration as two events need 
to occur to achieve the change and an intermediate form has not been 
described. Another possibility is that the mutation has occurred in a 
popUlation that has not been investigated thoroughly, such as south India. 
The popUlation of South India may still hold the key to this riddle as it has 
only been investigated on a very small scale for mutations that have been 
described in India and this does not include IVSI-I In conclusion, 
the mutation appears to have arisen at least twice in a population in the west 
and in Sri Lanka. 
The origin of the third most common mutation, HbE, found on the island 
IS of great interest as it superficially gives credence to the notion of a 
popUlation migration from north east India down to Sri Lanka without 
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passing through south India. In the population of Sri Lanka HbE was found 
on four haplotypes and was compared to other populations (Table 5.12) 
(Antonarkis et ai., 1982; Nakatsuji et ai., 1986; Hundreiser et at., 1988; 
Yongvanit et al., 1989; Fucharoen et al., 1990; Brown et al., 1992 and 
Fucharoen et al., 1997). 
Table 5.12 Haplotypes associated with HbE in different populations 
Haplotype Sri Northeast Myanmar Thailand Cambodia Vietnam Overall 
(Shimuzu/RFLp) Lanka India! 
Ban_gladesh 
% % % % % % % 
1 +----++ 0 5.3 1.1 0 0 17 1.2 
2 +----+- 25.5 63.2 15.4 27.7 26.1 17 31.5 
3 +-----+ 0 10.5 3.3 0 0 0 2.0 
5 -+-++++ 0 5.3 3.3 0 0 0 1.6 
6 -+-+++- 59.6 0 73.6 63.1 47.8 49 53.4 
7 -+-++-+ 0 0 0 6.2 26.1 0 4.0 
8 -++-+++ 0 0 0 0 0 17 0.4 
9 -++-++- 12.8 0 0 0 0 0 2.4 
12 - + - - + + - 0 0 0 1.5 0 0 0.4 
Others 2.1 15.7 3.3 1.5 0 0 3.1 
Chromosome No. 47 19 91 65 23 6 251 
Surprisingly, the (3-globin haplotypes observed in individuals originating 
from north east India did not include Shimizu haplotype 6 and was probably 
due to the low number of chromosomes examined. Haplotype 6 was the 
most common haplotype associated with HbE in all the other populations. 
Haplotype 2 also was found at high frequencies in all the populations. 
Haplotype 9 was only observed in Sri Lanka and represents a divergence 
from these other populations. The origin of HbE is not clear but may only 
have occurred as a single event around the ThailCambodiaIVietnam border. 
All the other haplotypes could have derived from this founder. 
In Sri Lanka the 3' (3-globin haplotype is always In the +/-
configuration in association with HhE. Only in Cambodia are people with a 
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different configuration -/+ found at high frequencies. The flow of genes 
between popUlations can be strongly implicated by these studies but many 
more chromosomes need to be defined so that the results reach statistical 
significance. 
Extended haplotype 
The repeated purine-pyrimidine sequence (AT)n(T)n 0.5kb upstream 
of the gene exhibits a great variation in length and configuration 
(Galanello et al., 1993). This motif lies within a negative regulatory region 
between -610 and -490 upstream from the gene and is the binding 
site for a putative negative regulatory transacting factor called BP-l. 
Anecdotal evidence exists that BP-l binds more avidly to the longer ATtract 
compared to the shorter ATtract resulting in a very mild 
phenotype with the longer AT isoform. 
Eleven different forms of this motif were observed with four major 
types accounting for almost 80% of the alleles observed. These were spread 
over 7, 8, 9 and 11 repeats of AT which should correlate with the strong and 
weak binding forms. The motif would probably warrant a closer 
investigation to see if it acts as a gene modifier in the characterised group of 
patients with A possible correlation between these 
isoforms and levels of HbF were not supported by our limited results. 
Which haplotype? 
This also opens up the question about the polymorphisms that should 
be included as part of a haplotype analysis. The polymorphisms that define a 
particular haplotype should form a series of variable markers such that the 
different combinations exhibit patterns that can be informative. The markers 
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used to define globin haplotypes were selected during the early 
developmental phase of DNA analysis. The polymorphisms were chosen 
because they mainly alter restriction enzyme sites and were reasonably 
spaced over the (X- and (3-globin clusters. Perhaps now with the aid of 
automation many more sites should be included to define a haplotype that 
include those that do not just alter restriction enzyme sites. Sequence 
analysis may reveal many nucleotides within a stretch of DNA that show 
some diversity based on both anthropological and phylogenetic diversity. 
Limited sequence analysis, in this current study, of both the duplicated (X-
and y-genes has shown that sequence variation and putative intergene 
nucleotide exchange can form subsets of a haplotype. These may have some 
relevance to expression of that gene but could also be used to follow the 
flow of particular genes through populations. 
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Chapter 6 Genotype - Phenotype correlation 
The subtly different clinical outcomes of patients with apparently 
identical globin genotypes depend on the mechanism of globin gene 
disruption and the different genes affected. Many factors modify the 
phenotype, either in the gene directly or as a distant regulator. A rigorous 
clinical examination of these patients was made to identify these factors 
and to highlight other anomalies that could account for a patient's 
phenotype. 
6.1 l3-glohin gene mutation 
Mutations within the l3-gene down regulate the expression of 
globins in more than one way. The mutations described in chapter 4 either 
have been previously defined (reviewed in Weatherall and Clegg, 2001) or 
were placed within one of these groups (Table 6.1). 13° -thalassaemia alleles 
included CD S (-CT), CD 6-10 (LlI3bp), CD 8/9 (+G), CD 15 (-T), CD 15 
CD 16 (-C), IVSI-l (G---7A) , IVSI-l (G---7T) , 2Sbp Ll, IVSI-130 
(G---7C), IVSI-130 (G---7A) , CD 41142 (-TCTT), CD 55 (-A), IVSII-l 
(G---7A) and 61Sbp d. 13+ (severe)-thalassaemia alleles included CD 30 
IVSI-5 (G---7C) and IVSII-745 (C---7G). f3+-thalassaemia alleles 
included -28 (A---7G) and Poly A tail (T ---7 C). Haemoglobin variants 
included HbS, HbE and HbD and one mutation was classified an unknown 
(IVSI-129 (A---7C)). The groups were outlined in section 1.2.2.2 13-
thalassaemia phenotypes. Two main groups were observed; transfusion 
dependent l3-thalassaemia major and l3-thalassaemia intermedia. 
Most of the l3-thalassaemia major patients express either no adult 13-
globin or only a very small amount and require blood transfusions every 3 
to 4 weeks. Clinical variations within this group of patients were not 
investigated. Two patients were treated as if they had l3-thalassaemia major 
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but were found to have a -thalassaemia allele in combination with a (3+-
thalassaemia allele. The mutations associated with a reduced globin output 
were the promoter mutation -28 in a single case and the 
polyadenylation signal mutation (Poly A tail (T in seven patients. 
These patients needed careful follow up examinations to observe whether 
they could have been classed as severe intermedia. Other 
possible candidates for a less severe fonn of the disease included one 
hundred and sixty eight patients who had one (3-thalassaemia allele in 
combination with a structural variant; I with HbD, 162 with HbE and 5 
with HbS. 
Table 6.1 Classification of mutations according to their predicted expression 
Globin Number Frequency 
(%) 
/30 329 27.0 
/3\Severe) 710 58.2 
W 9 0.7 
/3 Variant 168 13.8 
Unknown 3 0.3 
Total 1219 100 
The family with HbD was also found to have a /30 -thalassaemia 
(lVSI-l The index case, an 18 year old boy, had presented at the 
local clinic III Galle with continued jaundice (7 years), 
hepatosplenomegaly, a moderate anaemia and an unidentified abnormal 
haemoglobin. No blood transfusions were recorded. 
Five families were found to have the haemoglobin variant HbS. The 
presentation of their clinical phenotypes was incomplete. All of the index 
cases had required some blood transfusions but the normal range of 
symptoms associated with sickle cell disease were not reported. 
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All the other patients with structural haemoglobin variants were 
found to have HbE/(3-thalassaemia. The (3-thalassaemia allele was always a 
severe (3+- or (30 -allele. These patients demonstrated a wide variety of 
phenotypes ranging from almost undetectable carrier status to (3-
thalassaemia major. 109 of these patients were investigated more 
thoroughly to place them into different clinical subsets and then to assess 
the importance of different influencing factors. Four patients had mutations 
to which a clinical phenotype was uncertain and so remained unclassified. 
6.2 <x-gene arrangement 
Adult haemoglobin is a tetramer composed of two a- and two (3-
polypeptide chains. In (3-thalassaemia too many or too few a-chains can 
alter the outcome of the individual's phenotype (See section 1.2.2.2). This 
chain imbalance forms the basis of the pathophysiological outcome. 
Further analysis of the data from the transfusion dependent patients and 
their relatives were evaluated to examine the frequency of a-genotypes in 
different B-thalassaemia categories (Table 6.2). 
Table 6.2 
(X-genotype 
aaiaa 
-aiaa 
-ai-a 
aaaJaa 
aaaJaaa 
aaaaiaaaa 
Total 
Incidence of a-gene arrangement coexistent in the in patients and 
relatives with f3-globin mutations 
Patients Carriers 
HbEl/3-thalassaemia HbDorHbSI Homozygous or HbNE /3-trait 
/3-thalassaemia compound 
heterozygous /3-
thalassaemia 
112 (90.3) 2 (100) 223 (80.2) 6 (75) 79 (78.2) 
8 (7.3) 0(0) 40 (13.9) 1 (12.5) 19 (18.9) 
0(0) 0(0) 2 (0.8) 0(0) 1 (1) 
3 (2.4) 0(0) 12 (4.3) 1 (12.5) 2 (1.9) 
0(0) 0(0) 1 (0.4) 0(0) 0(0) 
0(0) 0(0) 1 (0.4) 0(0) 0(0) 
123 (100) 2 (100) 279 (100) 8 (100) 101 (100) 
Figures 10 parenthesIs represent genotype frequencIes 
The incidence of a-globin genotypes (-aJaa) was almost two times 
greater in B-thalassaemia major patients compared with HbElB-
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thalassaemia patients. This decreased frequency was also observed in the 
carriers for HbE compared with those that had trait. As the 
study involved transfusion dependent thalassaemia patients, the severe end 
of the phenotypic spectrum was mainly analysed. Patients with 
thalassaemia that had co-existing a-thalassaemia may have been modified 
to a milder form of the disease and hence would not have presented at 
clinic and subsequently required hospital treatment. Seven patients with 
this condition still presented at clinic with a need for blood transfusions but 
presented with steady state HbF levels between 2.7 and 32% (mean<10%). 
Although a-thalassaemia may have been of benefit in these patients their 
ability to produce HbF was poor and they remained anaemic. Interestingly, 
relatives of patients with that were carriers for HbE 
appeared to be associated with a high incidence in the aaa gene 
arrangement compared to those with trait. As these 
represented a smaller total number of individuals this may have been a 
statistical anomaly. 
Eighteen patients with extra a-genes were analysed at greater depth 
(Table 6.3). Two individuals presented with a normal phenotype. They 
were both found to have the a-gene arrangement aaa/aa and a single 
gene mutation. These individuals were relatives of transfusion dependent 
cases and were only picked up after family studies. The first was found in 
combination with the haemoglobin variant, HbE that is often associated 
with reduced red cell indices and can be classed as a mild 
allele. The relative chain imbalance for this individual should not be great 
but should become more exaggerated with a -thalassaemia mutation. The 
second was found in combination with such a mutation, IVSI-I 
but unaccountably presented with normal haematological indices. 
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Table 6.3 Genotype/phenotype correlation of individuals with extra a-genes 
a-genotype (3-genotype Phenotype Total 
Normal Mild Moderate Severe 
aaCJJaa HbAIE 1 1 
IVSI-I (G-7A)/13N 1 1 
Codonl6 (-C)/13N 1 1 
IVSI-130 (G-7c)/13N 1 1 
IVSI-5(G-7C)IHbE 3 3 
IVSI-5(G-7C)/ rvSI-5(G-7C) 3 3 
IVSI-5(G-7C)/ rvSI-l(G-7A) 1 1 
IVSI-l (G-7A)/ Codon 15 (-T) 1 1 
rvSI-5(G-7C)/Codon41142( -TCTT) 3 3 
Codon15 (-T)/ Codon55 (-A) 1 1 
aaCJJaaa Codon15 (-T)//3N 1 1 
aaaCJJaaaa IVSI-5(G-7C)/13N 1 1 
Total 18 2 0 2 14 18 
The individual with the genotype aaaJaa and (30 -thalassaemia trait 
(CDI6 (-C» presented at clinic at 3 years of age after the mother had 
noticed an enlarged cervical lymph node on the left-hand side. On 
examination the child was found to have pallor, hepatosplenomegaly and 
lymphoidenopathy. On investigation of the red cells the Hb level was found 
to be only 6.5g/dl and the patient had an elevated HbA2 at 5.8%. A blood 
transfusion was given and the red cell indices returned to nonnal. 
Currently, the boy is about II years old and has no overt problems but has 
low red cell indices and slight hepatosplenomegaly as shown in Table 6.4. 
The individual with 5 a-genes and the (3°-thalassaemia mutation 
(IVSI-130 presented at clinic with a history of abdominal pain 
aggravated by oily foods and a yellow discoloration of the eyes at the age 
of 46 years old. She was diagnosed as having cholecystitis due to 
gallstones. She was given a blood transfusion prior to cholecysectomy and 
splenectomy and examined haematologically. She had persistent 
haemolytic anaemia but sadly died some time after the operation. All the 
other individuals with 5 a-genes had mutations in both their f)-genes and 
were treated as severe transfusion dependent patients. 
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Table 6.4 Clinical picture of two patients with aaaJaa and a 13° -thalassaemia 
mutation 
Genotype RBC Haemoglobin MCV MCH MCHC Spleen Liver Jaundice 
(XlO"jIl) concentration (fl) (pg) (g/dl) 
[Hb] (g/dl) 
Codon16 263 5.4 55.4 20.7 37.3 Slightly Just uaa/au Enlarged Palpable 
NSI-130 278 7.2 70.1 26 37.1 Removed Enlarged 
aaa/aa 
An individual homozygous for the triple a-gene in combination with 
the single f3o-thalassaemia mutation (Codon15 (-T» presented as a boy with 
suspected f3-thalassaemia major. After DNA analysis he was found to have 
just one f3-gene mutation in combination with 6 a-genes. Upon further 
physical examination he was found to have pallor, jaundice, and 
hepatoslpenomegaly. A family study was initiated and other family 
members were examined (Table 6.5). 
Table 6.5 Haematology of family G with a triple a-gene arrangement 
Individual RBC [Hgb] Hct MCV MCH Spleen Liver Jaundice 
(XI04'jIl) (g/dl) (%) (0) (pg) 
Index case 204 4.9 14.8 72.5 23.9 Enlarged Enlarged Yes 
Mother 342 10.8 27.5 80.4 31.4 Normal Normal None 
Father 341 7.4 20.9 61.2 21.8 Normal Normal Yes 
Brother 1 352 11.4 29.1 82.7 32.5 Just Just None 
PalQable Palpable 
Brother 2 342 9.8 24.7 72.3 28.6 Normal Normal None 
Sister N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. 
The mother appeared normal but the father had both anaemia and 
jaundice. Only 2 of the three siblings were examined, brother 1 was normal 
and brother 2 had mild anaemia. The a- and {3-genes of the whole family 
were analyzed. Both parents and the sister were found to be heterozygous 
for the triple a-gene rearrangement whereas brother 1 was nonna! and 
brother 2 was a homozygote for this gene arrangement. At the f3-gene locus 
the mother and the two brothers were normal whereas the father and the 
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sister both were carriers for the same (30 -thalassaemia mutation found in the 
proband. Only the index case had needed the requirement for blood 
transfusions and was probably due to the exaggerated chain imbalance 
imposed by the loss of expression of one (3-gene and the inheritance of an 
extra a-gene from both parents. 
The final case was the individual homozygous for the quadruple (X-
gene arrangement in combination with the single severe (3+ -thalassaemia 
mutation (IVSI-5 who presented as a baby with suspected (3-
thalassaemia major. After DNA analysis he was found to have just one (3-
gene mutation in combination with eight a-genes. Upon further 
examination he was found to be pale with a large head. A family study was 
initiated and his parents were examined and the clinical status evaluated as 
highlighted in Table 6.6. 
Table 6.6 Haematology of family H with a quadruple a-gene arrangement 
Individuals RBC Hgb Hct* MCV MCH Spleen Liver 
(XIO")1l) conc. (%) (0) (pg) 
(gIdl) 
Index case 236 4.9 13.8 58.4 20.8 Splenectomy Slightly 
enlarged 
Mother 295 6.2 16.5 56.1 20.9 Normal Normal 
Father 375 8.7 22 58.5 23.2 Normal Normal 
* Hct IS an abbreviation of haematocrit 
The index case was splenectomised and afterwards was found to 
have severe anaemia, greatly reduced red cell indices and a slightly 
enlarged liver. Both parents were investigated and found to have the 
genotype aaaaJaa. and IVSI-5 (G-tC) trait. The parents appeared normal 
but had markedly reduced red cell indices and anaemia with the mother 
exhibiting a slightly more severe phenotype. 
The haematology, on these families, was performed by a technician 
within the clinic at the Kurunegala teaching hospital. The clinical 
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examinations were performed by Professor D.J. Weatherall, Dr A. 
Premawardhena and Dr N. Olivieri. 
6.3 HbF Level 
The amount of HbF in normal adults varies by more than ten-fold. 
Family studies of individuals at the low and high ends of this spectrum 
have indicated a strong genetic component involved in setting this level 
(Wood, 1993) Genetic and environmental factors contribute towards the 
final level of expression of HbF. The genetic determinants are probably 
located within and outside of the J3-globin gene cluster. 
In the absence of the normal adult J3-globin chain the foetal form ("y-
globin or Gy-globin) can substitute to form HbF so that haemoglobin 
switching does not occur. The regulation of this gene is critical to the 
outcome of the disease severity. A closer examination was made of the 
sequence in and around the y-genes to determine any association with the 
level of HbF. Methods and reagents were developed on a family that was 
referred to the NHRL that was suspected of having co-existing J3- and y-
thalassaemia. These methodologies were then applied to two different 
cohorts originating from Sri Lanka; cord blood samples and patients with 
HbE/J3-thalassaemia. 
The clinical presentation of patients with HbE/J3-thalassaemia spans 
from transfusion dependent to individuals who are seemingly normal and 
are only identified after haematological examination. The factors that 
govern this variation are largely unknown but elevated levels of HbF can 
rescue the patient from severe anaemia. Eighty five patients with this 
syndrome were closely investigated after at least six months without blood 
transfusions or just before a blood transfusion to attempt to determine the 
steady state haemoglobin levels. Patients with this syndrome demonstrated 
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a normal distribution pattern over a wide range of HbF values from under 
5% to over 70% with a peak around the 30-35% level (Figure 6.1). 
Figure 6.1 Distribution of HbF levels in patients 
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During the analysis of cord blood haemoglobins for the investigation 
of a-thalassaemia, the level of HbF was simultaneously evaluated using the 
13-thalassaemia short program. The cord blood samples were arranged in 
decreasing levels of HbF to show the distribution pattern (Figure 6.2). 
The cord bloods were arbitrarily assigned groups according to the 
level of HbF expressed (Table 6.7). The majority of cord blood samples 
(97.5%) showed a distribution between 52.1 and 88.9% HbF and 
constituted the normal reference range for the level of haemoglobin 
switching from HbF to HbA (See section 1.2.1.1). Factors like the absolute 
time post-conception and minor modifiers such as the Gy-promoter 
mutation (C--7T) at nucleotide -158 (Xmn-J) upstream of the cap site would 
probably alter the level of HbF observed. The distribution pattern for this 
haemoglobin at both centres were similar, probably as these maternity 
clinics were less than 50 miles apm1 and served overlapping communities. 
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Table 6.7 Distribution of HbF levels observed in cord blood 
Location HbF Level Frequency Mean Range SD 
(%) n % ±SE % 
Chilaw >50 46 95.8 75.5+1.0 56.5-86.5 7.0 
20-50 0 0 - - -
<20 2 4.2 1O.7±4.6 6.1-15.2 6.4 
Total 48 100 
Kurunegala >50 263 97.8 75.7±O.4 52.1-88.9 6.7 
20-50 3 1.1 39.8+8.3 23.2-48.5 14.4 
<20 3 1.1 8.1+1.5 6.6-11 2.5 
Total 269 100 
Overall >50 309 97.5 75.7±O.4 52.1-88.9 6.8 
20-50 3 0.9 39.8±8.3 23.2-48.5 14.4 
<20 5 1.6 9.1±1.8 6.1-15.2 3.9 
Total 317 100 
Overall, relatively few cord blood samples (2.5%) demonstrate HbF 
levels below this range and were divided into two groups. The fIrst set had 
a wide range of HbF between 20 and 50%. Samples close to 50% probably 
represent the more extreme end of the normal range but samples with very 
low HbF levels may have some form of y-thalassaemia or a dysregulation 
in the switching process so that early switching occurs. This is also the case 
with the last group that has HbF levels below 20% although there may be a 
danger that they represent maternal blood that was collected by mistake, 
although this seems somewhat unlikely. 
DNA analysis of patients and cord bloods 
Ten cord blood samples were investigated further. Only eight of 
these were analysed by Southern blot analysis using a y-probe (Table 6.8). 
The two samples that were not analysed were expected to have a nonnal y-
gene arrangement as they showed the highest level of HbF. K52 had a 
raised level of HbA2 that may have been due to this individual having (l-
thalassaemia or being a carrier for HbE. A normal y-gene arrangement was 
revealed so further investigation of the sequence was required to account 
for the variation of the level of HbF. 
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Table 6.8 y-gene analysis of 10 selected cord blood samples taken in Sri Lanka 
Cord Level of haemoglobins measured using the y-gene status 
Blood Biorad short column Southern blot 
HbF HbA HbA2 Hb Barts Total Hb Bgl II Hind II! 
N46 5.3 79.3 2.3 0.4 87.3 12.9 8/3.5 
K83 5.3 71.5 2 2 80.8 12.9 8/7.2/3.5 
K52 5.7 75.1 4.6 1.2 86.6 12.9 8/3.5 
K227 9.1 70.6 2.1 1.1 82.9 12.9 8/7.2/3.5 
N29 13.2 71.2 2.1 0.6 87.1 12.9 8/7.2/3.5 
K253 17.4 54.5 1.4 1.7 75 NR NR 
K257 37 37.2 1.1 1 76.3 12.9 8/7.2/3.5 
K113 44.1 30.6 0.6 0.8 76.1 12.9 8/7.2/3.5 
K93 60.8 8.8 0 4.1 73.7 ND ND 
N42 67.9 16.2 0 4.3 88.4 ND ND 
NR- No result ND= Not Done 
The substitution at position Cap -158 in the promoter region 
of the Gy-gene creates an Xmn-J restriction enzyme site that can be assessed 
by RFLP (See section 2.4). In Sri Lanka this polymorphism was correlated 
with the steady state haemoglobin level in patients with 
thalassaemia (Table 6.9), 
Table 6.9 
Xmn-I 
Status 
-I· 
+/. 
+/+ 
Correlation between Xmn-I status and HbF in patients with 
thalassaemia 
Number HbF(%) Total Hb (I:ldl) 
of patients Mean +SE SD Range Mean±SE SD Range 
15 20.4+2.5 9.9 5.5-38 4.9±O.2 0.8 3.0-4.2 
59 28.6+1.3 10.2 2.7-57.7 5.5±O.1 1.1 3.3-8.1 
11 41.1+2.2 7.3 31.4-50.6 7.O±O.2 0.8 5.6-8.4 
In keeping with other studies, a high level of HbF was associated 
with a +/+ Xmn-J configuration, lower levels with a -/- configuration and 
the +/- group was between these two. The -/- group was associated with a 
mean Hb concentration of 4.9 g/dl, the +/- group with 0.6 g/dl more 
haemoglobin and the +/+ group with 1.5 g/dl more haemoglobin than the 
intermediate group. Hence, the net effect of the + configuration of the Xmn-
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I polymorphism appears to correlate positively with the total haemoglobin 
concentration presumably by raising the level of HbF. 
Oligonucleotides were designed to amplify and sequence both y-
genes independently (See section 2.4) in a Sudanese family with neonatal 
haemolysis (Bayoumi et aI., 1999). y-gene sequence analysis was performed 
on 10 cord blood samples and 15 patients with HbE/B-thalassaemia. A 
complex situation was observed with five sequence variations in the 0y_ 
gene sequence and ten variations in the sequence (Table 6.10, 6.11 
and 6.12). The majority demonstrated the same changes in both groups 
studied and were tabulated with the relative levels of HbF (Table 6.11). 
Four of these mutations (Oy: IVSII-1l5 and Poly A Tail (-A); 
IVSII-24 and IVSII-115 were also described previously in 
the family from Sudan. Two mutations (Gy: Codon 20 and 
Poly A Tail +2 (T were found in an isolated case only. All the 
other mutations were relatively frequent in the limited number of samples 
available and the sequence chromatograms are shown in Figure 6.3. 
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T) Cod" 20 (GTG'ce, G,) 
IN! IWI N I _ , J'l1 
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rVSI-65 T) 
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II 1. \ 
IVSII-115 G) 
Heterozygous 
IVSII-Ll5 G) 
Homozygous 
Normal 
Poly A tail -6 (-A) 
Heterozygous 
Poly A tail -6 (-A) 
Homozygous 
Normal 
AAACGGTCCCTGGC 
AAACGGW.?,GGC 
GTGAATGCGGAAGAT CCAGGTfGCf GGGGTTGGGGTGAAG AAGCAATCAAATAATAAATC 
........... 
Cap Exon2 ( Exon3 : 
: I : ! I : tall 
...... .. . ...... 
Cap-222f22S (-
AGCA) 
.. : ............. . 
IVSII-32 
... . ... 
IVS II-59 CT Termination codon+3 
cAy 4 Gy) 
vv . 
Normal Normal Normal Nonna! Nonnal 
r t " /\ ,' 
TTGGGGGCcCcrrCCCCACAC GAGA TT ATCf GATGCCACAAAGCAC III . An \ ACAACGGAGTA TT CACfGAGCCf A TTG 
GGGCCCCTTCCCCACACfATC GAGGTTATCf GATGCCATAAAGCAC ACAACTGAGTATT CACfGAGCfCACfG 
Figure 6 3 Gamma gene mutations observed in TCAGCACfGTTGCCfTfA 
• TCAGCCCfGTTGCTTTTA 
patients from Sri Lanka TCAGCCCfGTTGCCTTTA 
Table 6.10 y-gene sequence analysis of 10 cord blood samples taken in Sri Lanka 
sequence 
Lab. HbF -158 Codon 20 IVSI-64 IVSll-115 Poly A tail 
No. (%) -6 (-A) 
N46 5.3 C/C TIT TIT GIG AlA 
K83 5.3 TIC TIT CIT AlA AlIJ. 
K52 5.7 C/C TIT TIT GIG AlA 
K227 9.1 C/C TIT CIT AlA NIJ. 
N29 13.2 C/C TIT crr AlG AlA 
K253 17.4 NR TIT NR NR NR 
K257 37 C/C TIT C/C AlA MI:1 
K113 44.1 TIC Trr CIT AlA AlI:1 
K93 60.8 C/C Trr CIT AlA MI:1 
N42 67.9 TIC TIC C/C AlA AlI:1 
-1-Gene sequence 
Lab. -222/-225 Cap+29 IVSl-64 CD75 IVSll-24 IVSll-59 lVSIl-1l5 3'URR TGA+3 Poly A tail- Poly A tail + 
No. 1:14bp 4bp AglGg cony. 6 (-A) 
N46 wt/wt GIG Trr Trr C/C TIT GIG wt/wt AlA TIT 
K83 wt/wt AlG CIT TIT AlC Trr AlA wt/wt AlIJ. TIT 
K52 wt/wt GIG TIT TIT C/C TIT GIG wt/wt AlIJ. TIT 
K227 wt 1IJ.4bp GIG CIC TIC C/C T/G GIG wt/con AlA TIC 
N29 wt 1IJ.4bp NR CIT TIC AlC T/G GIG wt/con AlA TIT 
K253 ND ND NO ND ND ND NO ND ND ND 
K257 NR NR NR NR NR NR NR NR NR NR 
Kl13 NR NR NR NR NR NR NR NR NR NR 
K93 wt/wt GIG CIT TIT AlC Trr GIG wt/wt AlA TIT 
N42 _\\'t I AlO C/C TIC AlC TIG AlG wt Ic0Tl. __ ,-----.!J A __ TIT - - - ---- - _ .. - --------- . - .- - . 
wt= wild type sequence 1:1= deletion NR= no result ND=notdone con=putative gene conversion 
Table 6.11 Gy-gene sequence analysis of patients 
Lab. No. TotalHb HbF HbF -158 IVSII-115 Poly A tail -6 (-A) 
(gldl) (%) (gldl) 
SL681K409 4.8 9.7 0.47 CIC Trr GIG Alb 
SL601K415 4.8 10.9 0.51 TIC crr AlA AlA 
SLl161K501 6.2 12.2 0.76 TIC crr AlA Alb 
SLl41K467 4.8 18.6 0.89 TIC crr AlA AlA 
K227/K259 4.3 27.2 1.17 CIC crr AlG Alb 
SL361K498 5.3 22.6 1.2 TIC crr AlA AlA 
SL2031K391 6.6 21.1 1.39 TIC crr AlG Alb 
SL51K466 5.6 27.5 1.57 ctc crr AlG Alb 
SL2001K474 4.3 45.2 1.94 TtC crr AlG Alb 
SL821K327 6.4 40.9 2.62 Trr CtC AlA AlA 
K2061K488 7.4 44.3 3.28 Trr err AlA AlA 
K306 7.5 44.2 3.32 Trr CIC AlA Alb 
SL351K469 8.1 45.6 3.69 TIC crr AlG Alb 
K362 6.5 57.7 3.75 TIC err AlG Alb 
SL1261K411 7.5 50.5 3.79 Trr etC AlA 
- '---- - AlA -
b= deletion NR= no result ND=notdone con=putative gene conversion 
;: 
VI 
Table 6.12 "v-gene sequence analysis of HbEl(3-thalassaemia patients 
Lab. No. -22V-225 Cap+29 IVSl-64 CD75 IVSII-24 IVSII-59 IVSIl-115 3'URR TGA+3 Poly A tail-
Mbp (A4G) (C4T) (ATA4ACA) (T4G) (A4G) 4bpAgiGg 6 (-A) 
conversion 
SL681K409 wt/wt GIG TIT C/C C/C TIT GIG wtlwt Alb. 
SL601K415 wt/wt GIG TIT C/C C/C TIT GIG wtlwt Alb. 
SLl161K501 wt/wt AlG C/C C/C AlC TIT AlA wtlwt AlA 
SLl41K467 wtlwt AlA TIT C/C C/C TIT GIG wtlwt Alb. 
K2271K259 wt/Mbp GIG CIT err C/C T/G GIG wt/con AlA I 
SL361K498 wt/Mbp GIG CIT CIT AlA TIT AlA wtlcon Alb. 
SL2031K391 wtlwt AlG C/C C/C AlC TIT AlA wt/wt AlA 
SLSIK466 wt/Mbp GIG CIT CIT C/C TIT GIG wt/con AlA 
SL2001K474 wtlwt GIG TIT C/C C/C TIT GIG wt/con Alb. 
SL821K327 wtlwt AlA C/C C/C AlA TIT AlA wtlwt AlA 
K2061K488 wt/wt AlA C/C C/C AlA TIT AlA wtlwt AlA 
1006 wtlwt AlA C/C C/C AlC TIT AlA wtlwt Alb. 
SL351K469 wtlwt AlA TIT C/C C/C TIT GIG wt/wt All!. 
K362 wtlwt GIG C/C C/C AlC TIT AlA wt/wt Alb. 
SLl261K411 wtlwt 
--'--- Clf:. _ C/C AlA TIT AlA wt/wt AlA - .. - - - - - - -
wt= wild type sequence l!.= deletion NR= no result ND=notdone con=putative gene conversion 
i 
r 
An analysis was made on all these cord bloods and patients with 
HbE/f3-thalassaemia to see if there was any correlation between any of 
these mutations and the level of HbF expressed. As there were many 
mutations found in all individuals and each mutation could have a positive, 
negative or no effect, the overall effect was the sum of all the individual 
effects and hence made the analysis more complex. Each mutation was 
analyzed independently and summarized in Table 6.13. 
Expression of the °y-gene is three times greater than the A.y-gene so 
mutations in the °y-gene should be associated with a slightly greater change 
of HbF level compared to those in the A.y-gene. The Xmn-/ polymorphism, 
as described earlier, showed a positive correlation between the + or (T) 
form and a higher level of HbF. Also in °y-gene, IVSI-64 (C---7T) was 
associated with a high level of HbF in a (CIC) homozygote but with a 
lower HbF level in a (TIT) homozygote and IVSII-115 (A---7G) appeared to 
have a lower level of HbF associated with (G) variant. In the A.y-gene three 
mutations were associated with a change in the level of HbF. Cap+29 
(A---7G) appeared to be associated with a higher level of HbF as an (AlA) 
homozygote, whilst IVSI-64 (C---7T) and IVSII-115 (A---7G) were the same 
as their counterparts in the °y-gene. 
The 4bp deletion at Cap (-222-225) in the promoter of the A.y-gene 
has been described previously. It was found in a number of apparently 
normal adults in linkage disequilibrium with the CD75 (ATA---7ACA). It 
was associated with a low A.y expression and may well affect the total HbF 
level (Huisman, 1997). In this study, this small deletion was not found in 
the homozygous state and hence was not observed. 
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Table 6.13 Putative correlation between polymorphisms in the y-genes and the 
level of expression of HbF 
Mutation I Sequence I Mean ±SE I J Range 
(%) 1 n 1 %1 (%) 
_Gy-gene 
A IT 45.0 ±2.0 4 16.7 -158 (T-tC) TC 31.9 +6.3 11 45.8 
CC 21.7 ±6.2 9 37.5 
B CC 48.1 +5.4 5 20.8 
IVSI-64 (C-tn TC 29.1 ±4.5 16 66.7 
IT 6.9 ±1.4 3 12.5 
C AA 33.4 +5.4 14 58.3 
IVSII-1l5 AG 33.9 +6.0 7 29.2 
GG 6.9 +1.4 3 12.5 
D Homozygote 32.7 ±6.4 8 33.3 
Poly A tail-6 (-A) Heterozygote 36.1 +8.9 7 29.2 
Wild type 23.6 ±S.8 9 37.5 
A Wild type 29.8 +5.1 16 70 
-222/-225 4bp d* Heterozygote 27.9 +8.5 6 30 
B AA 40.7 +4.6 6 28.6 
Cap+29 AG 26.6 +14.1 4 19.1 
GG 25.6 ±6.2 11 52.3 
C CC 38.7 +6.8 9 40.9 
IVSI-64 CT 26.1 +7.8 6 27.3 
IT 20.1 +6.7 7 31.8 
D AA 39.6 ±6.0 4 18.2 
IVSII-24 AC 35.3 +8.9 8 36.4 
CC 20.5 +4.9 10 45.4 
E AA 33.2 +6.1 9 40.9 
IVSII-115 AG 67.9 11 4.6 
GG 23.2 +5.3 12 54.5 
F Heterozygote 30.4 +7.6 7 31.8 
3'URR TGA+3 Wild type 28.9 ±5.3 15 68.2 
G Wild type 31.7 +6.1 12 54.6 
Poly A tail-6 (-A) Heterozygote 26.6 +6.2 10 45.4 
.. i denotes posItIve regulatIon to mcrease the level of HbF 
,J.. denotes negative regulation to decrease the level of HbF 
? unknown effect 
40.9-50.5 
5.3-67.9 
5.3-60.8 
37-67.9 
5.3-60.8 
5.3-9.7 
5.3-67.9 
23.2-57.7 
5.3-9.7 
9.1-60.8 
5.3-67.9 
5.3-50.5 
5.3-60.8 
9.1-67.9 
18.6-50.5 
5.3-67.9 
5.3-60.8 
9.1-67.9 
5.3-60.8 
5.3-45.6 
22.6-50.5 
5.3-67.9 
5.3-45.6 
5.3-57.7 
67.9 
5.3-60.8 
9.1-67.9 
5.3-60.8 
5.3-67.9 
5.3-57.7 
* This was invariably found in conjunction with CD75 
I SD I Effect on 
(%) HbF 
4 i 
21 None 
18.5 J, 
12.1 i 
18 None 
2.4 J, 
20.2 None 
15.9 None 
2.4 J, 
18 None 
23.6 None 
17.3 J,? 
20.4 None 
21 None 
11.3 i 
28.3 None 
20.5 J,? 
20.3 None 
19.1 J,? 
17.8 J, 
12.0 None 
25.1 None 
15.4 J, 
18.3 None 
? 
18.4 J, 
20.2 None 
20.7 None 
21 None 
19.7 J,? 
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The mutations, within and around the y-genes, make their analysis 
difficult. Many of these mutations may be linked to form a framework. 
Each framework may be associated with a phenotype. Higher levels of HbF 
are associated with (T/C/AI(-A) at positions A-D) in the Gy-gene and (wild 
type/AiC/AiAIA at positions A-G) in the Ay-gene. 
6.4 Other modifiers 
Haemochromatosis 
Transfusion dependent thalassaemia results in a loading in the body 
of iron. Any other factors that also result in the accumulation of iron can 
add to this overload. The aim of the study was to gain an assessment of the 
incidence of known causes of genetic haemochromatosis (GR) in Sri 
Lanka. A random screen was performed on the same cohort of patients 
under investigation for haemoglobinopathies. Two common mutations that 
account for the majority of all cases of the disease were investigated by 
standard PCR RFLP assays (See section 2.4). 
The allele frequencies were determined in three clinics on the island 
as shown in Table 6.14. The incidence of the common North European 
mutation for GH (C282Y) was only found in one isolated case from 
Anuradhapura giving an overall allele frequency of 0.2% for this mutation. 
The mutation C282Y was found as a compound heterozygote with the 
H63D mutation and represented an extremely rare occurrence in Sri Lanka. 
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Table 6.14 Allele frequency of the common haemochromatosis mutations in 13-
thalassaemia patients attending three different clinics in Sri Lanka 
Haemochromatosis Region 
status Anuradhapura Badulla Kurunegala Total 
n % n % n % n % 
Wild type 259 93.8 23 82.1 215 93.5 497 93.1 
C282Y 1 0.4 0 0 0 0 1 0.2 
H63D 16 5.8 5 17.9 15 6.5 36 6.7 
Total 276 100 28 100 230 100 534 100 
The total allele frequency for the mutation H63D was found to be 
6.7%. The H63D mutation appeared to be present at a much higher 
frequency in Badulla than the two other centres but was probably due to the 
relatively small number of patients investigated at this centre. A single 
homozygote for this mutation was identified in each of the centres studied. 
Further analysis showed that this mutation was evenly represented in both 
f3-thalassaemia major patients and also HbE/f3-thalassaemia patients (Table 
6.15). 
Table 6.15 Allele frequency of tbe common haemochromatosis mutations in 13-
thalassaemia patients attending three different clinincs in Sri Lanka 
Haemochromatosis Thalassaemia major HbEi Thalassaemia 
status n % n % 
Wild type 273 94.1 224 91.8 
C282Y 1 0.3 a 0 
H63D 16 5.6 20 8.2 
Total 290 100 244 100 
Patients with HbEl/3-thalassaemia were investigated further to 
evaluate the iron status of the patients. Liver biopsies were collected and 
prepared into either paraffin blocks or frozen at -20°C in Sri Lanka. 
Histological assessment was made of sections of the paraffin blocks by Dr 
K. Fleming at the John Radcliffe Hospital in Oxford. The frozen liver 
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biopsies were assessed for iron content by Professor M. Pippard in Dundee 
and serum ferritin was performed by the routine haematology laboratory at 
the John Radcliffe Hospital in Oxford. Preliminary data appears not to 
show any correlation between the haemochromatosis mutation H63D and 
the following parameters; hepatic iron concentration, serum transferrin 
level, liver fibrosis, haemoglobin concentrations or a-thalassaemia status. 
Further analysis was required to be confident that any biological parameter 
measured gave an accurate determination. A greater understanding of any 
other disorders that may be present within this population as well as any 
treatment that they receive should also be taken into consideration. 
Uridine Diphosphate Glycosyltransferase (UGTIA) 
An observation, by Professor D. Weatherall, was made that a number 
of patients had a profound jaundiced appearance. An investigation was 
made to examine if this characteristic was associated with an elevated level 
of bilirubin. The most common molecular lesion associated with 
hyperbilirubinaemia is a tandem repeat element in the promoter region of 
the UGTIA gene. An increased number of these repeat elements were 
linked with a lower activity of the enzyme (Bosma et al., 1995). A genetic 
characterization of this locus was investigated to determine the importance 
of the promoter element mutation in the population of Sri Lanka and to 
study its role in jaundice and gallstone fonnation in HbE/I3-thalassaemia. 
Eighty-five patients that were part of an ongoing study group were 
examined at least six months after the previous blood transfusion. Five 
patients on regular transfusions were characterised pre-transfusion. Each 
patient was examined by abdominal ultrasonography with special emphasis 
on the presence or absence of gallstones. The number of tandem repeat 
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elements was determined by sequence analysis as outlined earlier (See 
section 2.4). These were compared against 144 anonymous controls 
collected from the Kurunegala Teaching Hospital to determine the genetic 
status of the non-thalassaemic populations in Sri Lanka (Table 6.16). 
Table 6.16 Genotype and allele frequency for the 5' promoter repeat element 
Genotype Normal controls 
n % n % 
A(TA)6TAA/ A(TA)6TAA 15 17.6 43 29.9 
A(TA)6TAA/ A(TA)7TAA 48 56.5 68 47.2 
A(TAhTAA/ A(TAhTAA 22 25.9 33 22.9 
Total 85 100 144 100 
Allele 
A(TA)6TAA 78 45.9 154 53.5 
A(TA)7TAA 92 54.1 134 46.5 
Total 170 100 288 100 
Patients and control samples demonstrated a very high level of 
homozygosity for the A(TA)7 TAA motif at 25.9% and 22.9%, respectively. 
The HbE/B-thalassaeroia patients had a higher frequency for the longer 
isofonn (T Ah This was also reflected in the allele frequencies. 
thalassaemia patients were associated with an incidence of 54.1 % for the 
(TA)7repeat compared with 46.5% in the control group. 
These patients also were examined to look for any correlation 
between the steady state levels of haemoglobin, total and indirect bilirubin 
values, the frequency of gallstones and their genotype for the 5' promoter 
element (Table 6.17). Preliminary data were obtained for all parameters so 
means with standard deviations are presented. 
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Table 6.17 Promoter genotype correlation with biochemical phenotypes in 
HbElfi-thalasssaemia patients 
A(TA)nTAA Hb Total Indirect GallstoneslNo of patients 
Genotype (gldl) Bilirubin Bilirubin > 15 years old All ages 
(mmol/L) (mmol/L) Index % Index % 
(TA)c;I (TA)6 53.8 32.9 24.6 117 14 1114 7 
(TA)c;I (TAh 54 34.9 24.1 9/18 50 10/44 23 
(TA)7/ (TA)7 55.5 62.3 50.1 7/9 78 7/21 33 
The steady state haemoglobin levels were similar in all groups 
indicating that the degree of ineffective erythropoiesis and haemolysis was 
comparable. However, there was a highly significant increase in both the 
total and indirect bilirubin levels associated with the (TAh homozygote 
genotype. Gallstones were found in almost one quarter (18179) of the 
patients and all but one of these was in the over 15 years old age group. 
Glucose-6-Phosphate Dehydrogenase (G-6-PD) deficiency 
The aim was to estimate the incidence of the common enzyme 
deficiency (G-6-PD). The subsequent incidence in the transfusion 
dependent patients could then be compared and the molecular lesions 
common in the Indian subcontinent screened in this population. The 
phenotype of patients with both disorders could then be assessed. 
A neonatal screening strategy was employed on the same cord blood 
samples collected for the evaluation ofHb Bart's and was carried out by Dr 
S. Rajapakshe. A G-6-PD deficiency colorimetric assay was performed on 
the red cells shortly after collection as outlined earlier (See section 2.3). 
The assay was performed on 125 cord blood samples. One hundred and 
twenty of these samples showed normal enzyme activity but five (4%) were 
observed to have intermediate deficiency. However, as G-6-PD deficiency 
is inherited in an X-linked fashion, most of the cases reported are in males. 
173 
Hence, a G-6-PD deficiency in females is highly variable and is difficult to 
detect during screening (Iwai et al., 2001). As the sex of the cord blood 
sample individuals were not recorded the overall frequency for this enzyme 
deficiency was probably higher than that determined. 
The activity of this enzyme was also determined on 60 HbE/{3-
thalassaemia patients and their relatives from the Kurunegla Teaching 
Hospital with the help of Dr A. Premawardhena. Two of these families 
were found to have an intennediate deficiency to give a similar incidence 
of 3.33%. Again no allowance was made for any difference in activity of 
this enzyme between males and females and so the incidence is probably 
higher. 
DNA analysis was performed on transfusion dependent patients and 
some of their relatives. The patients were chosen at random and were not 
ideal candidates to have a G-6-PD mutation. Mutations found in India, 
especially from the North East, were identified as potential candidates to 
screen for in the population of Sri Lanka. In the Indian states of Orissa and 
Madhya Pradesh two mutations were reported, G-6-PD Mediterranean and 
G-6-PD Orissa. G-6-PD Mediterranean was reported in the urban 
popUlations and was thought to have derived from the Aryan popUlations 
originating from central southern Europe. G-6-PD Orissa was reported in 
the rural populations and was thought to have derived from the aboriginal 
groups of India (Kaeda et al., 1995). A third mutation in exon 11 at 
nucleotide 1311 (Beutler & Kuhl, 1990) was used as a crude marker for a 
European (T) or an Indian (C) associated haplotype. All three mutations 
were screened for as shown in Table 6.18. 
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Table 6.18 Incidence of G-6-PD mutations in Sri lanka 
G-6-PD Mutation Individuals RFLP Patterns 
studied Negative No result Positive 
G-6-PD Mediterranean 230 154* 71 5 
G-6-PD Orissa 125 97 28 0 
G-6-PD 1311 (TIC) 39 0 39 0 
* Some of these samples gave a different RFLP picture that required further investigation to clarify the 
cause of the unusual pattern. 
The screen for G-6-PD molecular lesions observed in India revealed 
the presence of the G-6-PD Mediterranean mutation. This was found in 
2.2% of the individuals assessed and constituted the major cause for G-6-
PD deficiency in Sri Lanka. The mutation was found in four relatives and 
one transfusion dependent patient from Anuradhapura. Two of the relatives 
were carriers for f3°-thalassaemia, one was a carrier for HbE and the last 
was uncharacterised. One patient with HbE/f3-thalassaemia was found to 
have the G-6-PD Mediterranean mutation. This patient was probably 
female as the RFLP appeared to give both nonnal and mutant alleles. 
Interestingly, there appeared to be no G-6-PD Orissa positive individuals 
tested in this population. The incidence of G-6-PD Mediterranean observed 
did not account for the predicted number of cases expected and so at least 
one other molecular lesion remains to be identified. 
Those individuals observed to have a G-6-PD mutation were not 
available to study further to gain an insight into any interaction between G-
6-PD and thalassaemia. However, another tentative link between the 
population of Sri Lanka and the Aryan population of the Indian 
subcontinent was established. 
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6.S Discussion 
A key problem In medical SCIences is to relate findings at the 
molecular level to the clinical outcome III the patient. The 
haemoglobinopathies represent the most common monogenic disease in 
humans and should represent the simplest model for predicting phenotypes 
from genotypes. On close examination of a population the phenotype of 
some patients with an identical genotype are quite variable. (3-thalassaemia 
has an extremely diverse clinical phenotype. At the severe end of the scale 
((3-thalassaemia major), many homozygous or compound heterozygous 
states are characterized by profound anaemia from early life and if untreated 
with blood transfusions lead to death in the first year. Conversely, many 
patients with the same genotype have a milder illness that ranges from a 
condition slightly less severe than (3-thalassaemia major through a spectrum 
of decreasing severity of anaemia to one which is without symptoms and is 
ascertained only by routine blood examinations. Even the heterozygous state 
for f3-thalassaemia demonstrates a spectrum of haematological abnormalities 
ranging from a dominantly inherited form to a completely silent form. The 
underlying causes in the inconsistencies in these correlations have remained 
elusive (Weatherall, 2000). 
A correlation between genotype and phenotype can be established if 
the details of specific genetic mutations and their effects on protein products 
can be linked. This would allow clinical genetics to become predictive of 
disease prognosis and a better-informed selection among therapeutic 
strategies can be made for any individual patient. Complex diseases may 
also be unraveled in this same manner. As mutations have been identified for 
a disease it has become clear that genotype and phenotype correlation is 
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incomplete and only a subset of all mutations reliably predict phenotype 
(Dipple & McCabe, 2000). 
These causes have been grouped according to the level of the 
interacting influence (Weatherall, 2001). Primary modifiers alter the gene 
under study directly, secondary modifiers change the gene indirectly and 
tertiary modifiers affect other biological systems and become interacting 
genes. To relate phenotype to genotype a consistent definition of the severity 
of the phenotype must be made. The common underlying factor that is 
present in thalassaemia is related to the degree of anaemia. Measurement of 
the steady state haemoglobin level should give a good classification for 
different genotypes. However, as many factors influence the level of 
haemoglobin that include age, nutrition, infection and treatment (eg. blood 
transfusions) all these factors must be considered when trying to correlate 
phenotype to genotype. 
6.5.1 Primary modifiers 
In individuals with a mutation in their the primary modifier is 
the nature of that mutation. Over 200 different mutations have been 
identified in the genes of patients with (Huisman & 
Carver, 1998). These mutations interfere with gene function either at the 
transcriptional, translational or post-translational level. The resultant 
thalassaemia reflects the output from this altered or 
correlating to complete, marked or mild reduction of f3-globin chains). 
Hospital based patients were selected for study due to their dependence on 
blood transfusions and were expected to form part of the more severe 
spectrum of mutations and hence exhibit only a small phenotypic variation. 
Indeed, 85.2% of the alleles from these patients were found to be either 
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severe f3+ or f30 and not capable of producing any significant amount of f3-
globin (Table 6.1). Patients that· were homozygous or compound 
heterozygous for these mutations presented with a transfusion dependent 
form of the disease. Any variation in disease severity between these patients 
would be expected to be small. However, due to the lack of time a closer 
examination of these patients was not possible. This will be targeted as one 
of the next phases of the project. 
A small set of patients (0.7%) were observed with mutations, -28 
(A-7G) and Poly A tail (T -7C), that were classed as f3+ thalassaemia alleles 
and were associated with a moderate clinical phenotype (Table 6.1). These 
patients were always found as compound heterozygotes with a f3o-allele and 
presented with severe anaemia at a young age. They were treated similarly to 
patients with f3-thalassaemia major and hence their clinical status was 
masked. If these milder forms of f3-thalassaemia exist in the homozygous or 
compound heterozygous state they have not presented at clinics around the 
island and hence remain unreported. 
A larger set of patients presented with a mutation that resulted in a 
structural variation of haemoglobin. Three f3-chain variants were identified; 
HbD, HbE and Hb S but only HbE was found in a significant number 
(13.8%) of transfusion dependent patients (Table 6.1). 
Patients with HbDlf3-thalassaemia are clinically very mild and present 
with symptoms marginally more severe than carriers (reviewed in 
Weatherall & Clegg, 2001). An 18 years old man that presented with this 
condition was found to have hepatosplenomegaly, jaundice and anaemia 
though he had not had any blood transfusions he should be classed as f3-
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thalassaemia intermedia. This patient required closer examination to identify 
any compounding factors that made the phenotype more serious. 
Patients with HbS/S or have sickle cell disease. 
can be classified into two broad groups; a severe type 
similar to HbS/S with little (up to 15%) or no HbA and a milder form with 
up to 30% HbA (reviewed in Weatherall & Clegg, 2001). Again HbS is an 
extremely rare mutation in this population and was only found in 
combination with a f3-thalassaemia allele. These patients were identified as 
part of the more serious transfusion dependent individuals and so the 
phenotypes are assumed to be severe. However these patients were found to 
have their HbS mutation associated with the ArablIndian haplotype. HbS 
found on the Indian! Arab haplotype is associated with a higher level of HbF 
expression as compared with other haplotypes associated with HbS. The 
higher levels of HbF sometimes present with a milder phenotype but the 
variability is not understood. These patients may benefit from a review of 
their disease management. 
HbE in the homozygous state is associated with an extremely mild 
form of thalassaemia with little elevated production of HbF (reviewed in 
Weatherall & Clegg, 2001). Only one relative had this condition and was 
deemed asymptomatic. However, patients with this structural variant and f3-
thalassaemia were relatively common on the island. A cohort with this 
condition was examined more rigorously. HbE/f3-thalassaemia is associated 
with a wide phenotypic heterogeneity ranging from transfusion dependent 
anaemia in early life to a clinically 'silent' condition that is ascertained by 
chance in middle age (de Silva et ai., 2000). These patients allowed other 
modifying factors to be investigated. 
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6.5.2 Secondary modifiers 
The severity of the anaemia of is reflected by 
chain production that leads to excess a-chains and their deleterious effects 
on red cell production and survival (See section 1.2.2.2). Hence, anything 
that modifies the magnitude of the surfeit of a-chains should have an 
important effect on the phenotype. 
a-gene status 
Rearrangements in the human a-globin cluster are amongst the most 
common genetic abnormalities observed in human populations. a-
thalassaemia coexists with at a high frequency in many 
populations and so it is not uncommon to inherit both conditions (reviewed 
in Weatherall & Clegg, 2001). Deletions are the most prevalent type of 
modification but a-gene duplications are also encountered as a result of 
these non-reciprocal crossover events (reviewed in Weatherall, 1997a). 
Levels of a-gene expression modulate the severity of to a 
minor degree. The interaction of either deletion or non-deletion a-
thalassaemia has a beneficial effect on the clinical phenotype of severe 
thalassaemia (Weatherall et al., 1981), especially and less of 
an effect on Heterozygotes for and aD_ 
thalassaemia have higher MeV and MCH values than those heterozygous 
for either trait alone. In contrast, extra a-chains would further exacerbate the 
chain imbalance and result in a more severe phenotype. Patients with aaa or 
aaaa gene arrangement and a concurrent present a 
thalassaemia intermedia phenotype. These patients generally have a more 
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severe phenotype than either a-gene triplication or in 
isolation (Rund et al., 1997; Ho et al., 1998a; Altay et al., 1998; Beris et at., 
1999). 
The incidence of a-gene rearrangement on the island is very high at 
18.3%, almost one fifth of the population. This form of thalassaemia was 
distributed at similar levels around the study centres with the one exception 
in Anuradhapura. Perhaps, this frequency has been attained not just due to 
the direct beneficial effect of a-thalassaemia against infant infection (Allen 
et al., 1997) but also to ameliorate the globin chain imbalance due to 
thalassaemia. Although the red cells of individuals who have inherited both 
types of thalassaemia might be hugely lacking haemoglobin, the anaemia is 
less severe and consequently the phenotype is milder. 
Further analysis of the patients studied showed that this incidence of 
a-thalassaemia was heterogeneous amongst different groups of individuals 
according to their haemoglobinopathy status. Carriers for HbE or 
thalassaemia (-78%) and patients homozygous or compound heterozygous 
for (-80%) had a similar incidence for a-gene rearrangement 
(Table 6.2). The carriers for a haemoglobinopathy had more cases of a-
thalassaemia and the transfusion dependent cases had more of extra a-genes. 
This reflects the deleterious effect of extra a-genes to result in a more severe 
phenotype for these patients. Surprisingly, the patients with 
thalassaemia had far fewer a-gene rearrangements (-10%) with about 3% 
due to extra a-genes similar to the other groups and only -7% of these 
patients presented with a-thalassaemia. The most probable possibility was 
that this secondary modifier was effective in this group of patients and that 
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patients with these genotypes may have been those that had a clinically 
'silent' phenotype. 
Individuals with only extra a-genes are clinically 'silent'. Patients 
with extra a-genes are relatively common in Sri Lanka. Such patients have 
presented with 5,6 and 8 a-genes. Anecdotally, the greater the number of a-
genes present the less perturbation of the j3-gene was necessary to result in 
the clinical necessity for frequent blood transfusions (Table 6.3). Individuals 
with five a-genes that carried a single j3-globin gene mutation were 
phenotypically moderate to normal (Table 6.4). A single case presented with 
130-Tr (CD15(-T» and aaaJaaa (Table 6.5) and another with f3+-Tr (IVSI-
and aaaaJaaaa (Table 6.6), both cases were phenotypically 
severe. All patients with j3Tr/j3Tr or HbE/j3Tr and the same a-genotype 
(aaaJaa) were all classed as severe. 
HbF production 
Normal children and adults produce small amounts of HbF that appear 
to be confined to a particular red cell population called F-cells (Rees et a/., 
1999). Some patients homozygous for /30 -thalassaemia have a mild clinical 
phenotype and are able to maintain a relatively high haemoglobin level 
comprised of HbF. This continued production of y-chains not only increases 
the level of haemoglobin but also combines with a-chains to reduce the a//3 
chain imbalance and the consequent ineffective erythropoiesis (reviewed in 
Weatherall & Clegg, 2001). Hence, the phenotypic results of j3-thalassaemia 
are not just controlled by the reduction in the level of f3-chains but are 
heavily linked with the ability of y-chains to replace them. The molecular 
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determinants that maintain a high level of y-chain production are poorly 
understood but should be regulated at many levels. 
The nonnal regulation of globins around the time of birth needed to be 
characterized in detail before abnormal regulation could be investigated. The 
second haemoglobin switch usually prior to birth substitutes f3- for y-chain 
production (HbA for HbF) and continues until adult levels are attained by 3-4 
years of age (See section 1.2.1.1). The pattern of HbF disappearance was 
reported in a cohort of 209 nonnal human neonates (Colombo etal., 1976). At 
birth the mean HbF level was 64.8 ± 1.2% and for 15 days remained at the 
same level. A rapid drop was observed over the next 15 weeks down to 10.2 
±1.2% after which the rate of decrease slowed dramatically. A similar 
pattern was also reported on a cohort of 266 infants in a French popUlation 
(Cheron et al., 1989). A smaller group with f3-thalassaemia trait was followed 
and showed a similar pattern but with a delay of 2-4 weeks in the postnatal 
decline (Wood et al., 1982). The effect of y-thalassaemia on the level of HbF 
has not been reported but may change the ratio of A.y to 0y expression and if 
severe reduce the total level of HbF or even the timing of Hb switching. 
Compared with the other globin chains the number of mutations 
identified that are associated with a reduction in the level of HbF is very 
sparse. Individuals with a serious fonn of y-thalassaemia would probably 
switch to express their adult globins to allow the foetus to have an oxygen 
transporter and hence survival. Any long-tenn effects on the neonate due to 
this early switching to adult haemoglobin are unknown. Individuals with 
coexisting f3-thalassaemia would probably be miscarried during pregnancy. 
In Sri Lanka, two groups of individuals allowed further investigation 
of the level of HbF expression, patients with HbE/f3-thalassaemia and cord 
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blood samples collected at the time of birth. The ability for some patients 
with to maintain high levels of HbF is well known 
(reviewed in Weatherall & Clegg, 2001). The steady state haemoglobin level 
was determined and these patients demonstrated a normal distribution 
pattern with a wide range of HbF (Figure 6.5). The level of HbF in these 
patients ranged from 5% up to 70% with a modal level at 30-35% (Figure 
6.5). This continuous range of expression suggests that there may be more 
than one controlling gene and that the overall expression is a sum of these 
positive and negative regulators. 
'}'Gene mutations associated with elevated HbF 
Specific rare mutations that are associated with an increased level of 
HbF include mutations in the (3-globin gene, deletions that remove the (3-
globin gene and point mutations in the promoters of one or other of the 
duplicated y-globin genes. They are all characterized by the persistent 
production of high levels of HbF into adult life (reviewed in Weatherall & 
Clegg, 2001 and Huisman et al., 1997)(See section 1.2.1). 
In Sri Lanka, a deletion that removed the (3-globin gene (8(3-
thalassaemia) was found in two families but remained uncharacterised (See 
Chapter 4). These mutations present as elevated HbF levels throughout 
adulthood. A random screen of schoolchildren indicated that factors 
increasing the level of HbF were rare. 
Sequence analysis of both y-genes and their surrounding DNA 
revealed many sequence variations. The Xmn-/ polymorphism upstream of 
the °y-gene had an important association with the level of HhF. Patients with 
a (+1+ or Trr) configuration were associated with over 10% more HbF than 
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with the (+1- or TIC) configuration that was in turn just under 10% more 
than the (-1- or C/C) configuration (Table 6.12). More importantly, the total 
steady state haemoglobin level was associated with levels of 7.0,5.5 and 4.9 
gldl, respectively. In this cohort of patients with a 
difference of 1.0 gldl in the baseline haemoglobin concentration appeared to 
potentially be enough to change the phenotype of that patient from severe to 
something significantly less than severe. 
This relatively common polymorphism at position Cap-I58 in the Gy_ 
gene is well known to be associated with an increased propensity to produce 
HbF under conditions of haemopoietic stress but has little effect in normal 
people (Gilman & Huisman, 1984; Labie et ai., 1985; Thein et ai., 1987). It 
has always been thought of as a minor modifier of HbF levels and results in 
a higher proportion of Gy-chains in HbF. This locus may be part of a butyrate 
response element (BRE) (Ikuta et ai., 1998). However, this association may 
be as part of a highly conserved set of DNA sequences linked along the 
cluster. A tandem repeat element (TA)9CACATATACG(TA)1O in the 5' 
hypersensitivity-2 site of the LCR was found to be linked with an Xmn-I (+) 
arrangement (Winchagoon et al., 1994). Also a different tandem repeat 
(AT)9(T)s was found 530bp upstream of the f3-globin gene linked to the 
Arab-Indian haploype that is associated with a high level of HbF in patients 
with sickle cell disease (Pissard & Beuzard, 1994). These associations could 
all be in concordance but more extensive sequence analysis for all these loci 
need to be undertaken on a fully characterized set of patients that have had 
their steady state haemoglobins determined. 
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,),gene mutations associated with ')'thalassaemia 
The only known form of y-thalassaemia IS a deletion and was 
excluded because of the observed heterozygous polymorphisms. Large 
deletions that remove other genes on the cluster as well as the y-gene, like 
heterozygous (Ey8f3)o-thalassaemia, result in haemolytic disease of the 
newborn. These babies are anaemic at birth and then recover to a clinical 
picture similar to f3-thalassaemia trait but with a normal HbA2 level. After 
birth y-thalassaemia is asymptomatic in most individuals. 
y-thalassaemia has been described at low frequencies in families from 
China, India, Europe and Africa and would appear to have a pan global 
distribution due to a single molecular lesion. The mutation is a deletion that 
removes 5kb of DNA between the Ay and the 0y genes resulting in a hybrid 
globin expressing only 50% HbF at birth (Huisman et al., 1997). In the 
normal individual two functional y-genes exist in series. Only one intact y-
gene is necessary for the presence of HbF and if all four y-genes are missing 
an early switch to f3-gene expression probably occurs. Hence, the neonate 
may undergo some form of transitory anaemia that would automatically 
clear up negating the requirement for further study. The phenotype needs to 
be assessed at this critical time. 
The primary structure in and around the y-genes is beset with many 
variations in the consensus sequence. These polymorphisms also appear to 
be linked to the expression of the y-genes as seen in combination with the u-
genes to form HbF. Some these molecular lesions appear to be associated 
with up regulation and some with down regulation of the y-genes. The level 
of HbF observed is as a net result of all these effects and hence the relative 
importance of any single alteration is masked. Speculative sequence 
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combinations are linked to elevated HbF levels and also the converse. 
Hence, the °y-gene combination of -158 (CIC); IVSI-64 (Ttf) and IVSII-
115 (GIG) should be associated with a low HbF level while -158 (Ttf) and 
IVSI-64 (CIC) should associate with a higher HbF level. Analogously with 
"y-Gene, the combination of cap+29 (GIG); IVSI-64 (Tff); IVSJI-24 (CIC) 
and IVSII-115 (GIG) should be associated with a low HbF level while 
cap+29 (NA); IVSI-64 (C/C) and IVSJI-24 (NA) with a higher HbF level. 
A method to detennine the importance of any and all the mutations needs to 
be developed. 
6.5.3 Tertiary modifiers 
Only a few mutations in other genes have been demonstrated to alter 
the phenotype of thalassaemia. Many remain elusive but closer examinations 
of large groups of patients with apparently the same genotype will allow its 
dissection. 
Haemochromatosis 
Virtually all organisms are dependent on iron for survival but are at 
risk from iron deficiency or iron overload. Homeostatic mechanisms 
regulating the absorption, transport, storage and mobilization of cellular iron 
are essential in iron metabolism. Iron is a particularly insoluble molecule 
and requires specialized molecules to maintain iron in soluble and bio-
available form. When intracellular iron exceeds cellular requirement the 
excess is retained from becoming toxic but still kept available by ferritin 
sequestration and deposition mainly in the cytoplasm of cells. Control and 
regulation of these complexes remains obscure. Cells requiring iron express 
transferrin receptors that provide for controlled access of transferrin to the 
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cells. Uptake of transferrin into cells is controlled by intracellular iron pools, 
which regulate proteins involved in iron metabolism through translational 
control mechanisms. Regulation is achieved via iron regulatory proteins and 
iron responsive elements via negative feedback mechanisms (Ai sen et al., 
2001). 
GH is a disease of iron overload leading to the accumulation of iron in 
specific organs including the liver, heart, pancreas and gonads. Iron 
absorption from the small intestines of these patients is abnormally elevated 
(Ai sen et ai., 2001). Excess iron results in cirrhosis, hepatoma, 
cardiomyopathy, diabetes, hypogonadism and arthritis. GH is an autosomal 
recessive disease and its gene product (HFE) encoding a 343 amino acid 
type I transmembrane glycoprotein was mapped to 6p21.3 near the HLA 
locus. HFE is similar to MHC class I molecules and binds 132 microglobulin. 
GH results from a loss of function of this transmembrane protein. A single-
base mutation in human HFE, converting cysteine to tyrosine at codon 282 
(C282Y) that disrupts a disulphide bridge, is associated with 83% of HH 
cases (Peder et ai., 1996). The mutant protein does not associate with 132 
micro globulin and is not transported to the plasma membrane (Peder et al., 
1997). HFE also forms a complex with transferrin receptors preventing the 
uptake of iron by cells. A second mutation converting histidine to aspartic 
acid at codon 63 (H63D) has been found at high frequencies in some 
popUlations but its role in gene dysfunction is not understood. Other 
mechanisms are important in the regulation of iron levels and different 
molecules have been associated with the transport of iron across membranes. 
These include molecules like the divalent metal transporter (DMTI also 
known as DCTI or Nramp2), hephaestin and ferroportin. 
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The C282Y allele has a remarkably high frequency in North European 
populations and is present in over 10% in the Irish. Evaluations of other 
populations away from Northern Europe demonstrate a decrease in the allele 
frequency to 1-5% around the Mediterranean and then only found in isolated 
individuals (Merryweather-Clarke et aZ., 1997). In Sri Lanka, a single case 
with the mutation C282Y was identified and after further analysis revealed a 
unique haplotype. It was thought to have arisen in Sri Lanka independently 
from the mutation in Europe (Rochette et ai., 1999). 
The incidence of H63D allele is consistent with levels detenruned on 
the Indian subcontinent (Merryweather-Clarke et al., 1997). This mutation 
H63D was reported at high allele frequencies in most European populations 
ranging from 5-20% and was also found in populations of Africa and SE 
Asia at frequencies between 1-10%. The mutation was not found in 
aborigines from Australia or from the indigenous American populations 
except in isolated individuals in association with European haplotypes 
indicating probable admixture of populations from Europe (reviewed in 
Merryweather-Clarke et ai., 2000). 
The mutation H63D is reported to be of low penetrance and causes 
disease in only a proportion of patients who are H63D/C282Y compound 
heterozygotes and in even fewer H63D homozygotes. Selective advantage 
conferred by HFE mutations was assumed to prevent iron deficiency and 
would include protection against hookwonn infestation, malarial anaemia, 
multiple pregnancies or dietary deficiency and should result in high levels of 
both these mutations. Other selective advantages may be present within this 
population and need to be identified to allow a better understanding of their 
clinical importance. 
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As the incidence of thalassaemia on the island is high the chances that 
these polymorphisms, even though they are only present at a low incidence, 
could coexist with a haemoglobinopathy is reasonable. Generalized iron 
loading of the organs has been recognized as a complication of thalassaemia 
for many years (reviewed by Weatherall & Clegg, 2001). The excess iron is 
derived both from intestinal absorption and from transfusion. Carriers were 
not studied for the HFE mutations but have been reported. 
trait is characterised by mild, ineffective erythropoiesis and erythroid 
hyperplasia but only in a minority of patients does this ultimately lead to 
iron overload. Patients homozygous for C282Y and heterozygous for 
thalassaemia tend to have higher rates of iron accumulation and the 
development of severe iron related complications (Piperno et al., 2000). 
The incidence of C282Y and H63D were mainly obtained from 
transfusion dependent patients with major or 
thalassaemia. A comparison of these two groups of patients revealed no 
major differences. major patients who are well managed for 
blood transfusions and iron chelation therapy' and have a single 
haemochromatosis mutation were reported not to get iron loaded but patients 
with two haemochromatosis mutations suffer from severe iron overload 
(Longo et al., 1999). Patients with major develop 
complications of iron overload mainly due to blood transfusions that 
introduce more iron into the body. This commonly occurs before the age of 
5 years. The excess iron tends to be deposited into the liver by use of the 
ferritin transport. If the liver iron exceeds 7mg/g dry weight and the ferritin 
level exceeds 1500jlg/l then the prognosis for the patient is extremely poor 
and will probably result in death (Telfer et al., 2000). 
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Uridine Diphosphate Glucuronosyltransferase 
Individuals with Gilbert's syndrome have mild, chronic unconjugated 
hyperbilirubinemia in the absence of liver disease or overt haemolysis. The 
disorder is autosomal recessive and has been mapped to chromosome 2 and 
may be a family of genes with homologues on other chromosomes. On the 
basis of serum bilirubin levels 3-10% of the general (Western) population 
are estimated to have Gilbert's syndrome (Bosma et al., 1995). The 
syndrome is considered harmless in adults but may be linked with some 
forms of liver disease. Hepatic glucuronidating activity, essential for 
excretion of bilirubin, is about 30% in patients with Gilbert's syndrome. The 
reduced glucuronidation results in an increased build up of bilirubin. 
Absence or severe reduction of the enzymatic activity results in a more 
severe form of hyperbilirubinaemia called Crigler-Najjar (CN) syndrome 
type I or type II respectively. CN-I and CN-II are extremely rare disorders 
with the type I associated with a severe neurologic syndrome resembling 
kernicterus (an infiltration of bilirubin into the brain and spinal cord that 
may cause deafness, cerebral palsy and mental retardation) and the type II 
with reduced hepatic glucuronidating activity around 10%. Serum bilirubin 
levels are influenced by many factors, both genetic and environmental. 
Beutler et al., (1998) suggested that unstable DGTIAI polymorphism may 
serve to 'fine tune' the plasma bilirubin level within population groups. At a 
high enough level it may provide protection against oxidative damage, but at 
a level that is sufficiently low to prevent kernicterus in infants. 
Mutations associated with an extremely mild phenotype included a 
promoter element mutation. The TATAA element between nuc1eotides -23 
and -38 was found to have 2 extra bases (TA) changing the repeat element 
191 
from A(TA)6TAA (6/6) to A(TA)7TAA (7/7). This homozygous change was 
found in patients with Gilbert's syndrome (Bosma et aI., 1995) resulting in a 
70% reduction in expression of the gene. This increased repeat element (717) 
was found to be prevalent in many populations (European 13%; Asian 3% 
and African 19%) (Beutler et at., 1998). Heterozygous and homozygous 
variants were found to associate with increased bilirubin levels in 
individuals with t3-thalassaemia and G-6-PD deficiency (Sampietro et at., 
1997). 
Surprisingly, the population of Sri Lanka demonstrated a very high 
frequency for two extra bases (T A) inserted into the 5' TAT AA promoter 
element more consistent with the African population than the Indian 
population. The shift from six repeats to seven repeats is even more 
pronounced in the patients with HbElt3-thalasssaemia and may constitute a 
mechanism of protection against the oxidative stress imposed. Total and 
indirect bilirubin levels were nearly twice the level from 32.9 mmollL and 
24.6 mmollL to 62.3 mmollL and 50.1 mmollL in the (T A)6 and (T Ah, 
respectively. The consequence of this elevated bilirubin level was observed 
in the incidence of gallstones rising from 14% to 78% of their respective 
groups. The variation in the promoter allele may be of considerable 
importance in the genesis of gallstones and gall bladder disease in patients 
with HbE/t3-thalasssaemia as they get older especially in this population 
with a high incidence of the allele. 
Glucose-6-phosphate dehydrogenase 
Deficiency of G6PD and its linkage to the X -chromosome was 
identified in the 1950s (Carson et at., 1956). More than 400 million 
individuals throughout the world have been found with the enzyme disorder 
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and over 200 different variants of the enzyme are found at high frequency in 
tropical areas (African, Mediterranean and Asiatic populations (Porter et aZ., 
1964)). Heterozygote advantage vis-a-vis malaria (Luzzato et aZ., 1969) has 
been shown to account for this epidemiological distribution. Over 440 
variants have been identified (Pietrapertosa etaZ., 2001). 
The enzyme G6PD catalyses the first step of the pentose phosphate 
pathway, the only NADPH-generation process in mature red cells, which 
lack the citric acid cycle. The mechanism of protection of G6PD-deficient 
cells against falciparum malaria was reviewed by Friedman and Trager 
(1981). As G6PD is critical to the regeneration of nucleotide precursors and 
NADPH, a coenzyme that is essential for protection against and repair of 
oxidative damage, red cells deficient in G6PD are more sensitive to 
hydrogen peroxide generated by the malaria parasite. The loss of potassium 
from the cell and from the parasite is largely responsible for the death of the 
parasite. 
Clinically, deficiency of the red cell enzyme is the basis of favism, 
primaquine sensitivity and some other drug-sensitive hemolytic anaemias, 
anaemia and jaundice in the newborn and chronic non-spherocytic hemolytic 
anemia (Beutler et al., 1968). The mature erythrocyte due to its non-
nucleated status has a diminished capacity to respond to oxidative stress. 
Uncompensated oxidative stress in the red blood cell leads to oxidation of 
the haemoglobin resulting in methaemoglobin, Heinz Body formation and 
membrane damage. In the extreme cases haemolysis ensues while less 
severe oxidant stress leads to their premature destruction. 
In G6PD deficient neonates, the bilirubin load is increased but the 
presence or absence of bilirubin does not appear to correlate with the 
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In G6PD deficient neonates, the bilirubin load is increased but the 
presence or absence of bilirubin does not appear to correlate with the 
severity of haemolysis (Kaplan et ai., 1997). If untreated by exposure to UV 
radiation neonatal jaundice can lead permanent neurological damage 
(kernicterus) or death. The most dangerous consequence of G6PD deficiency 
is neonatal icterus. Kernicterus has been documented repeatedly in 
popUlations in which class 2 variants are common and is an important 
preventable form of mental retardation. Phototherapy has been used to 
reduce bilirubin levels and phenobarbital has been used prophylactically 
with some success. Exchange transfusion is required if the bilirubin exceeds 
20 mg/dl. This enzyme deficiency may be another compounding problem 
towards hyperbilirubinaemia and gallstone formation. 
As populations prone to G-6-PD deficiency are the same as those that 
have high frequencies of thalassaemia it was interesting to try to establish if 
both these disease mechanisms that protect against malaria do so in concert 
or individually. A random screen for mutations in the G-6-PD gene found in 
populations on the Indian subcontinent was undertaken. Different 
populations of India showed a G-6-PD deficiency between 3 and 15% 
(Kaeda et al., 1995). The incidence has been reported in the population of Sri 
Lanka at wide variance from 1-2% to nearly 14% (Nagaratnam et al., 1969; 
Roberts et al., 1972). The incidence of this enzyme deficiency in our study 
was 3-5% (200-600 thousand people on the island) that was similar to the 
incidence of {3-thalassaemia. Also, the phenotype assessed on the 
thalassaemia patients may be artificially low as thalassaemia causes an 
increased activity of G-6-PD towards normality that is also true in young 
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erythrocytes (Tagarelli et aI., 2000). Hence, many people with G-6-PD 
deficiency may also have thalassaemia. 
In India, a previously unreported deficient variant, G6PD Orissa was 
found to be responsible for most of the G6PD deficiency in tribal Indian 
populations but was not found in urban populations where most of the G6PD 
deficiency was due to the G6PD Mediterranean variant (Kaeda et al., 1995). 
In Sri Lanka, only the G6PD Mediterranean variant was identified and 
G6PD Orissa was not found. Perhaps, if the Veddahs were studied in this 
respect G6PD Orissa might be observed. 
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Chapter 7 Past, Present and Future 
7.1 Out of Sri Lanka 
Sri Lanka has impressive health statistics for a developing country. 
This major demographic change in the pattern of the disease has followed 
improvements in nutrition, hygiene and basic medical care such that children 
that would have perished of infection or malnutrition in the first few years of 
life are now surviving, and are able to present for diagnosis and treatment. 
This success has allowed the scale of chronic health problems to be assessed. 
Prior to 1992 a quarter of all paediatric admissions to the Kurunegala 
Teaching Hospital were patients with pallor and hepatosplenomegaly. Most 
of these patients had no fmn diagnosis, and were queried to have 
thalassaemia or chronic malaria. A few had a definitive diagnosis of 
thalassaemia made, based on cellulose acetate electrophoresis. These 
patients were treated with occasional transfusions based on the availability 
of blood. 
In 1992, Dr S. de Silva, the newly appointed Consultant Paediatrician 
formed a Thalassaemia Society. One of its key successes was the initiation 
of a change in policy to the National Transfusion Service to allow 
chronically anaemic patients to receive more blood transfusions. In 1995, Dr 
S. de Silva invited Professor D.l Weatherall to visit the clinic whereupon an 
arrangement was made to screen blood samples from these patients in 
Oxford for thalassaemic disorders. In 1996, these blood samples started to 
arrive in Oxford and it soon became apparent that over 95 % of these patients 
had haemoglobinopathies. Soon afterwards a nation-wide population screen 
for the disorder was organised. 
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The initial aim was to define the molecular basis underlying globin 
disorders using the assumption that they would be similar to those observed 
in neighbouring populations or in populations with an historical link with Sri 
Lanka. The spectrum and frequency of different molecular lesions in the a-
and f3-globin clusters needed to be assessed. The genetic backgrounds were 
examined to try to find markers that would correlate with the degree of 
disease severity, or some attribute of the phenotype. Hence, groups of 
patients that appeared to have the same genotype but demonstrated a 
variable disease manifestation were investigated more thoroughly. The range 
of genetic variations could then be compared against other populations to 
examine the risk factors for different groups that may allow a more rational 
approach for disease management. 
The project had many difficulties to overcome. The greatest problem 
was imposed by the ongoing war in Sri Lanka that made conditions unsafe 
for patients, their families, and clinicians and for all support services. 
However, blood sample collection and clinical infonnation was collated in a 
most determined fashion. The second problem was due language. Although 
many people in Sri Lanka speak English labeling of specimens was 
performed phonetically such that many spelling variations caused great 
confusion and repetition of work. Only with the advent of a numbering 
system instituted in Oxford and the recruitment of a doctor from Sri Lanka, 
Dr A. Premawardhena, did most of these problems clear up. The other great 
technical problem to overcome was the distance between the patients and the 
laboratory in which the analysis was performed. Sri Lanka has a hot and 
humid climate that causes samples to degrade rapidly and this was a 
message that needed to be made clear to all collaborators. Biochemical and 
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DNA assays needed to be optimised and new assays developed. The 
accumulation of information that was attained in Oxford gave the necessary 
impetus to push the project forward. 
Prior to this study nothing had been reported about the molecular 
basis of thalassaemia in Sri Lanka. These studies have achieved many of its 
goals. The incidence and spectrum of a- and t3-globin gene mutations have 
been characterised on the island. The study has also allowed some genotype-
phenotype associations to be made to help unravel the complexity of 
haemoglobinopathies found that is typical of all populations. 
The incidence of a-thalassaemia observed in Sri Lanka was similar to 
popUlations from many tropical and sub-tropical zones that have reached 
these tremendously high levels because of selection. The genotype 
frequency was estimated to be very high at 13.8% and 0.4% for 
heterozygous and homozygous a+-thalassaemia, respectively. Hence, on this 
small island a predicted incidence of heterozygous and homozygous a+-
thalassaemia would be 2.6 million and 56 thousand, respectively. Only a+-
thalassaemia was observed (_a3.7 and _a4.2) but not aD_ and aT-thalassaemia. 
A similar distribution has been seen on the subcontinent of India except that 
aD-and a T-thalassaemia have been reported in isolated families. Under 
normal conditions these a+-thalassaemia mutations would be associated with 
a normal phenotype and would pose no notable health problems. 
The development of peR assays to determine the known molecular 
lesions causing a-thalassaemia on the island were developed that will allow 
subsequent studies to be perfonned more rapidly and at less cost (Liu et al., 
2000). Indeed, as only clinically less serious forms of a-thalassaemia were 
identified these assays do not need to be perfonned routinely but only on 
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cases where the genotype does not correlate with the phenotype. In fact, the 
use of a biochemical assessment at birth for the level of Hb Bart's has 
proved to be extremely accurate in predicting the nature of any underlying 
a-thalassaemia. 
The carrier frequency for B-thalassaernia and for HbE was determined 
at 2.3% and 0.8%, respectively. Hence. the number of individuals on the 
island predicted to have B-thalassaemia major or HbE/B-thalassaemia was 
2650 and 956. respectively. Treatment for thalassaemia would be estimated 
to consume 5-9% of the annual expenditure on health in Sri Lanka (de Silva 
et aZ., 2000; Perera et al., 2000). An estimated one sixth of the transfusion 
dependent thalassaemia patients were studied and revealed twenty-three 
different molecular lesions in or surrounding the (3-globin gene. This 
amazing repertoire represented over one tenth of the total molecular lesions 
of this kind reported in the literature. Previously reported studies almost 
always retain individuals that remain un characterized (Huisman et al., 1997). 
After a considerable effort, all thalassaemia patients attending the 
Kurunegala Teaching Hospital had their haemoglobinopathy status 
characterized. These extended investigations helped to reveal three new 
mutations; two in the coding regions and one in the first intron of the (3-
globin gene. 
Three f3-globin gene mutations were extremely common and would 
form the basis of a genotype screen that should reveal 84.1% of these 
mutations. This would allow about 75% of families to be resolved by a PND 
service. To provide a reasonably comprehensive service (>95% of successful 
cases) over 20 of these gene mutations would have to be tested for. 
199 
At least one laboratory needs to be established as a reference laboratory for 
Haematological and DNA analysis in the country. 
The spectrum of mutations and haplotype data on both the (l- and (3-
globin clusters in the population of Sri Lanka is very similar to that of India. 
supporting close genetic ties with the Indian subcontinent and confirmed 
some historical chronicles (Figure 7.1). 
Most notably. the comparison to the North-East region of India was 
striking mainly due to the high prevalence of HbE. The only large difference 
was due to the third most common mutation IVSI-l that was rare in 
South-East Asia but common in Southern Europe. The 3' haplotype was 
found to be unique and so suggested that this mutation had arisen 
independently on the island from the Mediterranean basin. Indeed. the 
genetic links with Europe were even further distanced when a patient with 
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the mutation in their haemochromatosis gene (C282Y) was found on a non-
European haplotype (Rochette et ai., 1999). 
In the thalassaemias the disease defining criteria is that of the level of 
haemoglobin that can be maintained. Influencing factors, direct or distant, 
modify the phenotype. Primary modifiers alter the expression of the {3-globin 
gene directly. Mutations can result in different reductions in the production 
of the {3-globin chain, the greater its reduction the more severe the anaemia. 
As the patients studied were hospital based the majority of individuals 
presented as homozygotes or compound heterozygotes with severe {3+- or {30-
thalassaemia alleles and could only be treated as severe transfusion 
dependent patients. Surprisingly, a high prevalence of individuals presented 
with a single copy of a severe {3+- or {3°-thalassaemia allele and a single copy 
of a mild {3+-thalassaemia allele or {3-chain variant, mainly HbE. This group 
presented with a wide range of phenotypes from high frequency transfusion 
dependent patients to unaffected individuals that presented more like {3-
thalassaemia carriers. 
Secondary modifiers affect other globin chains that form the 
haemoglobin tetramer. Transfusion dependent patients have severely 
defective {3-globin chain production that results in an excess of a-chains. 
Coexisting a-thalassaemia would normalize this chain imbalance and thus 
prevent immature red cells from being targeted for destruction. In contrast, 
the counterpart to non-homologous recombination resulting in a+-
thalassaemia was the extra a-gene arrangement. Two forms of extra a-gene 
arrangement were observed (aaaanti3.7 and aaaaanti3.7). In this popUlation 
the high incidence of a-gene arrangement would give a predicted carrier 
level of 0.76 million people with extra a-genes. These gene arrangements 
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persist, in the popUlation, and on their own they are quite innocuous and 
represent a neutral allele. However, in combination with 
further imbalance of the a- to B-globin chain ratio results in a deleterious 
transfusion dependent condition. Interestingly, patients with 
thalassaemia were found with a much lower incidence of a-thalassaemia 
suggesting a strong ameliorating effect from this mutation so that these 
patients rarely present at clinic. 
By the same rationale, elevated production ofy-chains would combine 
with the excess a-chains to form HbF that can substitute reasonably 
adequately for HbA. The control and regulation of y-chains is still poorly 
understood. Many polymorphisms in the B-globin gene cluster are associated 
with both higher and lower levels of HbF. The Xmn-I polymorphism is the 
best known of these and showed the most clear cut correlation with the 
absolute amount of haemoglobin in the circulating blood. A +1+ or (TIT) 
configuration gave a favourable prognosis. The difference between the -/- or 
(C/C) and the +/+ configuration and its association with HbF was about 
2g/dl of total haemoglobin. An increase of haemoglobin by this level should 
benefit the patient enormously. The mechanism of this association and also 
of the 'Indian/Arab' haplotype, a haplotype associated with the sickle cell 
mutation, remains elusive. All the other polymorphisms identified may be 
part of a conserved sequence with direct functional properties or exist on 
certain haplotypes and only exhibit an association with the high HbF 
phenotype. 
The distant or tertiary regulators remain more elusive but some that 
affect the level of anaemia have been established. These conditions are 
dynamic and exist in a state of balance that can easily be tipped down a 
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number of different biochemical paths. Indeed, some apparently innocuous 
polymorphisms can have profound effects for groups of individuals with 
other disorders and change the pathophysiology of 
Transfusion dependent patients that are poorly or moderately chelated 
tend to develop iron overload but some, even with good chelation therapy 
appear to have a tendency towards iron overloading. In this population the 
common HFE mutation H63D was observed at high a frequency. The 
association of this mutation with a disease phenotype is still under question 
and a host of other genes may well be involved. Factors responsible for the 
greater than expected levels of iron loading remain to be identified in this 
popUlation. 
The efficiency of the enzyme, UGTIA, is associated with a repeat 
element in the promoter of its gene. In the population of Sri Lanka there was 
a higher than expected frequency for the genotype (T A)7/(TAh and was 
even more pronounced in the patients with This 
probably constitutes an adapted protective mechanism against oxidative 
stress. Unfortunately, the unpleasant side effects of excess bilirubin result in 
higher frequencies of gallstones and gall bladder disease in older patients 
with HbE/f3-thalassaemia. 
The incidence of G6PD deficiency in our study was 3-5% (200-600 
thousand people on the island) and this was similar to the incidence of /3-
thalassaemia. The inheritance pattern of these two genes did not appear to be 
associated. However, a small subset of f3-thalassaemia transfused patients 
co-inherited a G6PD deficiency. Any variability that this imposes on the 
phenotype of the patient is unclear but may be different at critical times for 
the patient. 
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7.2 Genetics, biology and disease 
Prior to 1950, genetics in medicine relied on pedigree analysis. It was 
not until Beadle and Tatum (reviewed in Lehninger, 1978) gave the gene a 
functional definition in their demonstration of the one-to-one relationship of 
gene and enzyme that biochemical genetics became focussed and the 
description of inborn errors took off. The analysis of DNA followed and 
RFLP analysis allowed mutants associated with monogenic disease to be 
tracked and then diseases like sickle cell anaemia to be diagnosed 
antenatally (Kan & Dozy, 1978a). With the development of cloning and of 
peR amplification molecular genetics allowed inborn errors to be defined as 
specific molecular mutants and for extensive regions of chromosomes to be 
sequenced. 
Each disease exhibits its own character that enables us to diagnose 
and classify it further. Sequence comparisons of the human genome will 
provide a reference point to link more of these disorders with genes or 
markers to allow diagnosis, treatment, prognosis and prevention (Childs & 
Valle, 2000). The Human Genome Mapping Project (HGMP) has helped lay 
the foundations by providing a consensus working sequence and along with 
Expressed Sequence Tags (ESTs) has allowed estimations for the total 
number of genes (-30,000) and their loci to be established. Another 
consequence of the HGMP is the identification of many DNA sequence 
variants or SNPs in the human genome. Over 1.5 million SNPs were 
deposited in the public databases by 2000. The availability of an ultra-high 
density SNP map opens the possibility of studying by association genetic 
factors important in complex genetic traits in the human (K wok, 2001). The 
analysis becomes more powerful when SNPs are linked to form haplotypes 
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that can then be associated with a group of individuals exhibiting a 
similarity. 
The post genome era stilI needs to evolve to explain how these genes 
interact with one another and the environment to make each individual what 
they are. Evolution is based on the conversion of genetic variation between 
individuals into genetic variation between populations. However, natural 
selection acts on variation among phenotypes not genotypes. Phenotypes are 
buffered from change by genotypic and environmental variation and allow 
for the build up and storage of neutral genetic variation in phenotypically 
normal populations. Genetic buffering reduces evolvability and promotes 
evolutionary stasis. The translation of genetic differences into phenotypic 
differences requires a breakdown in phenotypic buffering to allow changes 
crucial to evolution. The dogma of the 'one gene one function' hypothesis 
developed the notion that genes can be understood in isolation and produce 
discrete and unambiguous effects on phenotype. However, set against a 
complex genetic and environmental backgrounds, alterations in a single gene 
can have unexpected consequences. In instances where parallel pathways 
feed into the same developmental process natural variation can change 
which pathway is rate-limiting and allow stabilising selection or drift to alter 
the genetic circuitry (Rutherford, 2000). 
Phenotypic variation is most dramatically observed in the case of 
monozygotic twins. Most traits show substantial heritabilities that are 
exhibited as either discrete states or a continuous variation. Such quantitative 
variation is typically determined by both environmental and genetic factors 
with either a few genes having a large effect or by many genes with small 
effects (Barton & KeightIey, 2002). 
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Comparison of sequence and alignment between individuals and 
between species can help to identify important regions. These could be 
coding regions for genes, cis-acting regulatory sequences and deriving 
models for the evolution of the genome and its regulation. The next goal is 
to emphasize functional studies of genomic regions. The consequence of a 
change in this conserved sequence can be linked to temporal and spatial 
patterns of gene expression and phenotypes and hence a greater 
understanding of the normal role of these genes (Hardison et ai., 1998). 
The genome represents a dynamic structure that adjusts to 
environmental stimuli and in tum can alter these factors. Epidemiology aims 
to identify determinants of disease, either risk or protective factors, and to 
quantify their role. Selection bias arises from lack of comparability of 
groups included in the study, misc1assification of the participants with 
respect to disease or exposure status or due to exposure to risk factors other 
than those under study (Boffetta, 2000). The genetic basis for susceptibility 
to infectious diseases has been indicated by twin, adoptee, pedigree, and 
candidate gene study. This has led to the identification of strong genetic 
associations with a few infectious diseases (malaria, mv infection, and 
infectious prion disease) and less strong associations with many others (Hill, 
2001). Detailed linkage dis-equilibrium mapping, resulting from genome 
wide SNPs, will allow much more precise mapping and also help define 
polygenic causes. 
All tests for selective advantage use predictions from the theory of 
neutrally evolving sites as a null hypothesis. Departures from equilibrium-
neutral expectations can indicate the presence of natural selection acting at 
either one or more of the sites under investigation or at a sufficiently tightly 
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linked site. Complications can arise in the interpretation of departures from 
neutrality if populations are not at equilibrium for mutation and genetic drift, 
or if populations are sub-divided, both of which are likely scenarios for 
humans (Kreitman, 2000). 
Human population history- its major epochs of migration and 
expansion, instances of geographic isolation, the mixing of sub-populations, 
and major and minor historical population bottlenecks gives alternate 
reasons for distribution of frequencies of polymorphisms. The advent of 
large-scale SNP data sets for human gene loci provides an opportunity to 
directly compare within-population allele frequencies (and also between-
population differences in allele frequencies) for synonymous (e.g. 
degenerate codons in an exon) and replacement polymorphisms (Kreitman, 
2000). 
The idea that gene differences among humans could inform us about 
the dynamics of human origins only became apparent in the last 15 years 
(reviewed by Harpending & Rogers, 2000). This gave great insight that the 
most recent common ancestor of human mitochondrial DNA existed within 
the last few hundred thousand years. Mitochodrial DNA and genomic DNA 
diversity both suggest a human population size of about 10-20,000 
individuals about 10,000 years ago (Harpending & Rogers, 2000). 
Analysis of data is fraught with problems as much information on 
human history is inferred (reviewed by Harpending & Rogers, 2000). The 
multi-regional evolution model (MRE) states that modern humans arose 
from a diffuse worldwide transformation of archaic humans whereas the 
Garden of Eden model (GOE) states that a focal origin from some unknown 
smaIl population of archaics grew and spread over the temperate Old World. 
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Human populations may have a tree-like history analogous to that of species 
or human differences reflect in situ differentiation in a geographically 
Structured population. Reality probably lies somewhere between these views 
but it is thought that the largest genetic differences are found between 
African and non-African populations. The genetic relationship among non-
African popUlations is less clear. 
We are demographically a young species, with most of our genetic 
variation tracing to a relatively small precursor popUlation, or popUlations, in 
Africa, that recently colonized the rest of the world. The term race implies 
groups that can be cleanly separated from one another, and within our 
species, but there simply are no such groups. Differences among groups are 
graded and any groupings are arbitrary (Goldstein & Chikhi, 2002). 
7.3 Disease screening in neonates 
Screening of newborn infants for genetic disease began over 35 years 
ago as a public health measure to prevent mental retardation in 
phenylketonuria (PKU) by Guthrie in (reviewed in Levy & Albers, 2000). 
By the mid-l 970' s this had extended to about half a dozen disorders 
(galactosemia, maple syrup disease, homocystinuria and congenital 
hypothyroidism). This has been applied for a few diseases in some cases but 
mass screening has generally only been applied to PKU. Tandem mass 
spectrometry is substantially enhancing the screening process and expanding 
coverage to many treatable genetic disorders heretofore not identifiable by 
newborn screening. Moreover, the ability to examine DNA is offering the 
possibility of molecular screening for almost any disorder (Levy & Albers, 
2000). 
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If one considers the use of cord blood and not a heel prick from a 
newborn infant a completely non-invasive system could be employed. Prior 
knowledge of critical genes or parts of genes to be investigated would be 
required to make a large scale screening program feasible. Indeed proposals 
are under discussion to implement a universal screen on heel prick blood 
from all babies for sickle cell disease by using a haemoglobin analyser, like 
the Biorad variant analyser. In the UK, there is a shortfall in the number of 
patients found to have sickle cell disease. This will not only increase the rate 
of detection but also allow the detection of a-thalassaemia. The success or 
failure of this plan will indicate its efficacy for other populations. 
The products of genes, the proteins are again becoming the focal 
points in the analysis of disease. Proteomics incorporates the structure, 
function and interactions of a cell's full complement of proteins. The 
proteins translate structure into function, and as the elements of structural, 
metabolic and homeostatic systems, they represent the essence of 
biochemistry and physiology. The complexity of the proteome exceeds the 
genome in that variable promoters, alternate splicing, and extensive post-
translational processing all serve to amplify and diversify genomic 
information. The phenotypes of complex disease need to be explained by 
locating several variant gene products with their relationship to each other in 
more physiological systems, each capable of communicating and integrating 
with others, explaining thereby the variability of the whole (Childs & Valle, 
2000). 
7.4 Future for thalassaemia 
Although most of the common natural mutants have been 
characterized, better information about the frequency and distribution of 
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different fonns of thalassaemia are essential. Indeed, it is now becoming 
clearer, that groups within a population, have a completely different 
frequency and spectrum of the molecular causes of thalassaemia, and each 
population needs critical assessment of each of these groups. Also novel 
molecular lesions may help greatly in elucidating our understanding of 
control and regulation of these genes in an unexpected manner. 
In Sri Lanka, the study of thalassaemia patients attending clinics has 
revealed an extensive diversity of a- and B-globin gene mutations. However, 
the remaining unstudied patients (>80%) may well hold some interesting 
surprises especially within relatively isolated communities (particularly the 
non-Sinhalese). A particularly interesting group is that of the native 
inhabitants of the island, the Veddah that may have direct links to the tribal 
groups in India. 
Technical developments, at the phenotype and genotype level, have 
now made large-scale popUlation screening feasible. However, the 
widespread nature of the haemoglobinopathies and the large number of 
different mutations that interact to give a phenotype still require the input of 
large amounts of resources to understand the nature of the disease globally. 
A reasonable evaluation of the incidence of these conditions can be 
assessed by biochemical analysis. Elevated levels of HbA2 and HbF give a 
good estimate for B-thalassaemia. Elevated levels of Hb Bart's give an 
accurate indication for the presence of a-thalassaemia. If a serious fonn of 
a-thalassaemia (aD) is present then individuals with HbH or greatly elevated 
levels of Hb Bart's would be observed. Indeed, if the analysis is performed 
during foetal development an estimate might be made on y-thalassaemia that 
could result in serious clinical consequences. As the causes of death due to 
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infectious agents have diminished and health care has improved, people with 
genetic variations are increasing in each population. Human fecundity is said 
to be as low as 25% and the loss of 75% of conceptuses is called 'fetal 
wastage'. Disease accounts for some part of this 'wastage' but chromosomal 
anomalies may playa major role. A routine screening program would allow 
a better overall assessment of the incidence of haemoglobinopathies on the 
island and allow rare cases to be investigated. 
Development of new reagents has allowed a much more reliable DNA 
analysis of the a-globin cluster. peR analysis has become fast, simple and 
robust. Remarkable advances in miniaturization technology are making it 
possible to develop microchips which will encompass large numbers of 
human mutations and which will enable rapid screening of large populations. 
As the cost of these new approaches fall it may be practicable for one or two 
laboratories in each country, with a high frequency of mutations, to provide 
services for popUlation screening. These would be cheaper and more 
effective than the use of simple approaches carried out in many different 
hospitals or clinics throughout these countries. Indeed, as a consequence of 
this program of research, the need for a central reference laboratory has been 
proposed and accepted. The logistics of this laboratory will be organised by 
the Wellcome Trust and the Sri Lankan Department of Health. 
Even though cases of HbH disease have been previously reported in 
Sri Lanka (Nagaratnam & Sukuram 1967; de Tissera et al., 1988) our survey 
would indicate that this disease is extremely rare. A further screen to find 
communities with these genotypes, aO- and aT-thalassaemia, would be of 
great clinical value. Further genetic classification of the single a-gene 
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deletions, _a3.7 and _a4.2, would allow greater comparison with other 
popUlations. 
A wide variety of f3-globin gene mutations have been identified but 
further mutations may be prevalent in isolated communities. The novel 
globin gene mutations still remain to be formally characterised and their 
mode of action demonstrated. The putative allele(s) 
revealed remain to be characterised. Once the breakpoints have been mapped 
a Gap-PeR method can be designed to allow the frequency of these 
molecular lesions to be estimated. 
As Sri Lanka is historically most closely associated with South India 
studies on the popUlation of South India may be extremely useful as a 
comparison. This may help to confirm a uni-centric or multicentric origin for 
the intronic mutation, IVSI-l and to establish if HbE extends down 
the East coast of India. 
The relationship between genotype and phenotype and the reasons for 
the remarkable heterogeneity of all the thalassaemias is still poorly 
understood; HbE/f3-thalassaemia is a good example. This disorder will affect 
hundreds of thousands of children throughout the Indian subcontinent and 
South East Asia. Still we know very little about the natural history of the 
disease that makes it impossible to make sensible recommendations about its 
best management. Reasons for the heterogeneity of forms of thalassaemia 
need to be understood so that screening and prenatal diagnosis programs can 
provide parents with appropriate counselling. 
Analysis of the genotype-phenotype correlation could be extended to 
investigate individuals with f3-thalassaemia that are transfusion independent 
or only require occasional blood transfusions. The phenotype should be well 
212 
characterised so that associations with genetic markers can be established. 
The molecular lesion in the j3-gene should be identified as well as the 
mOdifying factors around the globin gene cluster and also at distant loci. 
Bilirubin as an antioxidant needs to be further characterised to have a greater 
understanding of its protective role against free radical damage. 
Haplotype infonnation can also be used to compare the different 
ethnic groups may indicate connections with other populations. This can be 
even more infonnative when found in association with mutations that may 
be subjected to selection. This should go hand in hand with full SNP 
mapping of loci. Greater sequence analysis between different populations 
can highlight natural genetic variation and when compared with sequence 
analysis across species can identify conserved and non-conserved regions. 
Every country will have to decide how they wish to control the 
disease. Screening and prenatal diagnosis plans have proved enormously 
successful in some Mediterranean countries. However, other programs like 
premarital screening can be successful. If countries decide not to develop 
programs for the control of the disease, but to treat it when it occurs, they 
will have to work out the economics and how to develop their clinical 
services. In Sri Lanka, the development of a reference laboratory could be 
used in these capacities but PND is not sanctioned by the Buddhist faith 
within this population. 
Transfusion dependent thalassaemic children can develop nonnally if 
adequately transfused and their excess iron chelated. The development of 
simpler, cheaper and more effective chelating agent would improve patient 
care tremendously. An analysis of the 'iron status' in a well characterised set 
of patients with similar or identical genetic lesions in the globin clusters may 
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indicate compartments of iron regulation that require closer inspection. As 
other factors critical for the regulation of iron are revealed their importance 
in these patients can be assessed. This may lead to improvement of chelating 
agents. Even well iron chelated children develop endocrine damage 
requiring further work to understand and avoid these complications. Blood 
borne infections will remain a major problem and so a blood transfusion 
service would need to be developed to cope with an increase in the demand 
for blood transfusions. 
Ways of improving marrow transplantation between unrelated and 
unmatched donors, the use of stem cells and somatic cell gene therapy is 
progressing more slowly. As the underlying selective pressures that resulted 
in high a prevalence of thalassaemia is still present on the island this 
approach may have further problems to overcome. Although malaria was 
reduced it may well be making a comeback and great vigilance must be 
observed to prevent the ravages from this disease. It would ask the question, 
are man's efforts to control the effects of this disease better than nature? The 
evolutionary consequences will be interesting. 
Stimulation of HbF synthesis could be an answer for some patients. 
This may not be plausible in severely transfusion dependent patients but an 
increase of 1-2 g/dl may be enough to improve the phenotype of the 
intermediate forms of f3-thalassaemia. The relative amounts of y- and {3-
globin chain production, in adults, are in equilibrium presumably directed by 
regulatory molecules. Certain perturbations of erythropoiesis favour the 
expression of y-globin genes and this can be induced by a variety of drugs 
(Weatherall & Clegg, 2001). An understanding of the mechanisms that 
regulate HbF would allow treatments by these therapies to be optimized. 
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More individuals with steady state HbF levels should have their y-
genes examined so that the polymorphisms revealed can be assessed with 
greater statistical confidence. An assessment of the individual expression of 
both y-genes would allow mutations in either gene to be assessed more 
critically. 
In conclusion, the control of thalassaemia, especially in the poorer 
countries, remains a major question to be answered (Weatherall & Clegg, 
1996). Current technology can improve screening programs for 
understanding the frequencies of haemoglobinopathies and can indicate 
health burden. This must be done soon otherwise detrimental affects of this 
disease will be huge. Gene therapy, bone marrow transplants, stem cell 
therapy may help tremendously when these technologies are fully developed 
but they will be prohibitively expensive for the scale of the problem. 
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Appendix 1 
Equilibrium genotype frequencies will be reached in zygotes after one 
round of random mating. The expected genotype frequencies are predicted 
by the Hardy-Weinberg Equation with two alleles A and a: 
p2 + 2 pq + q2 = 1 
where p2 is the frequency of a homozygote trait AA 
q2 is the frequency of a homozygote trait aa 
2pq is the frequency of a heterozygote trait Aa 
A chi-square CX2) test is used to compare observed genotype frequencies 
to expected frequencies estimated assuming Hardy-Weinberg equilibrium: 
[ 
__ C 0_s_e_rv_e_d_-e_x_p_e_ct_ed_)_2_ 
expected J 
Small values of X2 indicate a good fit to expectation and large values a 
deviation. 
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